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Abstract 
Muscular dystrophies are rare diseases characterised by progressive muscle wasting and weakness. 
Putative therapies are being evaluated; the slowly progressive nature makes outcome measures 
difficult to design. Four pathological hallmarks of muscular dystrophies include: muscle necrosis, 
inflammation, fibrosis, and adipose transformation. This thesis evaluates novel methods of 
quantifying pathological hallmarks of muscular dystrophy in both skeletal and cardiac muscle using 
magnetic resonance imaging (MRI). 
To quantify fibrosis in a mouse model of Duchenne muscular dystrophy, EP3533, a collagen-specific 
contrast agent, was assessed in quantification of fibrosis in muscle. EP3533-measures correlated with 
functional tests and histological quantification of fibrosis.  
Extracellular volume (ECV) was calculated in a limb muscular dystrophy type R9 cohort (LGMDR9), a 
Becker muscular dystrophy cohort and healthy controls. ECV was found comparable to traditional 
measures of cardiac dysfunction and demonstrated regional dysfunction.  
A multicentre study followed up 24 participants with LGMDR9 over 6 years. The three-point Dixon 
method of fat fraction calculation was evaluated in this cohort and compared to functional 
assessments. All muscles showed significantly increased fat fractions over 6 years, which was more 
responsive than functional assessments.  
As patients with muscular dystrophies can have difficulties remaining supine during scanning, a 
method of reducing acquisition time in measurement of left ventricular (LV) indices was evaluated. 
Accelerated images were compared to conventional imaging with accelerated imaging producing 
images with a high fidelity. No significant changes were seen in LV functional indices or cardiac tagging 
measures over five years was assessed in an LGMDR9 cohort, this may be due to confounding 
variables.  
The MRI methods described can be successfully used to quantify progression of disease pathology in 
muscular dystrophies. These findings can be used to support further trials of EP3533 and ECV as an 
outcome measure in muscular dystrophies and to inform study design of future trials into LGMDR9. 
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Chapter 1. Introduction 
1.1 Muscular dystrophies 
Muscular dystrophies are heterogeneous inherited conditions that cause progressive muscular 
wasting and weakness. These conditions can present at any age from the antenatal period to late 
in adult life, and a similarly wide variation is seen in the rate of progression. While muscular 
dystrophies are associated with skeletal muscle weakness and loss of ambulation, certain muscular 
dystrophies involve cardiac and respiratory systems, leading to mortality due to respiratory failure, 
chest infections, arrhythmias or cardiomyopathy (Bushby et al., 2010b).  The advent of 
international collaborative networking such as ‘TREAT-NMD’ and international policies have 
facilitated research into rare diseases, which when considered as a whole affect 8-10% of the 
population (Treat NMD, 2017, European commission, 2008). Over the past two decades advances 
in basic science and genetics have led to the development of several promising therapeutic avenues 
for muscular dystrophies (Qiao et al., 2014, Stevens et al., 2013, Richard et al., 2016, Svahn et al., 
2015). The selection of appropriate outcome measures for clinical trials is of paramount importance 
in the pathway of translational research, and determines the value, power and feasibility of 
putative therapeutic agents. For a therapeutic agent to be licenced, trial design must maximise 
internal and statistical validity. When selecting clinical trial outcome measures, several factors have 
to be considered: what the intervention is aiming to improve, how best to measure this through 
existing outcome tools, and whether the outcome measure has sufficient sensitivity to detect 
change over time (longitudinal validity) (Liang, 2000, Coster, 2013). Among other barriers, muscular 
dystrophies are slowly progressive and therefore outcome measures may lack longitudinal 
sensitivity. Clinical trials into muscular dystrophies have also reported difficulty in demonstrating 
clinical efficacy outside of a narrow group of participants fulfilling specific inclusion criteria 
(Domingos and Muntoni, 2018).  
The pathology of many of the muscular dystrophies is caused primarily by the loss of one of the 
many proteins that are essential to the healthy working of a myocyte. Alpha-dystroglycan is a 
peripheral membrane protein which, through the many bonds formed by glycosylation, is central 
to the structure of the myocyte and membrane stability.  Dystrophinopathies such as Duchenne 
muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are caused by a defect in the 
dystrophin protein which bonds directly to α-dystroglycan to form the dystrophin-glycoprotein 
complex. Therefore, these conditions share a common pathway of pathogenesis with conditions 
affecting α-dystroglycan such as limb girdle muscular dystrophy type R9 FKRP-related (LGMDR9). 
Membrane instability and subsequent cation influx cause muscle fibre necrosis. Inflammation and 
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inability of the somatic repair mechanisms to manage the myocytic damage leads to fibrosis, 
replacement with adipocytes (fat replacement) and eventual muscular weakness. The four 
detectable hallmarks of muscular dystrophy pathology are: 1. Muscle fibre necrosis and 
inflammatory response, 2. Fibrosis, 3. Replacement of muscle with adipocytes, 4. Progressive 
muscle weakness. Outcome measures are typically based upon one or more of these hallmarks 
which demonstrate disease progression (Figure 1). Current approaches to quantification of disease 
pathology in muscular dystrophies are discussed in detail in Chapter 2. 
In current clinical trials, the most commonly used primary outcome measures are functional due to 
their clinical relevance to patients. Criticisms of functional assessments include: subjectivity, 
improvement through training effects, dependence on age or comorbidity and lack of longitudinal 
sensitivity (Bushby and Connor, 2011). Magnetic resonance imaging (MRI) has been shown to have 
utility as a diagnostic tool in muscular dystrophies (Mercuri et al., 2007, Wattjes et al., 2010). Some 
techniques of quantitative MRI are well established as outcome measures, whereas other novel 
methods require in vivo validation (Ricotti et al., 2016, Wren et al., 2008, Finanger et al., 2012, 
Dixon, 1984). It has been shown that MRI has potential to non-invasively detect change in skeletal 
muscle over a shorter period of time than functional assessments, and is fully objective (Willis et 
al., 2013).  
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Figure 1. An overview of disease pathology in dystrophin-glycoprotein complex associated muscular dystrophies with 
reference to outcome measure design. Numbered boxes are current approaches to quantifiable outcome measures 
with number 4 functional weakness being the most clinically evident (shown by the arrow to the right of the diagram), 
but the latest detectable pathology (shown by the arrow to the left of the diagram). There are advantages to 
successful detection of early pathological changes, which may be more sensitive to the disease process before 
weakness is detectable; this can reduce duration of clinical trials or be used to increase study design power.    
 
Muscular dystrophies are a heterogeneous group of rare genetic disorders. Muscular dystrophies 
encompass several different forms of inherited conditions, including DMD, BMD and the Limb girdle 
muscular dystrophies (LGMD). The LGMD were established as a separate entity from DMD in a 
seminal paper by Walton and Natrass in 1954 (Walton and Nattrass, 1954). DMD, BMD and 
LGMDR9 are caused by a defect of a gene which results in deficit of a functional protein essential 
in healthy myocytes. In the case of DMD and BMD there is a deficit of full-length functional 
dystrophin, a subsarcolemmal, cytoskeletal protein which assists in membrane stability (Kole and 
Krieg, 2015, Anthony et al., 2011).  Most types of muscular dystrophy are not confined to skeletal 
muscle and can affect multiple organs. The most severe types cause congenital malformation and 
involve cardiac and respiratory muscles.  
This first chapter provides an overview of the three types of muscular dystrophy that will feature 
in studies within this thesis, either as an animal model, or as clinical trial participants.    
Chapter 2 details how outcome measures have been used in the past to quantify different aspects 
of muscular dystrophies, with focus on methodology used in this thesis. Chapter 3 describes the 
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methods used in subsequent chapters. Chapter 4 discusses murine experiments of a novel, 
collagen-specific contrast agent (EP3533) in quantification of fibrosis as an outcome measure in 
skeletal and cardiac muscle. Chapter 5 details how quantitative MRI and physiotherapy-based 
assessments can be used to detect disease progression as an outcome measure in LGMDR9. In 
Chapter 6, extra cellular volume (ECV) quantification of the heart is measured as a potential 
biomarker of diffuse fibrosis and inflammation in participants with LGMDR9 and BMD. Chapter 7 
explores cardiac outcome measures in a LGMDR9 group over five years and evaluates whether a 
method of reducing acquisition time improves quantitative MRI as an outcome measure, whilst 
retaining image fidelity and providing accurate calculation of cardiac functional measures. Chapters 
8 and 9 discuss the findings of the studies contained within this thesis and place these findings 
within the wider context of muscular dystrophies and clinical trials.  
 
1.2 Overview of the muscular dystrophies involved within this thesis  
1.2.1 Duchenne muscular dystrophy 
DMD is an X-linked recessive disorder caused by mutations in the DMD gene. The DMD gene is 
located on the X-chromosome and measures 2.4Mb (Den Dunnen et al., 1992). Dystrophin is a sub-
sarcolemmal protein found in several tissues including smooth, skeletal, and cardiac muscle. 
Dystrophin is important for the membrane stability of myocytes; the stress of contraction of muscle 
is thought to be absorbed in a way analogous to a spring, reducing mechanical shear forces and 
supporting the membrane (Kole and Krieg, 2015, Anthony et al., 2011). A deficit of dystrophin leads 
to membrane instability and damage, allowing extracellular cation influx, leading to oedema and 
inflammation (Klingler et al., 2012). Development of muscular fibrosis is a common pathological 
hallmark of progression, with higher levels associated with a poorer prognosis in terms of 
ambulation and cardiac function (Desguerre et al., 2009, Puchalski et al., 2009, Walcher et al., 
2011). Dystrophin is expressed within neural tissue with reported signalling properties within the 
postsynaptic site of neurons (Hendriksen et al., 2015). Dystrophin expression within the brain may 
account for the higher incidence of learning difficulties, epilepsy, autism and attention deficit 
hyperactivity disorder found within this cohort (Donders and Taneja, 2009, Wicksell et al., 2004, 
Wu et al., 2005, Pane et al., 2013).  
DMD has an estimated worldwide prevalence of 1 in 3,300-5,136 (Mendell et al., 2012, Moat et al., 
2013, Emery, 2002). Newborn screening tests have been trialled in several countries though 
currently no country has a fully implemented ongoing neonatal screening programme for DMD 
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(Moat et al., 2013, Drousiotou et al., 1998, Beckmann et al., 1976, Greenberg et al., 1991). In the 
United Kingdom (UK), the mean age of diagnosis of DMD is 4.3 years old (Bushby et al., 1999). Onset 
of symptoms is typically much earlier (UK average of 2.7 years), with delayed gross motor 
milestones and development of Gowers’ sign (van Ruiten et al., 2014). Typically patients with DMD 
reach their developmental milestones late, reaching a plateau of improvement in motor function 
between 5-7 years old. Patients with DMD are unable to keep up with their peers, with increased 
fatigability and exercise intolerance (Bushby et al., 2010a). Due to the higher incidence of learning 
difficulties and autism, speech and language delay may be the presenting complaint. 
Without treatment, progressive muscle weakness leads to loss of ambulation; typically within the 
first to second decade of life. Weakness is more profound proximally in the hip and shoulder girdle 
muscles, with progression to distal muscles over a period of years. On examination, pseudo-
hypertrophy of the calf causes the appearance of an enlargement in the lower leg muscles. 
Development of scoliosis is common in steroid naïve patients. Progressive contracture 
development also occurs without appropriate orthoses and physiotherapy. Rhabdomyolysis is 
uncommon but can occur, typically only after extended exercise. Respiratory muscle weakness is 
progressive and includes the diaphragm; many patients require ventilation in the second decade of 
life. Cardiac dysfunction is seen in almost all patients with DMD by the age of twenty, and is 
associated with a reduced life span (Jefferies et al., 2005, Ramaciotti et al., 2006, Barp et al., 2015, 
Eagle et al., 2002).  
Patients with DMD have a reduced life span; without corticosteroids this can be restricted to the 
second decade of life (Eagle et al., 2002). The most common cause of death is due to respiratory 
insufficiency and chest infections, with an estimated 20% dying due to cardiac arrhythmias or 
cardiomyopathy (Passamano et al., 2012).  
Several blood markers are likely to be abnormal in patients with DMD, but are not specific to this 
condition. These include serum creatine kinase (CK) activity, several liver function tests (LFT) and 
lactate dehydrogenase (LDH). Muscle biopsy with immuno-histochemical staining reveals an 
absence of dystrophin. The diagnosis of DMD is confirmed by identification of a mutation within 
the DMD gene on molecular genetic testing (Bushby et al., 2010a).  
MRI is the most commonly used imaging modality to differentiate between neuromuscular 
disorders. In early DMD, standard T1 weighted imaging can have a normal appearance, with 
development of degenerative changes in the second half of the first decade of life (Lamminen, 
1990, Nagao et al., 1991, Matsumura et al., 1988). T1 values and appearances change initially in 
the gluteus maximus and adductor magnus, followed by the quadriceps (QUADS), rectus femoris 
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(RF) and biceps femoris muscles. There is reported sparing of the sartorius (Sar), gracilis (Gr), 
semitendinosus (ST), and semimembranosus (SM) muscles. In the calf, the gastrocnemius (GCN) 
muscles are affected earlier than the soleus (Sol) and the peroneus longus (PL) muscles. Specialist 
MRI techniques such as T2 weighted short T1 inversion recovery imaging (STIR) reveal areas of 
inflammation and oedema in muscles as yet not affected by fatty replacement (Mercuri et al., 
2007). In later stages of the disease, fatty replacement of the muscles almost eliminates all 
appearances of normal muscle.  
Care standards for DMD suggest that management is multidisciplinary (Birnkrant et al., 2018a, 
Birnkrant et al., 2018c, Birnkrant et al., 2018d). Physiotherapy, occupational therapy and 
educational services are important to involve from an early age (Bushby et al., 2010b). Cardiac 
review is recommended annually over the age of ten, with those under the age of ten 
recommended every two years (Birnkrant et al., 2018a). Respiratory function is reviewed at least 
annually, with non-invasive ventilation (NIV) recommended once forced vital capacity (FVC) falls 
below recommended levels, or the patient becomes symptomatic of nocturnal hypoventilation 
(Bushby et al., 2010b, Birnkrant et al., 2018a).  
Corticosteroids are the current recommended treatment for DMD. Beneficial effects of steroids 
have been shown even after loss of ambulation on respiratory and cardiac function (Matthews et 
al., 2016). To date, Translarna is the only UK licenced treatment which is specific to DMD with 
nonsense mutations. Eteplirsen has been approved by the Food and Drug Administration in the 
United States. With the advent of standards of care, current supportive treatments and 
corticosteroids, the course of DMD has changed over the past twenty years. Life expectancy has 
improved from 14.4 years in the 1960s to 25.3 years in the late twentieth century (Passamano et 
al., 2012).  
 
1.2.2 The mdx mouse model 
The mdx mouse is the best characterised and most widely used animal model of DMD. It has a point 
mutation within exon 23 of the Dmd gene, which leads to a premature stop codon. Other animal 
models of DMD include: piscene, rodent, feline, porcine, and canine (Bassett and Currie, 2003, 
Winand et al., 1994, Kornegay et al., 2012, Larcher et al., 2014, Klymiuk et al., 2013). The mdx 
mouse model has advantages over the majority of these other animal models, including speed of 
reproduction and overall cost. The average life span of an mdx mouse is reduced to over 20 months, 
compared to control mice (average life span over 25 months) (Chamberlain et al., 2007). Muscle 
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pathology is most pronounced in the first 3-4 weeks of life, with corresponding high serum CK levels 
(Collins and Morgan, 2003). Histological appearances are highly variable between mice but display 
diffuse extra cellular fibrosis with little adipose tissue deposition. The mild phenotype of mdx mice 
may be due to the relatively small housing environment, which reduces physical activity (Collins 
and Morgan, 2003).  
 
1.2.3 Becker muscular dystrophy 
BMD was identified in a paper in 1955 by Dr Peter Emil Becker, a German neurologist, psychiatrist 
and geneticist (Becker, 1955). Building on knowledge from an earlier family described in a 
publication with similar symptoms, he diagnosed a milder form of the X-linked DMD (Kostakow and 
Derix, 1937). In BMD, the DMD gene has in-frame deletion, allowing production of a truncated 
dystrophin protein. The truncated dystrophin protein imperfectly cushions the mechanical forces 
caused by myocyte contraction. Over time, myocytes go through the same pathophysiological 
processes as seen in DMD. Some studies have suggested that the severity of the phenotype of BMD 
is dependent on the location of the mutation in the DMD gene (Nicolas et al., 2015, Kaspar et al., 
2009).  
BMD is less common than DMD, with a suggested point prevalence of 7.29 per 100,000 population 
(Norwood et al., 2009a). BMD shows an incidence of 1 individual per 30,000 male births. In contrast 
to LGMDs, there isn’t thought to be a significant ethnic variation in terms of prevalence (American 
Academy of Pediatrics, 2005).  
Motor symptoms commence at 11-12 years old on average, but with a wide age range (van den 
Bergen et al., 2014). Proximal muscle weakness, myalgia, difficulty in ascending stairs and exercise 
intolerance are common presenting complaints. Pseudo-hypertrophy of the calf muscles may be 
seen, and Gower’s sign is often positive. Progression of weakness causes loss of ambulation at, on 
average, 27 years of age. Respiratory muscles are involved variably and deficiency may be 
progressive; respiratory failure may require NIV in the minority of patients. Cardiac dysfunction 
does not necessarily correlate to severity of skeletal muscle involvement, and can be very severe. 
Throughout their lives cardiac dysfunction has been suggested to be prevalent in up to 70% of 
patients with BMD (Nigro et al., 1995, Petri et al., 2015, Finsterer and Stöllberger, 2008).  
Similar to DMD, CK, LDH and LFT are commonly raised. The diagnosis of BMD is confirmed by 
identification of an in-frame mutation within the DMD gene on molecular genetic testing (Bushby 
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et al., 2010a). Muscle histology and muscle MRI show broadly similar results to DMD though 
typically less severe.  
There are only supportive treatments available for BMD, corticosteroids may have beneficial effects 
but are not routinely given due to side effects. Prevalence of cardiac dysfunction has been variably 
reported from 33-100% of patients throughout their lives; the most widely quoted prevalence is 
70% (Nigro et al., 1995, Petri et al., 2015, Finsterer and Stöllberger, 2008). Unlike other muscular 
dystrophies, cardiac pathology is not necessarily related to the level of ambulation, with cardiac 
involvement the most common cause of mortality in BMD (Finsterer and Stöllberger, 2008). There 
is a wide variation in the progression of cardiac fibrosis within patients with BMD. Angiotensin 
converting enzyme inhibitors, beta blockers, mineralocorticoids and diuretics are the mainstays of 
treatment. In severe cases, left ventricular (LV) assist devices and cardiac transplantation have been 
performed with positive outcomes (Hollander et al., 2016, Wu et al., 2010).       
 
1.2.4 Limb girdle muscular dystrophy 
Limb girdle muscular dystrophy is an umbrella term used to denote a group of rare, autosomally-
inherited diseases. The LGMD were first characterised in a seminal paper by Walton and Natrass in 
1954 (Walton and Nattrass, 1954). To date, over thirty sub-types of LGMD exist (Pegoraro and 
Hoffman, 1993). Recessively inherited cases make up the majority of LGMDs. Consensus on the 
nomenclature and classification of the LGMD was formalised in 1995, with a number assigned 
depending on mode of inheritance, 1 is dominant or 2 for recessive; a letter is then added in order 
of discovery (Figure 2) (Bushby, 1995). A recent European neuromuscular centre workshop has 
revisited the definition and classification. Subtypes are categorised with the character R or D 
depending on whether the condition is recessive or dominant respectively, a number is then added 
in order of discovery. The related protein is included in the name (Straub et al., 2018).  
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Figure 2. A depiction of the sarcolemma and LGMD subtypes associated with a defect in each protein. Modified to 
include the new classification from Murphy et al. (Murphy and Straub, 2015). 
  
Overall prevalence of LGMD worldwide has been estimated to be 1 in 14,500-45,000 (van der Kooi 
et al., 1996, Norwood et al., 2009a). LGMD displays wide variation in prevalence between 
ethnicities, and it has been suggested that this may be due to founder mutations (Hicks et al., 2011, 
Norwood et al., 2009b, Emery, 1991, Walter et al., 2004a). Some of the most recently identified 
LGMD subtypes have only been described in one to two families worldwide (Preisler et al., 2013, 
Chardon et al., 2015). 
LGMDR9 is one of the most common subtypes in northern Europe. Norwood et al. estimated that 
in the UK, of all of the LGMD subtypes the most common is LGMDR1 (26.5%), then LGMDR9 (19.1%) 
(Norwood et al., 2009b). LGMDR9 has an estimated prevalence of 0.43 per 100,000 in the UK 
(Norwood et al., 2009b).  
The Fukutin-Related Protein (FKRP) gene was first discovered by Brockington et al. in 2001 
(Brockington et al., 2001). FKRP has been implicated in the glycosylation of α-dystroglycan and is 
expressed in several tissues including skeletal and cardiac muscle, with several other tissues also 
containing this protein - however to a much smaller degree. Glycosylation is the process of adding 
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carbohydrates to proteins; glycosylation of α-dystroglycan through the addition of glycans allows 
multiple points of bonding and therefore greater structural support between the extracellular 
matrix (ECM) and the myocyte (Awano et al., 2015). Glycans have many possible structural 
configurations. Alpha-dystroglycan is a subtype of glycans known as an ‘O-glycan’. Alpha-
dystroglycan binds to important proteins such as laminin, perlecan, neurexin and agrin (Kanagawa 
et al., 2016).  
Kanagawa et al. suggested that FKRP works in tandem with Fukutin protein to produce Ribitol-5 
Phosphate, a substance essential in functional maturation of α-dystroglycan (Kanagawa et al., 
2016). FKRP has been found within the Golgi apparatus and the rough endoplasmic reticulum and 
is present at the cell membrane (Beedle et al., 2007). FKRP modifies α-dystroglycan by addition of 
terminating glycans, thus stabilising the dystrophin-glycoprotein complex (Kanagawa et al., 2016, 
Beedle et al., 2007).  
The most common mutation within the FKRP gene LGMDR9 population is the c.826C > A, 
p.Leu276Ile (L276I) (Walter et al., 2004a). Compound heterozygous mutations cause a more severe 
phenotype and have been likened in severity to the course of DMD (Sveen et al., 2006, Richard et 
al., 2016). Reported frequency of mutant alleles in Europe is estimated to be 1 in 200-600 (Sveen 
et al., 2006, Brockington et al., 2001, Walter et al., 2004b). Compound homozygous presentation is 
typically within the first decade of life, with ambulation lost during the second decade. In contrast 
to homozygous mutations cardiac involvement is seen in almost all patients, with respiratory 
support needed in almost all by the age of 30 (Richard et al., 2016, Poppe et al., 2004). 
Since the most common mutation within the FKRP gene is L276I, description of the clinical 
presentation will focus on this genotype.  
LGMDR9 can present between 2 to 40 years old, with the mean reported age of presentation with 
skeletal muscle weakness is at 15.2-18.0 years (Sveen et al., 2006, Poppe et al., 2004). The most 
common symptoms include proximal muscle weakness, myalgia, and exercise intolerance. One 
study suggested that in 45% of patients, initial onset of symptoms was proceeded by a viral illness 
(Richard et al., 2016). LGMDR9 affects the skeletal, respiratory, and cardiac muscles. Muscular 
weakness is progressive over the course of several years. Calf hypertrophy is evident in 66% of 
patients, with eventual loss of ambulation in an estimated 22% of patients (Sveen et al., 2006, 
Richard et al., 2016). Progression of muscular weakness has not been shown to correlate 
necessarily to respiratory or cardiac severity (Poppe et al., 2004, Petri et al., 2015, Richard et al., 
2016). 
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Respiratory involvement is often variable but frequently progressive. One study suggested that 
above the age of twenty, predicted FVC drops by 6-20% over five years (Poppe et al., 2003). A 
relatively small proportion (5%) of patients require respiratory support (i.e. NIV) (Sveen et al., 
2006).  
There are significantly fewer studies investigating LGMDR9 cardiac dysfunction, and the 
development of fibrosis remains comparatively poorly characterised (Rosales et al., 2011, Petri et 
al., 2015). Poppe et al. suggested that cardiac involvement may be present in 38% of patients, with 
onset of cardiomyopathy seen most commonly after the third decade of life (Poppe et al., 2003). 
Onset of cardiomyopathy may be present in childhood (Rasmussen et al., 2014, D'Amico et al., 
2008), and this demonstrates the importance of cardiac surveillance, which is recommended 
annually (Rasmussen et al., 2014). Treatment of cardiac manifestation secondary to LGMDR9 is 
based on the same principles and medication as for BMD. There have been isolated case reports of 
patients with LGMDR9 requiring surgical intervention for cardiac disease (D'Amico et al., 2008). It 
is not known whether the prognosis of LGMDR9 is dependent on cardiac involvement in the same 
way as in other NMDs (Eagle et al., 2002, Finsterer and Stöllberger, 2008).  
Serum CK activity is between 10-20 times the upper limit of normal. Muscle MRI has an important 
utility in aiding differentiation between types of muscular dystrophies. The pattern of LGMDR9 
muscle involvement does depend on the progression of the disease, with early involvement of the 
gluteus maximus, adductor magnus and biceps femoris (Wattjes et al., 2010, Willis et al., 2014). In 
the thigh the ST and SM muscles are also more commonly affected. The RF and vastus lateralis (VL) 
muscles are affected later in the disease, with the Sar and the Gr muscles reportedly relatively 
spared (Wattjes et al., 2010, Willis et al., 2014). In the calf, diffuse changes are seen in the GCN and 
Sol muscles. Eventually these become severely affected, with the tibialis anterior (TA) muscle 
relatively spared (Wattjes et al., 2010, Willis et al., 2014). 
There is evidence of differences in manifestations of LGMDR9 along gender lines. Studies have 
found differences in patterns of muscles affected on MRI (Willis et al., 2014). The speed of 
ambulatory decline and cardiac involvement have been suggested to be less severe in affected 
females (Poppe et al., 2004).   
Diagnosis may be suspected following a muscle biopsy with pathological levels of α-dystroglycan, 
though findings may be variable (Rasmussen et al., 2014). Genetic confirmation of mutations within 
the FKRP gene is diagnostic.  
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1.3 Conclusion 
Research into muscular dystrophies has burgeoned; with several therapeutic avenues to be 
explored there is a pressing need for appropriate clinical outcome measures. Muscular dystrophies 
represent a cohort with unique challenges for the design of clinical trial outcome measures. 
Although functional assessments are the most commonly used primary outcome measure for 
therapeutic trials, quantitative MRI has several potential advantages in its ability to evaluate 
different hallmarks of muscular dystrophy non-invasively. This PhD explores several novel methods 
of how quantitative MRI can be used as an outcome measure for clinical trials.  
Three forms of muscular dystrophy are described within this chapter, the most severe of which is 
DMD. BMD and LGMDR9 are often considered together in studies due to their phenotypic 
similarities. To date, few studies have investigated clinical outcome measures in the slowly 
progressive BMD or LGMDR9.  
 
1.4 Aims 
The overall aim of this thesis is to evaluate novel methods of quantification of the pathology of 
muscular dystrophy and to apply existing methods to a muscular dystrophy cohort.  
Chapter-specific objectives are detailed below. 
1. Quantification of fibrosis via a collagen-specific contrast agent: The first objective is 
threefold: firstly, to assess whether the novel collagen-specific contrast agent (EP3533) can 
be used to quantify the different levels of fibrosis found within control (BL10) and mdx mice 
cardiac and skeletal muscles. Secondly, to correlate skeletal muscle signal post-EP3533 to 
histological methods of fibrosis quantification. Thirdly, to use EP3533 to investigate 
whether fibrosis can be quantified and used to monitor disease progression in response to 
administration of an established anti-fibrotic (halofuginone).  
2. To apply Dixon fat fraction (FF) quantification to a LGMDR9 cohort over a six year period. 
To compare this to how functional assessments can detect disease progression and to 
evaluate the most sensitive muscle groups or compound muscle groups, for analysis.  
3. The third objective is to quantify the extracellular volume (ECV) for the measurement of 
fibrosis in cardiac muscle of patients with LGMDR9 and BMD. Comparing the ECV in 
different segments of the heart and correlating these to other methods of detecting global 
cardiac dysfunction such as left ventricular mass (LVM), left ventricular ejection fraction 
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(LVEF), measurements of cardiac strain, presence of late gadolinium enhancement (LGE), 
and wall motion abnormalities (WMA). To perform a preliminary evaluation of ECV as a 
measure of cardiac disease progression with reference to cardiac indices.  
4. To evaluate accelerated imaging in the acquisition of LV indices in muscular dystrophies 
using Bland Altman analysis compared to conventional imaging techniques. The second 
objective is to assess whether LV indices and measures of strain and torsion significantly 
change over a five year period in a LGMDR9 group.  
 
1.5 Hypotheses 
1. Administration of EP3533 will cause a quantifiable change in signal to noise ratio (SNR) and 
R1 change within skeletal and cardiac muscle. 
2. Quantification of fibrosis ex vivo demonstrates a statistically significant correlation with R1 
change post-EP3533 administration in cardiac and skeletal muscles. 
3. EP3533-derived R1 values will be able to quantify differences in disease progression 
following a 12-week administration of an established anti-fibrotic (halofuginone) compared 
to untreated mice.  
4. In a LGMDR9 cohort there will be significant increases in skeletal muscle fat content from 
baseline to six years.  
5. MRI measurement of FF is more sensitive to disease change compared to standardised 
functional assessments over six years. 
6. ECV values will be higher in cardiac segments in BMD and LGMDR9 cohorts compared to 
control participants.    
7. Segmental and global measurements of ECV correlate with other methods of detecting 
cardiac dysfunction such as ejection fraction, LGE, WMA, and cardiac strain and torsion. 
8. Accelerated imaging demonstrates no significant bias in LV indices compared to 
conventional imaging with clinically acceptable LOA.  
9. The accelerated imaging technique employed has a greater level of agreement with the 
conventional imaging technique compared to other studies utilising similar accelerated 
imaging techniques. 
10. LV indices and measures of strain and torsion significantly decline over a six year period in 
a LGMDR9 group.  
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Chapter 2: Outcome measures in muscular dystrophy 
 
2.1 Introduction 
There are several putative therapies in development for the treatment of muscular dystrophies. 
Translarna is the only disease-specific medication currently licenced in the UK for the treatment of 
a muscular dystrophy, with therapy aiming to slow clinical deterioration (Haas et al., 2015). 
Therapeutic approaches include exon skipping (Clinical Trials.gov, 2017, Mendell et al., 2016, 
Charleston et al., 2018), gene therapy (Clinical Trials.gov, 2018d), myostatin inhibition (Clinical 
trials.gov, 2018b), histone deactylase inhibition (Clinical trials.gov, 2018a), and anti-fibrotics 
(Clinical Trials.gov, 2016, Kirschner et al., 2010, Buyse et al., 2015, Raman et al., 2015, Udelson et 
al., 2010). The pathology of muscular dystrophies has several hallmarks which may be used to 
demonstrate disease progression as an outcome measure or be targeted as a therapeutic avenue. 
A good outcome measure is repeatable, minimally invasive, has low inter and intra-observer 
variability, is clinically relevant, and sensitive to disease fluctuations over the short and long term. 
In the context of the slowly progressive muscular dystrophies, clinically meaningful outcome 
measures can be insufficiently sensitive to disease progression over short periods of time.  
Muscle biopsy is used to quantify dystrophin in clinical trials targeting production of dystrophin 
(Charleston et al., 2018). Whilst muscle biopsy and subsequent histology allows measurement of 
dystrophin and can quantify other disease processes such as fibrosis (Beekman et al., 2018, 
Beekman et al., 2014, Pessina et al., 2014b), the test is invasive and involves standard surgical risks 
of infection and issues specific to neuromuscular disease around general anaesthetic (Blatter 
Joshua and Finder Jonathan, 2013). As pathology in muscular dystrophies is not uniform, with some 
areas of muscle affected by focal fibrosis, muscle biopsies run the risk of over- or underestimation 
of pathology. Kinali et al. assessed histology as an outcome measure against semi-quantitative MRI 
in assessing disease (Kinali et al., 2011). Muscle biopsy samples were taken from the extensor 
digitorum brevis muscle and were compared to muscle MRI findings using a semi-quantitative 
scale. The histological quantification of disease progression and fat replacement correlated 
significantly with the semi-quantitative MRI measurement (r=0.81 p<0.001, r=0.62 p<0.05 
respectively) (Kinali et al., 2011). Due to the subjective nature of semi-quantitative scales of muscle 
involvement on MRI, and significant overlap between grading of muscles, such scales have largely 
been superseded by quantitative measures (Willis et al., 2013, Willis et al., 2014, Carlier et al., 2015, 
Forbes et al., 2014, Forbes et al., 2013, Diaz-Manera et al., 2018). Regarding muscle biopsy as an 
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outcome measure, other technologies (i.e. MRI) have potential to show disease progression in a 
less invasive manner, and potentially can show disease progression over larger areas of muscle.  
The three muscular dystrophies discussed within this thesis DMD, BMD and LGMDR9 have similar 
mechanisms and hallmarks of pathology with a variable rate of progression. This chapter discusses 
the four hallmarks of muscular dystrophy pathology as detailed in the introduction (muscle fibre 
necrosis and inflammatory response, fibrosis, replacement of muscle with adipocytes and muscular 
weakness); identifying how these can be used as outcome measures, with a focus on previous work 
around methods used within this thesis. 
 
2.2 Pathology of muscular dystrophies within this thesis 
In DMD and BMD, weakness is an end-stage pathology due to reduced contractile skeletal muscle, 
increased fibrosis and adipose replacement. Dystrophin has been suggested to be analogous to a 
spring, cushioning mechanical forces during muscle contraction and reducing membrane instability. 
In the absence of fully functioning dystrophin, membrane instability leads to it becoming porous, 
allowing the influx of extracellular cations such as calcium and sodium. Changes of intracellular 
sodium concentration cause osmotic influx within myocytes (Klingler et al., 2012). Calcium overload 
occurs due to the newly established diffusion gradient, leading to mitochondrial uncoupling and 
eventual production of reactive oxygen species and acidic metabolites. Necrosis and apoptosis 
occurs within the myocyte, which in turn releases cytokines and causes further inflammation 
(Klingler et al., 2012).  Transforming growth factor beta 1 (TGF-ß1) stimulates precursor cells to 
differentiate into fibroblasts and is thought to be one of the main mechanisms by which fibrosis 
occurs in DMD and BMD. TGF-ß1 is a cytokine which signals via receptor proteins, to allow 
phosphorylation of the downstream Smad 2/3 proteins. The Smad proteins are translocated into 
the nucleus, where they bind to DNA to regulate transcription of pro-fibrotic genes. Smad 3 is a 
strongly pro-fibrotic molecule, which has been suggested to be central to TGF-ß1-mediated fibrosis 
in pathological states (Zhao et al., 2002, Bonniaud et al., 2005). 
Other inflammatory pathways include interleukin-6 release in response to increased irregular 
myocyte strain. This has been implicated in the placement of connective tissue, if not collagen 
directly. Platelet derived growth factor (PDGF), Insulin-like growth factor (IGF) and connective 
tissue growth factor (CTGF) are implicated in fibrosis formation and proliferation of myofibroblasts 
and satellite cells (Klingler et al., 2012, Wynn, 2007). Precursor myocytes are used to replace the 
damaged myocytes, and eventually the pool of satellite cells is exhausted (Rahimov and Kunkel, 
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2013). Fibro-fatty tissue increases within the ECM and replaces healthy muscle tissue (Barp et al., 
2017). 
Another possible mechanism of myocytic damage is due to vasoconstriction. Neuronal nitric oxide 
synthetase (nNOS) is important in the production of nitric oxide (NO), a powerful vasodilator.  A 
reduction in nNOS is associated with an absence of dystrophin (Bia et al., 1999). This reduces the 
concentration of NO available to the microvasculature of the muscle, and may cause 
vasoconstriction and subsequent myocyte damage (Sander et al., 2000). To lend further support to 
the role of nNOS, animal models of DMD have been shown to be ameliorated by the replacement 
of nNOS (Wehling et al., 2001).  
Central to the stability of the sarcolemma is the dystrophin-glycoprotein complex which links the 
cytoskeletal actin and the extracellular matrix. The dystrophin-glycoprotein complex is made up of 
α and β dystroglycan. An important factor in maintaining sarcolemmal membrane stability is the 
correct glycosylation of α-dystroglycan, which is modified by both N and O-linked glycosylation. 
FKRP is thought to be important in O-linked glycosylation of α-dystroglycan. Mutations in FKRP have 
been shown to reduce the molecular weight of α-dystroglycan (Esapa et al., 2002). Glycosylation of 
α-dystroglycan is also thought to be important in binding to laminin, neurexin and agrin. In 
LGMDR9, where there is an absence of functional FKRP, this leads to hypoglycosylation of α-
dystroglycan. The structural link between extracellular matrix and cytoskeleton is weakened as 
there are fewer binding sites to important extracellular matrix proteins (Vannoy et al., 2017). The 
membrane is therefore less stable and becomes porous, this then follows the same pathway as 
seen in dystrophinopathies of: influx of extracellular cations, myocytic damage and necrosis, 
inflammatory response, eventual fibrosis, adipocyte replacement of muscle, and muscular 
weakness.   
 
2.3 Pathological hallmarks of muscular dystrophies - Inflammation and somatic repair 
Inflammatory response and subsequent repair is the earliest part of the mechanism of pathology 
in muscular dystrophies. Due to the many complex pathways of inflammation and repair, 
biomarkers based upon quantity of a single protein or enzyme may not reflect the disease 
progression fully. Levels of proteins and enzyme may vary throughout the disease process or due 
to the development of comorbidities. 
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2.3.1 Therapeutic avenues related to inflammation 
Corticosteroids are the longest standing pharmacological agent aimed at amelioration of DMD 
(Bushby et al., 2010a, Birnkrant et al., 2018b). Corticosteroids reduce inflammation within muscle, 
thereby allowing more time for somatic mechanisms to repair myocytes before fibrosis and 
adipocyte replacement. A study of ciclosporin A, a targeted anti-inflammatory medication, had no 
success in a clinical trial aimed at reducing deterioration of ambulation (Kirschner et al., 2010). 
 
2.3.2 Outcome measures related to inflammation and somatic repair mechanisms 
CK is the most widely used serum biomarker used to assist in the diagnosis of DMD, with a 
specificity of 94% and sensitivity of 100% (Anaya-Segura et al., 2015). CK is raised in several 
muscular dystrophies, and therefore has limited value in differentiating between different 
muscular dystrophies. Liver enzyme tests are commonly raised in DMD; however, similarly to CK, 
levels are variable and not necessarily related to disease progression (Anaya-Segura et al., 2015). 
Several serum biomarkers for DMD have been evaluated, mostly utilising elements of the 
inflammatory cascade to detect disease progression. Previously identified biomarkers include, 
among others, micro-ribonucleic acid (Cacchiarelli et al., 2011), interleukin-17 (De Pasquale et al., 
2012), several types of serum matrix metalloproteinase (Nadarajah et al., 2011, Anaya-Segura et 
al., 2015), tissue inhibitor of metalloproteinases 1, myostatin and follistatin (Anaya-Segura et al., 
2015). Proteomics, the large-scale assessment of proteins, has been used to identify several 
biomarkers of muscular dystrophies, which may be useful in the diagnosis or in following disease 
progression (Hathout et al., 2015, Spitali et al., 2018). Further studies are required to show 
correlation to existing outcome measures; greater understanding of how the serum proteins vary 
throughout the course of the disease has potential to demonstrate multifaceted disease 
progression or amelioration. Urinary biomarkers have been identified as significantly higher in 
DMD, including urinary ferritin (Rouillon et al., 2018) and amino terminal titin fragment (Robertson 
et al., 2017). These urinary molecules may have a link to the active disease process and reflect 
muscle breakdown. Longitudinal data on urinary molecules is lacking and such factors are likely to 
vary over the course of the disease.  
Monitoring the progression of cardiac dysfunction primarily involves imaging technologies. Serum 
biomarkers such as troponins, and natriuretic peptides have been evaluated in the acute period 
and in monitoring of chronic dysfunction of several cardiac diseases (Bodor et al., 1997, Mori et al., 
2002, Doust et al., 2005). Mori et al. found that in DMD cardiac biomarkers were only raised in the 
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presence of severe heart failure (fractional shortening <15% on echocardiogram), suggesting that 
these biomarkers were not sensitive enough for early detection of cardiac dysfunction (Mori et al., 
2002). Rises in cardiac biomarkers are transient in response to myocytic damage, and have been 
used to stratify risk following acute events such as unstable angina or myocardial infarction (MI) 
(Morrow et al., 2000). In muscular dystrophies, cardiomyocyte damage is a chronic process and is 
asymptomatic until late stage heart failure (Bushby et al., 2003).   
 
2.3.3 Imaging modalities  
Most imaging technologies rely on the detection of tissue differences, due to a property of the 
tissue which alters the returning signal. To detect inflammation, the majority of imaging 
technologies rely on the detection of extracellular oedema or an increased extracellular space. 
Imaging technologies may be unable to differentiate between oedema and fibrosis unless they are 
contrast enhanced (Mavrogeni et al., 2017). 
Ultrasound scanning (USS) has been shown to be a safe, painless, quick technique which is effective 
at imaging superficial and some deep tissues. Fat and skin transmit sound and the subtle changes 
in density allow recognition of borders between layers. Bone and more dense tissues reflect almost 
all of the sound back to the transducer, producing a high intensity signal and preventing deeper 
imaging.  
USS is not widely used in the diagnosis of muscular dystrophies. Several studies have explored using 
USS as a diagnostic tool (Pillen et al., 2007, Zuberi et al., 1999, Brockmann et al., 2007), and some 
have suggested high positive predictive values of 88-91% (Brockmann et al., 2007, Pillen et al., 
2007). These studies looked at a range of neuromuscular disorders, focussing on whether USS could 
differentiate between these conditions, which may have significantly different mechanisms of 
pathology (i.e. neurogenic versus myopathic) (Brockmann et al., 2007, Pillen et al., 2007). These 
studies had only a minority of participants with muscular dystrophies; one detailed a false negative 
result in a presymptomatic participant with DMD (Pillen et al., 2007). USS as a diagnostic tool in 
muscular dystrophies may therefore have limited utility as a way to non-invasively differentiate 
between diagnoses (Pillen et al., 2007).  
USS studies in healthy children have established normal parameters for echo intensity, which 
appear to be more strongly correlated with height, weight and age than factors such as muscle 
strength (Jacobs et al., 2013). Quantification of fibrous and fatty tissues using backscatter and echo 
intensities has been trialled using semi-quantitative scales and grey scale analysis. These have been 
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shown in DMD to correlate significantly with both histological measures of fibrosis (Pillen et al., 
2009) and function (Jacobs et al., 2013, Jansen et al., 2012). Zaidman et al. suggested that skeletal 
muscle USS modalities demonstrated disease progression when functional assessments continued 
to improve in younger patients with DMD (Zaidman et al., 2015). USS has been evaluated 
longitudinally as an outcome measure, demonstrating progressive increases in muscle echo-
intensity under the age of 12 years. Echo intensity after this age reached a plateau and did not 
increase further, potentially due to extensive replacement of muscle by fibrosis and adipose tissue 
(Jansen et al., 2012). USS therefore has several advantages as an outcome measure: it is readily 
available, cheap and non-invasive. Several studies have suggested limited utility in diagnosis, and 
higher signal has been correlated to disease progression over time (Jacobs et al., 2013, Jansen et 
al., 2012). Unlike contrast-enhanced MRI, it lacks specificity for the disease processes and may 
reflect oedema rather than fat or fibrosis. There may also be a limit to the use of USS as an outcome 
measure longitudinally over 12 years of age, which may be due to the muscles examined – however 
further studies are required to confirm this (Jansen et al., 2012).  
It is possible to ascertain the biochemical composition of tissue using magnetic resonance 
spectroscopy (MRS), and thereby assess skeletal muscle metabolism. MRS uses the properties of 
different metabolites to display unique resonances at different chemical shifts within a magnetic 
field. The chemical shift is used to discern different metabolites as each molecule appears at a 
different point along the x axis (measured in parts per million). Metabolites of interest include: 
creatine, phosphocreatine (PCr), phosphodiesters, and lipids.(Lamb et al., 1999, Canese et al., 2016, 
Kim et al., 2016).  
Several studies have used MRS to investigate muscular dystrophies (Arpan et al., 2014, Carlier et 
al., 2016, Crilley et al., 2000, Hollingsworth et al., 2013b, Wary et al., 2015, Barnard et al., 2018), 
and abnormalities in MRS metabolites have been detected in patients with DMD, BMD, carriers of 
dystrophin mutations and LGMDR9 (Kemp et al., 1993, Hollingsworth et al., 2013b). Lower total 
amounts of certain phosphate-based compounds have been suggested to be due to loss of healthy 
muscle and replacement with fibro-fatty tissue (Carlier et al., 2016). Phosphodiesters and inorganic 
phosphate have been shown to be higher in dystrophic muscle, in the case of inorganic phosphate 
this may be due to a porous membrane with insufficient homeostatic mechanisms (Wary et al., 
2012, Hooijmans et al., 2017). Altered ratios of metabolites such as PCr and adenosine triphosphate 
(ATP) have been found in dystrophic skeletal and cardiac muscle (Wokke et al., 2014a, Cui et al., 
2015a). This has been found earlier in disease than other measures of dysfunction or fibrosis but 
have poor correlation to measurements of function and disease progression (Hollingsworth et al., 
2013b, Crilley et al., 2000, Kim et al., 2015, Lodi et al., 1997). Changes in MRS metabolites have 
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been shown in DMD in response to corticosteroid therapy (Arpan et al., 2014), exon skipping (Le 
Guiner et al., 2014) and loss of ambulation (Wary et al., 2015). One study showed spectral 
abnormalities in BMD prior to detectable fat replacement, suggesting that MRS may be sensitive 
to early stages of the disease process (Wokke et al., 2014a). As with other biomarkers based on 
early pathology there is likely to be significant intra-subject variability in metabolite levels over time 
and volume of remaining functional muscle.  
 Some studies have suggested that native T1 weighted imaging is able to demonstrate disease 
pathology when comparing healthy controls to participants with muscular dystrophies in both 
cardiac and skeletal muscle (Fatehi et al., 2017, Florian et al., 2014c, Garrood et al., 2009, Soslow 
et al., 2016). Native T2 measurement has been extensively examined in muscular dystrophies, and 
is linked to fat replacement; this has been shown to significantly correlate to functional 
assessments (Kim et al., 2010, Kim et al., 2015, Willcocks et al., 2014, Wansapura et al., 2010, 
Mankodi et al., 2017). Native T1 and T2 measurement lacks specificity to the disease process 
reflecting overall pathology and oedema. 
Diffusion weighted imaging (DWI) is a technique which has been used to demonstrate diffusion of 
water molecules and to evaluate structural changes in skeletal muscle fibres and has been linked 
to injury and repair (Zaraiskaya et al., 2006, Anneriet and Bruce, 2007). DWI metrics in skeletal 
muscle have been shown to correlate to a significant degree to functional measures and MRI 
calculated FF (Ponrartana et al., 2015, Li et al., 2016). It has been suggested that DWI can be 
affected by muscular lipid replacement due to fat-related artefacts and the low self-diffusion 
coefficient of lipids compared to water, which may reduce the accuracy of DWI in reflecting 
myofibre structure (Williams Sarah et al., 2013, Ponrartana et al., 2015). 
Murine studies have suggested that sodium entry in mdx myofibers is higher than in controls (Hirn 
et al., 2008). Sodium-based MRI has been piloted, showing significantly higher signal intensity of 
intracellular sodium in skeletal muscle in individuals with DMD compared to healthy volunteers 
(Weber et al., 2011). To date, no large scale studies have investigated the use of sodium imaging; 
however initial studies have suggested potentially important features of the nature of muscular 
oedema (Weber et al., 2011). 
Contrast-enhanced MRI may be able to infiltrate skeletal muscle in the presence of sarcolemmal 
damage or necrosis in animal models of DMD (Thibaud et al., 2007, Amthor et al., 2004). Garood et 
al. used a non-specific gadolinium (Gd) agent to attempt to quantify differences between normal 
and corticosteroid treated participants with DMD, further evaluating Gd enhancement post-
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exercise. The relatively spared TA muscles were the only muscles to show a significant increase in 
enhancement post-exercise (Garrood et al., 2009).    
Binding of Gd directly to monoclonal antibodies allows targeting of a specific protein (Boros et al., 
2015, Caravan, 2006). A Gd-based probe with moderate affinity to albumin was evaluated by 
Lauffer et al. (Lauffer et al., 1998). Some preclinical studies have investigated an albumin-targeted 
contrast probe in dystrophic muscle. The albumin-specific contrast probe was able to diffuse into 
areas of tissues with damaged membranes (Amthor et al., 2004, Straub et al., 2000). Such probes 
were able to be used to detect fibre damage, and showed increases in signal intensity in several 
muscles. The authors of these studies suggested that probes of this type could be used as outcome 
measures or, with modification, as a therapeutic vector (Amthor et al., 2004, Straub et al., 2000). 
Another study, using a discrete targeted multimer agent, attempted to identify extracellular 
deoxyribonucleic acid (DNA) post-MI; this was potentially useful in monitoring levels of cell death 
(Huang et al., 2011). Targeted particle assembly method was used in in vivo experiments targeting 
fibrin (Flacke et al., 2001, Uppal et al., 2010). Using this method, only vascular targets are possible 
due to the relative molecular size of the Gd-based probe (Caravan, 2006). To date, none of these 
agents have been used to quantify disease progression. Such probes are reliant on myocytic 
membrane damage, which may vary over time. 
Another approach to demonstrating early pathology in dystrophic muscle uses manganese 
enhancement MRI (MEMRI). This process relies on the uptake of manganese via calcium channel 
receptors (Hu et al., 2001). Increase in manganese enhancement has been suggested to correlate 
to calcium channel influx, and therefore demonstrate inotropic effects within the heart (Hu et al., 
2001). In mdx mice, MEMRI was shown to be reduced compared to a disease model of 
sarcoglycanopathy, and was used as an outcome measure alongside functional cardiac assessment 
– though no significant difference was demonstrated between the treated and untreated groups in 
the study (Blain et al., 2013, Greally et al., 2013). MEMRI has been evaluated in vivo in skeletal mdx 
muscle as a measure of calcium influx. Loehr et al. demonstrated significant differences between 
disease and control groups in skeletal muscle, suggesting a significant correlation to function (Loehr 
et al., 2016). To date, this method has not been evaluated in humans, and carries a higher risk to 
other contrast agents as it is neurotoxic and has been shown to accumulate within the brain 
(Alaverdashvili et al., 2017).  
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2.4 Pathological hallmarks of muscular dystrophies - Fibrosis 
The term ‘fibrosis’ refers to the replacement of normal tissue with collagen and other ECM 
components. Fibrosis is a secondary process of tissue replacement following irreparable tissue 
damage (Wynn and Ramalingam, 2012). Collagen is a structural protein involved in the fibrotic 
response. Collagen is detectable within healthy organs in relatively high concentrations ranging 
from 1-20nmol/g (Neuman and Logan, 1950). Fibrosis is a prominent histological feature of human 
muscle affected by muscular dystrophies and has been suggested to have value as a prognostic 
feature (Klingler et al., 2012, Desguerre et al., 2009).   
 
2.4.1 Therapeutic avenues related to fibrosis 
Anti-fibrotic therapies have advantages over mutation-specific putative therapies, as they can be 
given to any muscular dystrophy exhibiting significant fibrosis irrespective of gene mutation. Anti-
fibrotics are commonly administered to patients with autoimmune diseases, and either have global 
immunosuppressive effects or target specific inflammatory pathways. Although in theory anti-
fibrotics could be given to any muscular dystrophy exhibiting a fibrotic phenotype, studies exploring 
anti-fibrotics in muscular dystrophies have focussed on DMD as the most common and well 
described form of muscular dystrophy. Studies have also examined models of sarcoglycan-null mice 
and suggested these phenotypes may have a more fibrotic phenotype compared to the mdx mouse 
(Gibertini et al., 2014).  
Studies using anti-fibrotics in mdx mice have aimed to reduce muscle pathology by reducing the 
pro-fibrotic molecule TGF-ß1 with mixed results (Andreetta et al., 2006, Gosselin et al., 2004, 
Gosselin and Williams, 2006, Huebner et al., 2008, Turgeman et al., 2008, Taniguti et al., 2011). 
Other anti-fibrotic compounds studied include: inhibition of PDGF (Ito et al., 2013, Huang et al., 
2009), and phosphodiesterase-5 inhibitors (Adamo et al., 2010, Leung et al., 2014, Percival et al., 
2012). Ciclosporin A (Kirschner et al., 2010), idebenone (Buyse et al., 2015), and eplerenone (Raman 
et al., 2015, Udelson et al., 2010) have been evaluated in human trials. The latter two agents 
providing significantly positive results in terms of respiratory function and cardiac function 
respectively (Buyse et al., 2015, Raman et al., 2015, Udelson et al., 2010).  
Halofuginone is a potent anti-fibrotic that  inhibits phosphorylation of Smad 3 and attenuates of 
gene expression of collagen-α1 in fibroblasts, this leads to a reduction in collagen deposition and 
reduction in fibrosis (McGaha et al., 2002, Barzilai-Tutsch et al., 2016). Inhibition of phosphorylation 
of Smad 3 promotes satellite cell survival, which is central to muscle renewal (McGaha et al., 2002, 
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Barzilai-Tutsch et al., 2016). Halofuginone is used in the treatment of inflammatory and 
autoimmune diseases (Cui et al., 2015b, Zion et al., 2009, Pines, 2014). Halofuginone has been 
trialled as an anti-fibrotic in the treatment of mdx mice with success in vivo (Turgeman et al., 2008, 
Huebner et al., 2008, Barzilai-Tutsch et al., 2016). Turgeman et al. administered halofuginone to 
mice from three weeks of age over a period of three months, demonstrating statistically significant 
improvements in measures of skeletal muscle function and laboratory measurements of fibrosis 
(Turgeman et al., 2008). Huebner et al. investigated halofuginone administered to mice above 30 
weeks of age. There was a statistically significant reduction of skeletal muscle fibrosis following 10 
weeks of treatment (Huebner et al., 2008). Beneficial effects were seen in skeletal muscle 
functional assessments, functional recovery post-exercise, and reduced susceptibility to exercise-
induced injury (Huebner et al., 2008). A clinical trial evaluating halofuginone in the treatment of 
DMD was commenced in 2016 however the trial was halted for over a year due to a serious adverse 
event, it has since restarted  (Clinical Trials.gov, 2016).  
 
2.4.2 Non-contrast-enhanced imaging of fibrosis 
MRI detection and quantification of fibrosis without contrast enhancement can be technically 
difficult, particularly in diseases with diffuse patterns of fibrosis, as found in muscular dystrophies. 
With non-contrast enhanced MRI, the aetiology of signal change is not always clear and may be 
due to inflammation, oedema or other disease processes. 
A non-contrast enhanced MRI technique, ultrashort echo time (UTE), is based upon the very short 
T2 relaxation time of collagen in skeletal muscle in response to a radiofrequency excitation pulse. 
The technique involves suppression of the longer T2 values from water and fat, as these mask the 
shorter T2 values. This technique is a promising approach to fully non-invasively quantify fibrosis; 
in vitro there was a strong positive correlation with collagen content (r=0.999 p=0.009) (Ericky et 
al., 2017). This technique has been piloted in skeletal muscle of healthy volunteers with positive 
preliminary results compared to collagen containing phantoms. It has not yet been investigated as 
an outcome measure or correlated with histology (Ericky et al., 2017). Ericky et al. highlight the 
importance of fat signal subtraction, as this will interfere with T2 values (Ericky et al., 2017). UTE is 
in its infancy and currently requires a long acquisition time. The variable and high volume of adipose 
replacement in skeletal muscle in muscular dystrophies could reduce the efficacy of this technique.  
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2.4.3 Contrast enhanced MRI of Fibrosis  
Contrast agents distinguish between different tissues that appear magnetically similar, but are 
histologically distinct (Manus et al., 2012). An ideal contrast agent would be quickly excreted, highly 
tissue specific, and at as low a dose as possible to limit toxicity (van Zijl and Yadav, 2011). 
One group of contrast agents are ‘relaxation agents’ which alter either T1 or T2 relaxation times of 
different tissues. Paramagnetic agents typically reduce relaxation time of T1 in water molecules of 
tissues where absorbed, providing a bright area termed a ‘positive contrast’.  
Gd-based contrast agents are considered to be paramagnetic (Hermann et al., 2008). Gd III complex 
with diethylenetriaminepentaacetic (DTPA) was first approved for use in clinical practice in 1988 
(Hermann et al., 2008). Most Gd-based probes are charge neutral molecules that are readily 
excreted via the kidneys. In clinical practice, Gd-based agents are used with caution in the extremes 
of age (<1 year or >65 years old); this is because of the risk of reduced excretion due to impaired 
kidney function. Gd molecules are chelated in clinical contrast agents to reduce toxicity.  
Non-specific Gd contrast agents are routinely used in cardiac magnetic resonance imaging (CMRI) 
to delineate fibrosis. The seven unpaired electrons of the Gd ion lead to a reduction in T1 relaxation 
times of the protons of nearby water molecules. Gd readily diffuses out of the capillaries into the 
extracellular space of the cardiac tissue but is unable to cross an undamaged healthy membrane. 
Both healthy and abnormal myocardial tissue accumulates contrast agent in the extracellular space. 
Contrast between healthy and remodelled tissue is due to a combination of altered kinetics and an 
increase in the volume of the extracellular space in unhealthy tissue (Weinmann et al., 1984, Moon 
et al., 2013). To determine the correct inversion time to null healthy myocardium, an inversion 
recovery sequence is performed. This sequence involves a series of images at different T1 values. 
The series of images can be chosen based upon which visually demonstrates nulled myocardium. 
LGE is dependent on fibrotic or damaged tissue having a slower efflux of contrast agent compared 
to the nulled myocardium. Images taken 10-15 minutes post-Gd administration allow comparison 
between healthy and remodelled tissues. Recognition of LGE is usually qualitative and dependent 
on a visually detectable difference in contrast in the myocardium. Diffusely fibrotic tissue, as found 
in muscular dystrophies, may be difficult to appreciate due to the minimal contrast between 
healthy and fibrotic tissues (Puntmann et al., 2016). In spite of this limitation, LGE can enable non-
invasive, accurate detection of focal fibrosis within the heart (McCrohon et al., 2003). Animal 
studies correlating the extent of LGE in the heart to histological findings, found that LGE can 
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demonstrate the extent of fibrosis to a highly sensitive degree (Pop et al., 2013, Schelbert et al., 
2010). The ability to perform LGE is therefore a major advantage of MRI over echocardiogram 
(Wong et al., 2013). Presence of LGE has been shown to be an adverse prognostic factor for 
dysfunction, arrhythmia and death in several conditions, including non-ischaemic cardiomyopathy 
(Wu et al., 2008b, Kuruvilla et al., 2014, O'Hanlon et al., 2010, Gulati et al., 2013, Pozo et al., 2016, 
Shin et al., 2016, Schelbert et al., 2015). LGE can demonstrate cardiac dysfunction in DMD before 
functional parameters have declined (Ashford et al., 2005).  
Other than the previously mentioned drawback around diffuse fibrosis, quantification of LGE is a 
controversial topic. This is due to uncertainty around baseline measurement of remote 
myocardium; areas of myocardium not adjacent to the area of cardiac disease, which may be 
remodelled or affected due to altered cardiac dynamics. Attempts to standardise quantification 
recommended a cut off of >2 standard deviations from the mean signal intensity in healthy 
myocardium (Kramer et al., 2008); however, this is not widely accepted, with other studies using 
other cut offs for quantification. One study compared seven different methods, including visual 
interpretation. These methods yielded significantly different results (Flett et al., 2011). The most 
variability was seen with hypertrophic obstructive cardiomyopathy (HCM), which, of the diseases 
included, is the most similar to the dystrophic heart in terms of fibrosis (Flett et al., 2011). The 
authors posited that the most reliable method was the full width at half maximum method, which 
measures maximal signal intensity and includes all contiguous regions where signal is at least 50% 
of this (Amado et al., 2004, Flett et al., 2011). Controversy over this and other methods continues; 
several studies in muscular dystrophies use segmental LGE as a dichotomous variable (Giglio et al., 
2014, Florian et al., 2014a, Florian et al., 2014c, Raman et al., 2015).    
ECV is calculation of the extracellular compartment volume using T1 mapping to measure T1 
relaxation times pre and post-Gd contrast within each voxel of the myocardium and the LV blood 
pool (aus dem Siepen et al., 2015). Intracellular compartments are dominated by myocyte mass 
while the extracellular compartment contains ECM and connective tissue. An increase in this 
extracellular compartment is likely to reflect an increase in interstitial fibrosis (Moon et al., 2013, 
Bull et al., 2013). Increase in ECV may be non-specific to fibrosis and could be influenced by the 
presence of oedema. Studies have, however, attempted to validate ECV histologically by looking at 
myocardial biopsies, these demonstrated significant correlations ranging from r=0.55-0.98 (Flett et 
al., 2010, Miller et al., 2013, White et al., 2013, Fontana et al., 2012). Increases in ECV may have a 
negative prognostic value in cardiac disease (Wong et al., 2012, Wong et al., 2013). ECV has been 
associated with earlier detection of fibrosis than LGE (Wong et al., 2012, Kellman et al., 2012, 
Schelbert et al., 2011, Tham et al., 2013). This technique has also been used as an outcome 
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measurement providing quantification of fibrosis (Moon et al., 2013, aus dem Siepen et al., 2015, 
Daniel et al., 2006, Kawel et al., 2012).  
In ECV quantification, the difference between T1 values pre and post-contrast agent allows a 
measurement of the distribution volume of Gd. This allows calculation of the relaxation rate (R1), 
the reciprocal of T1, which is proportional to Gd concentration. Calculation of ECV requires 
equilibrium of the concentration of contrast agent between myocardium and the blood pool. 
Originally this was achieved by using a bolus of the contrast agent, followed by a slow infusion 
(Miller et al., 2013, Everett et al., 2016). Due to the increased duration of an infusion and 
subsequent acquisition, this has been replaced by a Gd bolus. Equilibrium between tissues is 
assumed 15-20 minutes after a bolus of contrast agent (Miller et al., 2013, Everett et al., 2016). T1 
mapping values are obtained from a series of images at a number of inversion times following an 
inversion recovery imaging experiment, with cardiac gating used to enable acquisitions at identical 
time points within the cardiac cycle. 
ECV is quantified by selecting a region of interest (ROI) and calculating the average T1 value within 
the ROI in both enhanced and native acquisitions. The difference in the reciprocal of these values 
(i.e.ΔR1) is divided by the difference in values of the blood pool to give the partition coefficient, 
which is then corrected for the patient haematocrit (Hct) to yield the ECV, as demonstrated in 
equation 1. The concentration of Gd within cardiac tissue is calculated using equation 2.  
 
𝐸𝐶𝑉 = (1 − 𝐻𝑐𝑡) × ( 
(1 𝑇1𝑚𝑦𝑜 𝑝𝑜𝑠𝑡⁄
) − (1 𝑇1𝑚𝑦𝑜 𝑝𝑟𝑒⁄
)
(1 𝑇1 𝑝𝑜𝑠𝑡 𝑏𝑙𝑜𝑜𝑑⁄
) − (1 𝑇1 𝑝𝑟𝑒 𝑏𝑙𝑜𝑜𝑑⁄
)
 )                                        (1) 
 
𝑅1𝐺𝑑 = 𝑅1𝑃𝑟𝑒−𝐺𝑑 + 𝑘[𝐺𝑑]           (2) 
 
Where k is the T1 relaxivity of Dotarem at 3T (Guerbet, France) (3.89mm-1s-1) (Vander Elst et al., 
2013). 
There is a wide range of values of ECV in healthy tissue. The highest values considered normal are 
in the range 0.23-0.27 (Sado et al., 2012, Banypersad et al., 2013, Radunski et al., 2014, Ugander et 
al., 2012, White et al., 2013, Florian et al., 2014b) (Table 1).  
A 
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Several studies have reported a global ECV measurement, using a single or an averaged ROI value 
for the left ventricle (Sado et al., 2012, Ugander et al., 2012, Banypersad et al., 2013, Radunski et 
al., 2014). This approach may take account of the diffuse nature of fibrosis in these cohorts, but 
may give falsely normal results if there are areas of focal fibrosis surrounded by normal tissue, as 
seen in some conditions (i.e. acute MI).  
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Author Disease Mean control ECV values Mean abnormal values Significant correlations 
(Sado et al., 2012) Anderson-Fabry, 
DCM, HCM, MI, AS, 
Amy 
0.253 ±0.035 
 
Male 0.273 ±0.029 
Female 0.233 ±0.029 
DCM 0.25 ±0.004 
HCM 0.291 ±0.005 
AS 0.276 ±0.044 
MI 0.585 ±0.076 
Amy 0.466 ±0.076 
DCM and Amy displayed 
significant correlation to EF. 
Control, DCM, and Amy 
correlated to LV mass. 
(Ugander et al., 2012) MI 0.27 ±0.081 0.36 ±0.022 EF 
(Banypersad et al., 2013) Amy 0.254 0.4 LV mass, EF, 
(White et al., 2013) DCM, HCM, MI, AS, 
Amy 
  High values (>0.4) correlate with 
histological values 
(Radunski et al., 2014) Myocarditis 0.25 (range 0.24-0.27) 0.31 (range 28-34)  
(Florian et al., 2014b) BMD 0.24 ±0.005 0.29 ±0.0174 EF 
(aus dem Siepen et al., 2015) DCM 0.23 ±0.03 0.25 ±0.04 Early 
DCM, >0.27 ±0.04 
established DCM 
Weak correlation with EF 
(Olivieri et al., 2017) DMD 0.26 ± 0.33 0.279 ± 0.058 Native T1 
Table 1. To show previous findings of reported ECV values in different diseases for reference. Values given as mean and standard deviation unless otherwise stated. Key: DCM, Dilated 
cardiomyopathy, HCM, hypertrophic obstructive cardiomyopathy, MI, myocardial infarction, AS, Aortic stenosis, Amy, Amyloidosis, EF, Ejection fraction, LV, left ventricle, LGE, Late 
gadolinium enhancement, BMD, Becker muscular dystrophy, DMD, Duchenne muscular dystrophy. 
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2.4.4 Molecule-specific contrast agents - Focus on EP3533 
Gd-based contrast agents with an affinity to target molecules have also been developed but are not 
currently used in clinical practice (Amthor et al., 2004, Caravan et al., 2007, Caravan et al., 2013, Farrar 
et al., 2015, Fuchs et al., 2013, Helm et al., 2008, Huang et al., 2011, Polasek et al., 2012). EP3533 (EPIX 
pharmaceuticals, United States) is a collagen-specific contrast agent with potential for use as a 
biomarker of fibrosis in muscular dystrophies. EP3533 contains three Gd molecules with DTPA 
moieties bonded to a polypeptide with affinity for type one collagen (Caravan et al., 2007). EP3533 is 
a paramagnetic agent providing positive contrast with a molecular size of approximately 5kDa (Helm 
et al., 2008). Compared to standard Gd (DTPA), the relaxivity of EP3533 is five times higher per Gd 
atom. The high relaxivity is likely to be a result of the larger size of EP3533, which results in a longer 
correlation time (Caravan et al., 2007). The relaxivity rate of EP3533 in human plasma at 1.4T is 
15.6mM-1s-1 (Caravan et al., 2007). Similar relaxivity values of EP3533 were reported in another study 
(Helm et al., 2008).  
Caravan et al. compared EP3612, an isomer of EP3533, identical with the exception of an inverted 
cysteine group (Caravan et al., 2007). Assuming the same number of equivalent binding sites between 
the two agents, EP3533 had a dissociation constant of 1.8µM ±1, compared to the ten times higher 
dissociation constant of EP3612. This was suggested to be due to the affinity of the molecule to 
collagen. EP3533 was calculated to have a half-life of 19 minutes ±2 in both fibrotic and control 
subjects (Fuchs et al., 2013). The biodistribution of EP3533 was assessed in four mice, fifteen minutes 
after administration.. EP3533 had a higher signal intensity compared to EP3612 in organs containing 
higher levels of collagen, i.e. liver, heart, and kidneys (Caravan et al., 2007). EP3533 has a slow tissue 
washout time; in the presence of fibrotic myocardium this may be more than three hours on average 
(Helm et al., 2008). 
EP3533 has been used in murine models to identify areas of fibrosis post-MI (Helm et al., 2008), liver 
fibrosis (Fuchs et al., 2013), and pulmonary fibrosis (Caravan et al., 2013) (Table 2). In vivo studies have 
assessed the specificity of EP3533 to collagen compared to similar Gd-based contrast agents (Caravan 
et al., 2013, Polasek et al., 2012). EP3533 has also been used to accurately stage fibrotic disease (Fuchs 
et al., 2013), and to detect response to anti-fibrotic therapy (Farrar et al., 2015).  
Helm et al (Helm et al., 2008) induced MI in eight mice by occluding the left anterior descending 
coronary artery for an hour. Six weeks after the induced MI, fibrosis would be expected to be fully 
formed (Ross et al., 2002). MRI scanning took place pre-MI, at 24 hours post-MI, and at six weeks post-
MI. For comparison, a standard Gd (gadopentetate dimeglumine) contrast agent and EP3533 were 
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given intravenously. The results showed a significant difference in washout time of contrast agent in 
both the scar tissue and the normal myocardium. There was a strong correlation between 
circumferential extent of EP3533 at 40 minutes, and the levels of fibrosis as quantified by histology 
(R2=0.97) (Helm et al., 2008). 
Experiments using murine models of liver fibrosis compared EP3533, Gd (DTPA), and ex vivo 
quantification of collagen (Polasek et al., 2012). They found strong positive correlation between 
collagen as assessed by hydroxyproline quantification and Gd in liver tissues (R2=0.74-0.77). The semi-
quantitative ‘Ishak score’ and hydroxyproline quantification correlated well with the half-life of 
EP3533 in the liver; (R2=0.64-0.81) the authors suggested that EP3533 could therefore be successfully 
used to quantify liver fibrosis (Polasek et al., 2012). A further study used EP3533 to successfully stage 
liver fibrosis using SNR post-contrast (Fuchs et al., 2013). The authors also compared this to other MRI 
techniques (apparent diffusion coefficient, T1 relaxation time, T2, magnetisation transfer ratio), 
finding only a weak correlation between them and levels of fibrosis and Ishak scoring (Fuchs et al., 
2013). Assessment of fibrosis treatment response has been evaluated using EP3533 in murine models 
of bile duct ligation (Farrar et al., 2015).  
Imaging of pulmonary fibrosis has also been investigated using EP3533 and a model of pulmonary 
fibrosis (Johnson et al., 2013). Caravan et al. found that lung signal increased significantly in the mice 
using EP3533, compared to those imaged with EP3612 and a control group (p<0.0001) (Caravan et al., 
2013). Good correlation was also seen between Gd levels in the lungs and hydroxyproline 
quantification (R2=0.90) (Caravan et al., 2013).   
 
 
Author Disease model Field strength (T) Dose (µmol/kg) 
(Helm et al., 2008) Myocardial Infarction 4.7 25 
(Polasek et al., 2012) Liver Fibrosis 4.7 20 
(Fuchs et al., 2013) Liver Fibrosis 4.7 10 
(Caravan et al., 2013) Pulmonary fibrosis 4.7 10 
(Farrar et al., 2015) Bile duct ligation 1.5 10 
(Polasek et al., 2017a) Pancreatic cancer 4.7 10 
Table 2. Summary of publications assessing the use of EP3533 in detection of fibrosis in various disease models. 
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2.5 Pathological hallmarks of muscular dystrophies - Adipocyte replacement of muscle 
Fat replacement of muscle is considered an end-stage pathology of muscular dystrophies. The exact 
mechanism is unclear (Wagatsuma, 2007). Several studies have found that skeletal muscle tissue has 
adipose precursor cells and these can differentiate into full adipocytes in vitro (Sato et al., 1996, 
Hausman and Poulos, 2004). Abnormalities in serum lipid and skeletal muscle lipid metabolism have 
been reported in muscular dystrophies (Srivastava et al., 2017, Nishio et al., 1990), though it is unclear 
whether this is due to phospholipid layer breakdown of skeletal muscle, corticosteroid administration, 
or a pro-adipogenic factor.  
 
2.5.1 Imaging of adipocyte replacement of muscle 
Dixon FF measurement was first described in 1984. It exploits the chemical shift difference between 
the water and main fat resonances. It consists of two MRI images of the same anatomy with in-phase 
and out of phase echo times, giving rise to images with constructive and destructive interference of 
fat and water respectively (Dixon, 1984). Off-resonance frequency effects mean that the water images 
are contaminated by fat and the converse is true. Several studies suggested that a third measurement 
would enable quantification of the value of off-resonance frequency effects, and therefore could give 
a more accurate quantification of the FF (Ma, 2008, Glover and Schneider, 1991). The Dixon technique 
is used widely in clinical practice, both in suppressing fat signals to provide clear anatomical 
information, and in quantification of fat contained within many soft tissues (Wokke et al., 2013, 
Hetterich et al., 2015, Homsi et al., 2015). 
Skeletal muscle FF quantification has been used in several studies to correlate well with functional 
methods of assessment in both DMD and LGMDR9 cohorts (Willis et al., 2013, Wren et al., 2008, 
Fischmann et al., 2013). Changes in FF calculations over a one year period are sensitive enough to 
change for both LGMDR9 and DMD cohorts (Willis et al., 2013, Arpan et al., 2014). Several studies 
have supported quantitative FF measurement as an outcome measure in DMD and BMD (Akima et al., 
2012, Barnard et al., 2018, Burakiewicz et al., 2017, Gaeta et al., 2012, Kim et al., 2013, Willcocks et 
al., 2016b, Wokke et al., 2013, Wokke et al., 2014b, Wren et al., 2008). 
 
2.5.2 Focus on previous studies into Dixon fat fraction in LGMDR9 
In 2013, Willis et al. published the largest natural history study investigating LGMDR9 (Willis et al., 
2013). Four centres took part in the study: Newcastle University (UNEW), UK and University College 
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London, UK, The University of Copenhagen, Denmark, and the Institute of Myology, France. Willis et 
al. recruited 38 ambulant participants with the most common homozygous mutation in the FKRP gene 
(L276I). 32 out of 38 participants completed the one year follow up study, which involved both 
quantitative MRI scans and standardised functional assessments (Willis et al., 2013). The aim was to 
assess which outcome measures were able to monitor disease progression over one year.  
The standardised physiotherapy assessments included myometry of the lower limbs (knee extension 
and flexion, hip adduction and abduction), timed tests (timed up and go, six minute walk test (6MWT), 
and 10 metre walk or run, chair rise, stair climb and descend), and spirometry testing (Willis et al., 
2013). The authors used the semi-quantitative scale of muscle fat replacement on MRI published by 
Mercuri et al. to grade T1 weighted images (Mercuri et al., 2002, Willis et al., 2013), and compared 
the grade to calculation of the FF using the Dixon technique.  
Patient demographics were recorded, including the nature of first motor symptoms, cardiac and 
respiratory involvement. Of the 38 recruited initially, the age range was 18-64 years. The most 
commonly reported first motor symptoms were difficulties in climbing stairs (28%), difficulty running 
(21.1%), myalgia (21.2%) falls (10.5%) and difficulties rising from a chair (10.5%). Serum CK activity 
was measured and ranged from 222units/L to 23,858units/L. Documented cardiac involvement was 
reported in 42% of patients; with the majority males (77%), mean age of onset was 44.4 years. 
Respiratory involvement was present in 33% of participants, as indicated by less than 75% of FVC 
predicted for height (Willis et al., 2014).  
Willis et al. demonstrated that there was a significant increase in FF in nine of the fourteen muscle 
groups assessed over the twelve month period: biceps femoris long head (BFLH) (p=0.0004), ST 
(p=0.02), semimembranous (p=0.02), Sar (p=0.01), Gr (p=0.02), VL (p=0.03), RF (p=0.03), medial 
gastrocnemius (MG) (p=0.01) and the lateral gastrocnemius (LG) (p=0.01) (Willis et al., 2013). The most 
variable increase in FF for a muscle was in the ST. No statistically significant differences were seen in 
the myometry or the timed tests over the same period. Spirometry was the only functional test to 
show a significant difference over the year (p=0.001). Use of the Mercuri scale to grade T1 weighted 
images showed significant overlap between the middle grades (2a, 2b and 3), with comparatively low 
rates of inter-observer reliability (Willis et al., 2013).  
The findings of the study provided support for the efficacy of quantitative MRI as an outcome measure 
in LGMDR9. Willis et al. demonstrated that over a one year period, calculation of the FF via MRI is able 
to detect and quantify disease progression, whereas the majority of functional assessments were 
unable to demonstrate a significant difference (Willis et al., 2013). The 6MWT, the most commonly 
used primary end point in therapeutic trials in muscular dystrophy, showed a marginal increase in 
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distance walked (baseline median 312m, 1 year follow up median 353m p=0.77) (Willis et al., 2013). 
This result suggested that this test may not be appropriately sensitive to disease progression and that 
there might be an element of participants learning how to better perform the task, rather than 
improvement in ability. The study identified several muscle groups which could be targeted for 
quantitative MRI in future trials: the MG, VL, Gr, and RF muscles. These muscles were chosen based 
on variability of involvement, ease of ROI placement, and rate of disease progression (Willis et al., 
2013). The findings of this study have important implications for the design of prospective 
interventional trials into LGMDR9.     
 
2.5.3 Cross sectional area and contractile cross sectional area 
Longitudinal measurement of FF in muscle relates to increasing pathology caused by muscular 
dystrophy. Using MRI, cross sectional area (CSA) of muscle can be measured, and reflects trophicity of 
muscle tissue; in healthy individuals there is a relatively linear relationship between CSA and muscle 
strength (Maughan et al., 1983). Hypertrophy of dystrophic muscle fibres has been demonstrated on 
muscle biopsy, and increased CSA has been demonstrated in the triceps surae of individuals with DMD 
(Wokke et al., 2014b, Cros et al., 1989). A high degree of inter-muscle variation in FF and CSA suggests 
that these factors are distinct pathological processes (Wokke et al., 2014b).  
The area of muscle not taken up by fat (i.e. 1-FF) can be multiplied by the total CSA, to calculate the 
remaining contractile cross sectional area (cCSA) of a muscle. cCSA has been shown to significantly 
correlate to functional measures of strength in muscular dystrophies (Lokken et al., 2016, Wokke et 
al., 2014b, Vohra et al., 2015). The non-uniform distribution of fat throughout muscle may be 
important and is not accounted for using cCSA. This method of demonstrating advancing disease 
pathology also fails to take into account fibrotic tissue, which may alter the dynamics of muscle 
contraction. Regardless of these factors, cCSA may be able to demonstrate disease progression by 
showing loss of healthy muscle tissue rather than increased pathology.  
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2.6 Pathological hallmarks of muscular dystrophies – Progressive muscular weakness 
2.6.1 Musculo-skeletal functional assessments 
Physiotherapy assessment is readily available in many centres, and if standardised with sufficient 
training, reliability tests show high levels of inter observer correlation (Connolly et al., 2015). 
Functional assessments are the most clinically meaningful to patients and are important in 
demonstration of efficacy of therapies in clinical trials. Functional assessment has the benefit of 
including whole muscle groups, rather than individual muscles which may demonstrate significant 
variability. Drawbacks of functional testing include a dependence on age and intellectual ability, as 
well as some subjectivity due to patient effort (Alfano et al., 2014). Functional assessments may lack 
the sensitivity to detect deterioration over shorter periods of time (Willis et al., 2013).  
Manual muscle testing (MMT) using scales developed by the Medical Research Council has been used 
in clinical practice. MMT has been criticised as lacking sufficient objectivity to be an endpoint for 
clinical trials (Escolar et al., 2001). Studies have shown that MMT assessors who have reliability 
assessments regularly can demonstrate high levels of inter-observer correlation (Florence et al., 1984, 
Escolar et al., 2001). Quantitative muscle testing (QMT) using a strain gauge has also been used to test 
maximal voluntary isometric contraction. In contrast to MMT, QMT has a consistently higher inter-
observer correlation of 0.93-0.99 (Escolar et al., 2001). Criticisms of QMT include cost of equipment, 
complexity of use and the need to keep assessing repeatability to ensure accurate results (Escolar et 
al., 2001).    
The 6MWT is a standardised assessment that measures the distance a patient is able to walk 
uninterrupted over a six minute period on a flat surface (American Thoracic Society, 2002). A major 
strength of the 6MWT is that it assesses a clinically relevant function (McDonald et al., 2010). The 
6MWT has been used to assess both adult and paediatric diseases (de Groot et al., 2011, Geiger et al., 
2007, Kierkegaard and Tollbäck, 2007, Wraith et al., 2004). Results of the 6MWT have been seen to 
correlate in specific cohorts with oxygen consumption, aerobic fitness, exercise induced desaturations 
and lung function; as well as other variables such as age, height and weight (Li et al., 2005, Haass et 
al., 2000, Burr et al., 2011, Dogra et al., 2015, Chen et al., 2012). The 6MWT has been shown to be a 
reproducible, valid test in assessing function in DMD (Kempen et al., 2014). Studies have suggested a 
high test-retest reliability correlation, between 0.91-0.94 (McDonald et al., 2010, Li et al., 2005, 
Kempen et al., 2014). The 6MWT is not appropriate for children with severe learning difficulties or 
very young patients (McDonald et al., 2010). The 6MWT may be biased by multiple factors, including 
cardio-respiratory comorbidities, and motivation (Slaman et al., 2013).  
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The North Star Ambulatory Assessment (NSAA) is a validated functional assessment tool used in 
clinical practice to assess boys with DMD (Scott et al., 2012, Ricotti et al., 2015). The NSAA uses 17 
domains to assess patients and can be performed in 10-15 minutes (Mayhew et al., 2013b). The score 
was developed as a disease specific scale for use in clinical practice with potential to detect meaningful 
deterioration in ability (Scott et al., 2012, Mayhew et al., 2013b). In contrast to other neuromuscular 
scales such as the Egen Klassification, the NSAA was designed for use in ambulant patients (Steffensen 
et al., 2001). With appropriate training, the NSAA has a high inter-observer reliability score of 0.99 
(Mazzone et al., 2009). The NSAA can be criticised as it is not designed for non-ambulant patients. 
Similar to the 6MWT, the assessment would therefore not be expected to be sensitive to further 
deterioration in patients.  
 
2.6.2 Cardiac functional assessment 
In all neuromuscular diseases which affect the heart, regular cardiac surveillance is recommended 
(Bushby et al., 2010b, Romfh and McNally, 2010, Ho et al., 2016). Therapeutic trials aimed at 
amelioration of cardiac dysfunction in neuromuscular disease have used echocardiographic and CMRI 
measurements as an outcome measure (Uhlir et al., 1997, Silversides et al., 2003, Ishikawa et al., 1999, 
Duboc et al., 2005, Duboc et al., 2007, Ogata et al., 2009, Raman et al., 2015, Witting et al., 2014, 
Leung et al., 2014). Petri et al. reported the longest follow up study of LV indices in a mixed muscular 
dystrophy cohort, demonstrating that over nine years, LVEF significantly fell by 1% per year in a BMD 
cohort (n=25), and 0.4% per year in LGMDR9 (n=28) (Petri et al., 2015). Cross-sectional measures of 
strain and torsion using cardiac tagging have been reported in a LGMDR9 cohort (n=10), finding that 
peak torsion (PT) was reduced and torsion to strain ratio (TSR) was significantly lower than controls 
(Hollingsworth et al., 2013b). To date, no studies have reported cardiac tagging values in BMD or 
longitudinal changes in a LGMDR9 cohort. 
CMRI is more sensitive than echocardiogram, due to increased accuracy of functional measurement 
and the reliability of obtaining good quality images (Ashford et al., 2005, Mavrogeni et al., 2009, 
Brunklaus et al., 2015, Gardner et al., 2009, Raman et al., 2015). The slow progression of cardiac 
fibrosis in neuromuscular conditions requires sensitive outcome measures to detect change over short 
time periods. Routine CMRI to obtain cardiac indices, such as LVEF, typically involves acquisition of 
contiguous short axis slices to cover the left ventricle with a temporal resolution of 40ms with 
approximately 25 cardiac phases (Walsh and Hundley, 2007). CMRI uses retrospective 
vectorcardiogram (VCG) gating to allow for the continuous movement of the heart during the cardiac 
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cycle, and to allocate acquisitions to a predefined number of cardiac phases. To reduce respiratory 
artefact, the majority of CMRI is performed during patient breath-holding. Significant processing time 
is required during CMRI acquisitions with a typical resolution of 1.85mm x 1.54mm (reconstructed to 
1.37 x 1.37mm), and a field of view (FOV) of approximately 350 x 315mm in 12-14 slices. For the 
patient, during a typical assessment this involves repeated periods of breath holding (BH) for up to 10 
seconds each (Fratz et al., 2013).  
Reducing scan times is important in imaging of patients with neuromuscular diseases. Scoliosis and 
respiratory muscle weakness make it difficult for patients to remain supine for long periods and 
maintain breath-holds (Hull et al., 2012). Additionally, for children and those with learning difficulties, 
conventional CMRI can be uncomfortable, distressing and may require anaesthesia to produce 
sufficiently good quality images. Successful reduction in scan times may reduce burden on patients, 
free up scanner time, and potentially have financial implications. Any method that reduces acquisition 
times must however, maintain the quality of the image compared to conventional acquisition, and 
give reproducible results free of significant artefacts (Lin et al., 2016).  
 
2.6.3 Focus on reducing acquisition times for cardiac magnetic resonance imaging 
functional indices via accelerated imaging 
The time taken for MRI acquisition relies on several factors. In processing terms, the acquisition is 
complete once sufficient samples of the raw signal are collected to fulfil the Nyquist criterion (Lustig 
et al., 2008). The Nyquist criterion states that the only way to perfectly reproduce an image from an 
analogue signal is to sample at more than twice the maximum frequency of the signal. In practice, 
once the FOV and resolution of the desired MRI acquisition is chosen, then an equivalently sized matrix 
of raw (k-space) data has to be collected (Hollingsworth, 2015). 
Parallel imaging uses multiple surface coil elements to under-sample the k-space matrix in a regular 
way. The multiple receiver coils enable quicker acquisition; each of these coils is most sensitive to the 
nearby tissue, allowing spatially dependent sensitivity to be used (Hollingsworth, 2015). As it is only 
the magnitude of the MR signal not the phase that is important for cine imaging, partial Fourier 
imaging can be used to omit nearly half of the k space by taking advantage of conjugate symmetry of 
magnitude images in k-space (Hollingsworth, 2015), at the cost of a reduction in SNR (Hollingsworth, 
2015, McGibney et al., 1993, Bydder and Robson, 2005). Compressed sensing approaches are based 
upon the large amount of similarities in images through the cardiac phases, permitting a reduction in 
the amount of acquired k-space (Tsao and Kozerke, 2012). The acquisitions can be transformed into 
37 
 
sparse domains, allowing a reduction in the volume of data to be collected whilst maintaining image 
fidelity. Additionally, some investigators have reduced the amount of data that they need to collect 
by guide-point modelling techniques. Rather than collecting contiguous slices of the heart, a limited 
number of non-contiguous slices and views are collected, and an “average” heart model is applied 
based on defining a few key points on the endocardial and epicardial boundaries (Young et al., 2000, 
Young et al., 2011). These approaches have been combined with other acceleration techniques, such 
as compressed sensing (Vincenti et al., 2014). With any under sampling method, loss of fidelity 
compared to the conventional image can occur. If blending of information throughout the cardiac 
phases is present, this might result in reducing the end diastolic volume or increasing the end systolic 
volume, which would lead to inaccurate measurement of cardiac indices.  
Several different approaches have been explored to reduce CMRI acquisition times. The majority of 
studies have not established clinical validity, focussing on image quality metrics (particularly the root 
mean square error between conventional and accelerated images) rather than the effect on functional 
indices (Hollingsworth, 2015). In clinical trials, longitudinal changes in cardiac indices are important. 
Studies are lacking which assess how much bias and variability may be introduced using accelerated 
imaging techniques. Studies evaluate the presence of artefacts and preservation of LV function; these 
require definition of the epicardial and endocardial boundaries. The majority of studies utilise the 
balanced turbo field echo (TFE) sequence (a sequence with mixed T1/T2 weighted contrast). This leads 
to bright blood, mid-grey myocardium and bright epicardial adipose tissue. Although this produces 
clear endo- and epicardial boundaries in most of the cardiac phases, basal images and boundaries at 
systole may be difficult to identify. It is used because it is the most efficient sequence for collecting 
high SNR images per unit time. If the reconstruction of under-sampled data transfers too much 
information between cardiac phases, this can lead to loss of boundary definition with subsequent 
inaccuracies in the segmentation of the left ventricle, leading to inaccurate LV indices. 
 
2.6.4 Cardiac tagging 
Measures of strain and torsion using cardiac tagging have been reported in a LGMDR9 cohort (n=10), 
finding that PT was reduced and TSR was significantly lower than controls (Hollingsworth et al., 2013b). 
To date, no studies have reported cardiac tagging values in BMD or longitudinal changes in a LGMDR9 
cohort. Cardiac strain is a useful measure of myocyte movement. Strain is defined as a relative change 
in a defined linear dimension of the heart, compared to end diastole (Taylor et al., 2015). 
Measurement of myocardial strain has been shown to be a sensitive measure of cardiac dysfunction, 
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and may be more sensitive than measurement of regional wall thickening in detection of regional 
cardiac dysfunction (Gotte et al., 2001). Cardiac tissues have a complicated architecture, with sub-
epicardial fibres running obliquely in a spiral at 75°. Sub-endocardial musculature fibres run in the 
opposite orientation to the sub-epicardial at -70°, mid-wall fibres run circumferentially (MacGowan et 
al., 1997). Shortening of these fibres in various planes enables contraction of the heart; however, 
dysfunction due to fibrosis often increases measurements of torsion.  
Cardiac tagging is a technique first described by Zerhouni et al. in 1988 (Zerhouni et al., 1988), with 
subsequent refinements (Axel and Dougherty, 1989, Osman et al., 1999, Osman et al., 2001, Abd-
Elmoniem et al., 2008, Basha et al., 2009). Cardiac tagging works by the application of radiofrequency 
pulses to cancel signal from the diastolic myocardium, leaving a localised grid pattern of areas of nuclei 
excitation. Distortion of the grid pattern as the heart undergoes systole allows calculation of torsion 
and circumferential strain (Hollingsworth et al., 2013b).  
Cardiac tagging techniques have been used in muscular dystrophies. Use of cardiac tagging has been 
investigated in DMD (Hagenbuch et al., 2010b, Raman et al., 2015, Hor et al., 2009). Patterns of 
abnormal torsion have been found to be evident before global measures of dysfunction, such as 
decline in LVEF or fractional shortening (Hor et al., 2009, Hagenbuch et al., 2010a, Ashford et al., 2005, 
Rosales et al., 2011). Hollingsworth et al. investigated a cohort of patients with LGMDR9, 
demonstrating that peak cardiac torsion was significantly lower than healthy controls, with selective 
preservation of some strains. The findings showed the unusual pattern of impaired torsion and 
preserved circumferential strain, which is not reflected in studies reporting cardiac tagging in other 
cardiac disease (MacGowan et al., 1997, Hollingsworth et al., 2013b).      
 
2.7 Conclusions 
As putative therapies for muscular dystrophies move toward clinical testing, there is a need for 
minimally invasive, sensitive outcome measures related to muscle pathology. Outcome measures 
based upon earlier stages of disease pathology may have a greater likelihood of being sensitive to 
disease progression over shorter periods but are less clinically relevant. This chapter highlights 
promising ways to monitor disease progression, including collagen-specific contrast agents, extra 
cellular volume, longitudinal Dixon FF calculation and cardiac tagging. Improvement in the speed of 
acquisition of CMRI would be beneficial as a study outcome measure reducing study burden. This 
thesis will evaluate some of these methods, comparing against traditional ways of demonstrating 
disease progression.  
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Chapter 3: Methods 
 
To fully explore the topic of this thesis, investigation of novel methods of using quantitative MRI in 
assessing the pathology of muscular dystrophies, it was necessary to perform both animal and clinical 
experiments. Methods are therefore described in two sections:  
• Section 1: Animal (basic science) methods  
• Section 2: Clinical methods  
 
3.1 Section 1: Animal assessments  
3.1.1 Ethics 
All animal experiments described conform to directive 2010/63/EU of the European parliament and 
under the auspices of the terms of the animals (scientific procedures) act 1986, authorized by the 
Home Secretary, Home Office, UK. All animal experiments were carried out under Project Licence 
70/8538, and personal licence I8E4D5AEF approved by the Home Office.  
 
3.1.2 Animal anaesthesia 
Animals were anaesthetised using isoflurane 5% in 0.5L/min of oxygen. Prior to cannulation of the tail 
vein, anaesthetic was maintained at 1-1.5% isoflurane in 0.5L/min of oxygen. Heart rate, ECG, 
respiratory rate and core body temperature were monitored throughout all procedures.   
 
3.2 Overview of EP3533 experiments (Chapter 4) 
3.2.1 Pilot study of EP3533 
One 48 week old mdx mouse and an age-matched control (BL10) were scanned. The aim was to 
optimise the imaging protocol and assess timing of greatest signal change within skeletal muscle. The 
timing of maximal signal increase could then be used as timing for subsequent experiments.   
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The animals were individually anaesthetised and cannulated. Following initial scouting images and 
shimming, both mice underwent pre-contrast baseline imaging and subsequent bolus of 20µmol/kg 
of EP3533 administered. This dose was chosen based on previous studies using EP3533 (Helm et al., 
2008). Post-contrast agent, continuous repeated scanning was performed over two hours. The mice 
were scanned using T1 weighted 3d gradient echo (GRE). MRI analysis was performed using hand-
drawn ROI in skeletal muscle. 
 
3.2.2 Cross sectional assessment of EP3533 
Nine mdx and five BL10 mice were age-matched to approximately 40 weeks of age. Animals were 
anaesthetised, monitored and underwent tail vein cannulation. For each mouse, two scans were 
performed a week apart. In the first week the contrast agent was with standard gadolinium agent 
(SGd), with EP3533 used in the second week. To incorporate both skeletal and cardiac muscle 
acquisitions into the same scan, the mouse was first positioned with the lower limbs at the level of 
the centre of the radiofrequency coil. This position was marked to ensure repeatability of positioning. 
Once skeletal muscle baseline acquisitions were completed, the mouse was repositioned with the 
level of the heart at the centre of the radiofrequency coil. Baseline cardiac images were obtained, 
then contrast administered with post-contrast acquisition until completion at sixty minutes. After this 
time the mouse was repositioned back to the original marked position for skeletal muscle imaging 
(Figure 3). 
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Figure 
 
Figure 3. Depiction of the imaging protocol and how the mice were repositioned during the scan to place heart or skeletal 
muscle within the centre of the radiofrequency field. This figure demonstrates how the different contrasts were over a 
week apart to ensure no contamination of gadolinium (Gd) during the second scan.  
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3.2.3 Longitudinal assessment of EP3533 as an outcome measure 
Four groups of age-matched (16 ±3 weeks) mdx and BL10 mice were obtained. The first group, referred 
to as ‘treated mdx’ (n=8), were treated for twelve weeks with halofuginone (Sigma-Aldrich, 2018) 
7.5ug three times per week via intraperitoneal (IP) injection based on a previous study (Turgeman et 
al., 2008). A control group of mice, ‘treated BL10’ (n=3), received the same treatment as the first 
group. A second group, ‘untreated mdx’ (n=13), were begun on a course of 3 weekly IP injections over 
twelve weeks of 150µl of dimethyl sulfoxide (DMSO) (5%) and saline (0.9%) (vehicle). A corresponding 
group of control mice, ‘untreated BL10’ (n=5), received vehicle only. Halofuginone was reconstituted 
as a stock solution in saline (0.9%) and DMSO (5%). For long term administration Halofuginone was 
aliquoted into separate tubes and frozen at  
-20°C. 
All IP injections were administered by an animal technician with appropriate training. Daily welfare 
checks and weekly weight documentation were completed. No side effects or adverse events relating 
to the drug were noted in any of the four groups of mice.  
Due to the high degree of correlation between EP3533 and histology seen in skeletal muscle in initial 
experiments as well as the clinical relevance of skeletal muscle in human muscular dystrophy, it was 
decided to limit the scans to skeletal muscle. Both treated mice groups (treated mdx and treated BL10) 
and the untreated mdx mice were imaged at baseline, then recovered to commence a 12-week course 
of either halofuginone or vehicle administration. Following this, all mice underwent two and four limb 
strength assessments, then were imaged within a week and finally humanely killed. As little variation 
is expected on imaging in BL10 mice, the only BL10 mice that were imaged at baseline were the treated 
BL10. Vehicle treated mice were imaged when they reached the same age as the mice receiving 
halofuginone. 
Following administration of 20µmol/kg of EP3533, mice underwent T1 weighted GRE imaging in a 1:2 
ratio with gradient echo multi-slice inversion-recovery Look-Locker (gemsIR-LL), continuing until 
seventy minutes post-contrast when the final gemsIR-LL was performed. The muscles to be analysed 
included hamstrings (HMS), QUADS, GCN, and TA. 
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3.3 MRI protocol 
Magnetic resonance scanning was performed on a 7-Tesla micro-imaging system (Varian; Agilent 
Technologies, Santa Clara, United States) equipped with a 12cm micro-imaging gradient insert 
(maximum gradient, 40mT/m). Pre and post-contrast timings differed between sections.  
 
3.3.1 Skeletal muscle protocol 
The skeletal muscle imaging protocol for both upper and lower legs involved a T1 mapping sequence 
using a gemsIR-LL with 1 slice of 1mm thickness selected through lower leg muscles with the following 
parameters: repetition time (TR) inversion = 5s, 10 inversion times (from 0.1 to 5s), TR/echo time (TE) 
= 9.68/4.86ms, echo train length (ETL) = 4, flip angle (FA) = 4o, FOV 30 x 30mm, matrix = 128 x 128. 
This sequence was alternated with a series of T1 weighted GRE acquired pre and post-contrast 
enhancement with TR/TE = 9.46/4.75ms, FA = 20o, FOV = 30 x 30 x 30mm, matrix 128 x 128 x 128, band 
width = 20KHz.  
For the lower leg muscles, mice were positioned with the upper border of the FOV beginning at the 
lower border of the knee. For the upper leg (only performed in section 3), mice were positioned with 
the centre of the knee joint as close as possible to the centre of the radiofrequency coil. Four slices 
were used to obtain the gemsIR-LL, two positioned above (+0.6mm, 1.2mm) and two below the knee 
joint (-0.6mm, -1.2mm). This enabled homogeneity in positioning for analysis.  
 
3.3.2 Cardiac protocol 
Only the second experiment looking at cross sectional measurement of fibrosis included cardiac 
imaging. Following initial scouting images and shimming, baseline cardiac acquisitions were obtained. 
Following power calibration, four transverse images were acquired as a pilot from which single slice 
sagittal and coronal acquisitions were obtained at the level of the mitral valve and the apex of the 
heart planes. A short-axis stack of slices was acquired covering the whole heart using a spoiled 
gradient-echo cine sequence with parameters as follows: TR=5ms, TE=1.42ms, FA = 15°, FOV 30mm × 
30mm, data matrix 128 × 128, 1 mm slice thickness, maximum of 12 slices depending on heart size, 4 
averages. Images were gated to the R wave of the heart cycles to coincide with ventricular contraction 
with a cine delay of 15ms.  Following morphological imaging, a quantitative T1 map dataset was then 
acquired using a gated-gemsIR-LL with 3 axial slices of 1mm thickness through the mid-point of the 
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left ventricle with the following parameters: TR inversion = 5s, 10 inversion times (from 0.1 to 5s), 
TR/TE = 9.68/4.86ms, ETL = 4, FA = 4o, FOV 30mm × 30mm, Matrix = 128 × 128. Finally, gated-baseline 
T1 weighted GRE images were acquired with identical parameters to the skeletal muscle acquisition. 
Using anaesthetic titration median heart rate was kept closely to 400 beats per minute (bpm) 
throughout the scans.  
 
After cine imaging and baseline images were taken, contrast was administered. A continuous series of 
T1 weighted GRE scans was acquired in succession, then a single gated gemsIR-LL as close to 40 
minutes as possible. Immediately after this a continuous series of T1 weighted GRE scans was 
performed until approximately 60-65 minutes post-contrast, when the mouse was repositioned for 
skeletal muscle imaging. 
 
3.4 Skeletal muscle: analysis and ROI selection 
All scans were analysed using ‘Aedes software’ (Niskanen). Creation of T1 maps was performed by 
pixel-wise fitting of the lower limb datasets to equation [3]. Where s(TIR) is the pixel intensity in the 
image collected at inversion time TIR and So is the equilibrium signal intensity. Gated T1 maps were 
created using the same method, but with TIR adjusted for gating by recording of the contemporaneous 
heart rate and inputting the inversion times manually prior to fitting and ROI drawing.  
𝑠(𝑇𝐼𝑅) = 𝑠0(1 − 2𝑒
𝑇𝐼𝑅
𝑇1 )      (3) 
Lower leg muscle ROI were selected by hand based on previous MRI-based murine studies (Zhang et 
al., 2008) (Figure 4). For section 3, which included upper leg muscles, ROI selection in the thigh has 
not previously been reported, selection was therefore based upon anatomical position (Charles et al., 
2016). The anterior compartment of the thigh corresponded to the dissection of the QUADS muscles, 
with the posterior compartment corresponding to the dissection of the hamstring muscles. Muscles 
were located using the T1 weighted GRE, and then approximated on the same position as the T1 map 
(Figure 5). These are referred to throughout this chapter as HMS and QUADS.  
 
  
45 
 
 
Figure 1. T1 weighted image to demonstrate the selection of regions of interest within the lower limb mouse muscles. 
Key: green, tibialis anterior (TA), red, gastrocnemius (GCN), P, posterior, A, anterior, L, left, R, right, S, superior, I, inferior. 
 
 
Figure 5. T1 weighted image to demonstrate the selection of regions of interest within the lower limb mouse muscles. 
Key: blue, Hamstrings (HMS), red, Quadriceps (QUADS), P, posterior, A, anterior, L, left, R, right, S, superior, I, inferior. 
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3.4.1 Cardiac muscle: MRI analysis and ROI selection 
Images were zero-filled to a matrix size of 256x256 (Schneider et al., 2006). Scans were analysed using 
‘Segment v1.8’ (Medviso, Lund, Sweden) (E. Heiberg, 2010). For cine imaging ROI segmentation of the 
left ventricle and right ventricle was performed by hand, with measurement of LVM, LVEF and right 
ventricular ejection fraction (RVEF).    
 
ROIs were selected from a mid-cavity slice in the axial plane by hand using Aedes software (Niskanen), 
ROI included the complete slice of the myocardium in axial view (Figure 6). 
 
Figure 6. Gated T1 weighted image to demonstrate the selection of ROI within the cardiac muscle in axial view.  
Key: blue, cardiac ROI, P, posterior, A, anterior, L, left, R, right, S, superior, I, inferior. 
 
For the purposes of calculating SNR, noise was obtained as the value of signal of air next to the animal. 
Change in SNR was calculated using the equation [4]: 
𝐶ℎ𝑎𝑛𝑔𝑒 𝑖𝑛 𝑆𝑁𝑅 (%) = ((𝑆𝑁𝑅𝑝𝑜𝑠𝑡 − 𝑆𝑁𝑅𝑃𝑟𝑒)/𝑆𝑁𝑅𝑃𝑟𝑒) x100    (4)  
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3.5 Ex vivo quantification of fibrosis 
Mice were humanely killed, with organs harvested (Section 2: the heart, both TA, and GCN muscles, 
section 3: both TA, both GCN, HMS and QUADS muscles). Samples were snap frozen in liquid nitrogen 
cooled isopentane and stored at −80°C. The left-sided muscles were collected for quantification of 
fibrosis markers via hydroxyproline, while right-sided muscles were obtained for histological analysis. 
In all muscles cryosections were cut 8μm thick. To ensure more coverage of the muscle to detect focal 
fibrosis, sections were spaced 200μm apart.  
Cryosections were stained with Masson’s trichrome (MT) (section 2 and 3), Haematoxylin and eosin 
(H&E) (section 2 and 3), sirius red (section 2), and for collagen 1 (immunofluorescence, section 3).  
Cryosections were stained with MT using the HT15 staining kit (Sigma-Aldrich, UK). Slides were air 
dried then placed within Bouin’s solution at room temperature overnight and washed in tap water. 
The slides were then stained in Weigert’s haematoxylin for five minutes, then washed with distilled 
water for five minutes, and they were then placed in Beibrich scarlet acid fuchsin before being rinsed 
again. Slides were then placed in working phosphotungstic/phosphomolybdic acid solution for five 
minutes. Finally slides were placed in Aniline blue and acetic acid (1%) for five and two minutes 
respectively. Slides were dehydrated using increasing alcohol concentrations, cleared in histoclear and 
mounted using DPX mountant.  
Percentage of fibrosis was quantified by hand using ROI analysis of the slides stained with MT. Imaging 
software (Fiji 64 bit) was used to calculate the area of fibrosis as a percentage of the total area of the 
muscle. This is referred to as MT quantification. 
Tissue sections were incubated with formalin for ten minutes, then washed with water, five minutes 
of incubation with hematoxylin, then washed again in water. Slides were placed within Eosin for 30 
seconds prior to ethanol dehydration and mounting in DPX.   
Slides were fixed in a 3:1 solution of paraformaldehyde (PFA) (4%) and 90% alcohol for 45 seconds, 
then rinsed with water. Haematoxylin was added for 15 minutes, then rinsed with water for ten 
minutes prior to incubation of the slides for 15 minutes in direct red (0.1%) in 1% picric acid. Slides 
were dehydrated in 99% alcohol for one minute, then mounted in DPX mountant.  
A rabbit anti-collagen 1 antibody was used (Novus biologicals, 2018). Slides were air dried at room 
temperature, then fixed in methanol for 10 minutes before being washed twice in phosphate buffered 
saline (PBS). Sections were identified and drawn around using an immunohistochemistry barrier pen. 
Slides were blocked using PBS with Tween 20 (PBST) in 1% bovine serum albumin (BSA), for 30 
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minutes, at room temperature. The primary antibody (1 in 250) in 1% PBST (0.1%) was added to the 
slides overnight at 4°C. The slides were washed three times for five minutes in PBS then incubated in 
(1:500) secondary antibody (anti-rabbit raised in donkey) (Li-Cor, United States) for one hour in the 
dark. The slides were then washed three times further in PBS in the dark. The slides had 4',6-
Diamidine-2'-phenylindole dihydrochloride (DAPI) added with a cover slip.    
 
3.5.1 Hydroxyproline assay 
The hydroxyproline assay was performed for ex vivo quantification of fibrosis for direct comparison 
with MRI acquisitions. The hydroxyproline assay method was modified from the skeletal muscle 
specific standard operating procedure available from the TREAT-NMD website (Carlson, 2014). 
Individual muscles were weighed before being hydrolysed in 5N hydrochloric acid, at 110°C for 18 
hours, and at a concentration of 10mg of muscle per ml. All samples were performed in triplicate, a 
50µL sample of the hydrolysate was diluted to a volume of 2.3ml with distilled water and neutralised 
with (0.1N) potassium hydroxide. Sodium borate buffer 0.5ml (pH 8.7) was added with 2ml of 0.2N 
chloramine-T dissolved in distilled water, with sodium citrate buffer, and 2-methoxyethanol solution, 
this was then incubated for 25 minutes. 
Sodium thiosulfate (3.6N) 1.2ml was added to the solution. To remove contaminating impurities, 
2.5ml of toluene and 1.5g of potassium chloride was added to each of the tubes. The contents were 
mixed thoroughly, and then centrifuged at 400g; the toluene was then removed and discarded. The 
remaining solution was heated at 100°C for 30 min, and the final reaction product was removed by 
adding a further 2.5mls of toluene, appropriately mixed and then centrifuged at 400g. 1.5mls of the 
toluene phase was removed into separate containers, with 0.6mls of Ehrlich's reagent added to each, 
and incubated at room temperature for 30 minutes. Spectroscopy at 560nm was used to compare 
hydroxyproline standards (0μg, 0.75μg, 1.5μg, 3μg, and 6μg) to the experimental samples. Regression 
analysis was performed using the trend line from the hydroxyproline standards, with values divided 
by the weight of the muscle from the hydrolysate (0.5mg) to give the value of hydroxyproline content 
in μg/mg (Graham et al., 2010, Carlson, 2014). 
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3.6 Pharmacokinetics sampling 
To confirm serum levels of halofuginone, pharmacokinetics (PK) was performed by a private company 
in four halofuginone-naive mdx mice of similar ages to the experimental groups, using liquid 
chromatography – mass spectrometry/mass spectrometry (LC-MS/MS). Venesection of the saphenous 
vein was performed using a needle and capillary tubes after IP administration of halofuginone. To keep 
within UK Home Office guidance for volume of venesection per mouse, the samples were taken from 
four mice at different time points (UK Home Office, 2018). The first sample was 150µl, and the second 
was 150µl from a terminal cardiac sample. The timings were as follows: mouse one 5 and 15 minutes, 
mouse two 30 minutes and 1 hour, mouse three 2 and 4 hours, mouse four 8 and 24 hours. These 
were stored as serum in lithium-heparin bottles and stored at -80°C prior to transport.  
LC-MS/MS allowed quantification against a calibration curve from 0.5-1000ng/ml. A stock solution of 
halofuginone in DMSO (5%) and saline (0.9%) was provided at a concentration of 10mM as well as 
serum from a halofuginone naive mdx mouse. Quality control samples (3, 30 and 700 ng/mL) and 
mouse samples were mixed with organic solvent (methanol) containing a mixture of three generic 
internal standards. Samples were treated at a ratio of 3:1 solvent to sample. Following protein 
precipitation, samples were then centrifuged (30 minutes at 5000g). The resulting supernatant was 
diluted with double distilled water at a ratio of 2:1 parts of supernatant in a 96-well plate. The plate 
was sealed, vortex mixed and analysed by LC-MS/MS with incurred samples quantified from the 
calibration line. 
 
3.7 Functional assessment of grip strength 
Prior to the final scan, grip strength was assessed using a grip strength apparatus (BioSeb, Chaville, 
France), with both fore-limb assessment (referred to as two limb assessment) and all four limbs 
assessed. These were tested using a ‘T’ shaped bar attachment, and an 8cm x 8cm grid respectively 
(Figure 7). The test relies on the tendency of mice to grip a bar or grid if pulled by the tail with nothing 
else to hold on to. Mice were placed upon the apparatus and pulled gently backwards by the tail. Mice 
had three attempts with at least a one minute rest between assessments. To ensure homogeneity of 
the test, the same examiner performed each test. Mice were assessed on one occasion in the same 
temperature controlled, quiet environment. The weight and the maximal recorded value from the 
three attempts was used to calculate the normalised force (force/body weight) (Tinsley et al., 2014).  
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Figure 7. Photo of grip strength testing using the grid attachment to measure four limb strength, two limb strength was 
measured using a metal bar attachment shaped like the letter ‘T’.  
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3.8 Section 2: clinical methods  
To explore how MRI can be used to show disease progression in muscular dystrophies, two cohorts 
were examined: a group of participants with BMD, and a group with LGMDR9. For comparison in the 
ECV and the accelerated imaging studies (Chapters 6 and 7), 10 age-matched healthy control 
participants were recruited. To provide six year longitudinal cardiac and skeletal muscle data, 
participants were recruited that had taken part in a previous LGMDR9 natural history study performed 
by Willis et al. from June 2009 (Willis et al., 2013).  
 
3.8.1 Ethical approval 
All clinical studies complied with the declaration of Helsinki, and were run in line with the principles 
of ‘Good clinical practice’. For the LGMDR9 six year follow up study (Chapter 5), local ethical approval 
was sought for each site. For the UK based sites (UNEW and University of central London (UCL)), ethical 
approval was sought from national research ethics service committee South Central Oxford C (Ref 
15/SC/0037). Approval was granted for the LGMDR9 study in the UK in January 2015.  
For the BMD cohort a separate ethical approval was required. This was granted by the National 
Research ethics service committee Newcastle and North Tyneside 2 (Ref 12/NE/0070) as an 
amendment to an existing approval in December 2014.  
 
3.8.2 Recruitment 
Participants were recruited from participants of the original LGMDR9 study by Willis et al. (Willis et 
al., 2013). Willis et al. recruited from local patient databases with the following inclusion and exclusion 
criteria: all participants must be homozygous for the c.286C>A Leu276I FKRP mutation, ambulant 
without support for more than 50m, not requiring ventilator support, able to lie supine, and have no 
contraindications to MRI. In the original study, validation testing of the physiotherapy assessments 
was performed at four weeks and six months after the first assessment. Thirty-eight participants were 
recruited. Due to several reasons, such as pregnancy and comorbidities during the study period, 32/38 
participant data sets were complete (Willis et al., 2013).  
Participants with BMD were selected with the following inclusion and exclusion criteria: a genetically 
confirmed diagnosis of BMD (in frame mutation within the DMD gene), ability to lie supine, with no 
MRI contraindications. The age-matched control group was male without cardiac conditions.  
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After informed consent was obtained, each participant underwent a brief medical history and physical 
examination, including routine observations (i.e. heart rate, blood pressure, respiratory rate, oxygen 
saturation and temperature); this was to ensure they could safely undergo the study procedures.  
 
3.9 MRI protocols 
Acquisitions consisted of four distinct sections:  
• Skeletal muscle protocol and analysis  
• Conventional and accelerated cine imaging for cardiac indices 
• Cardiac tagging  
• Imaging pre and post-Gd administration  
 
 
3.9.1 Skeletal muscle protocol and analysis 
There were some minor differences in protocol details between sites, all scans were performed on 3T 
scanners (Philips Achieva, Siemens TIM Trio) using surface coil arrays. Three point Dixon images were 
acquired using a spoiled gradient echo sequence, UNEW and UCL used 2D TR/TE 
=100/3.45,4.6,5.75ms, FA of 10 degrees, 10 slices of 10mm slice thickness with a 5mm gap. Paris used 
3D TR/TE 10/2,0.75,3.95,5.15ms, with a FA of 3 degrees, 64 slices of 5mm thickness. Copenhagen used 
a similar TR/TE but with 3D 36 slices per acquisition, and 2 point Dixon with correction for 
homogeneity of B0.   
To ensure consistency between sites of positioning, acquisitions in the legs were positioned with the 
patella anterior and the calf images centred by locating the broadest region of the calf and recording 
the distance from the lower border of the patella. Positioning of the thigh images was ensured by 
locating the superior border of the patella and acquiring one third between this and the anterior 
superior iliac spine. A matrix of 160x160 interpolated to 256x256, FOV 200x200mm was used, with 
each leg imaged separately. Separate fat and water images were obtained and quantitative FF maps 
were produced by expressing the fat signal as a percentage of the total signal per voxel. The Paris site 
was able to scan both left and right legs at the same resolution using FOV 448x244mm. 
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To further ensure homogeneity of acquisition across sites, phantom images with known fat water 
content were quantified and healthy volunteer images were taken in each site. These were then 
compared by a MRI physicist at the UNEW site.  
In contrast to the original study, skeletal muscles were not graded using the Mercuri scale, because 
such semi-quantitative scales have been long superseded by the less subjective, more reliable 
measures such as the Dixon technique. Skeletal MRS was not repeated due to the findings of the 
original study, which suggested that although there was a change in metabolites in LGMDR9 muscle 
detected, this was less significant compared to other muscular dystrophies. Unpublished data 
suggested that the scope for these values to change over time was limited. Taken together with the 
long acquisition time for MRS, it was decided to not include these in the final protocol. 
Both functional assessment data and MRI were anonymised and assigned unique patient identifiers 
prior to secure electronic transfer to UNEW for analysis. Information from all four sites was collated 
electronically onto a master sheet.  
MRI acquisitions were all analysed at UNEW. Once assigned the unique identifier code for each 
participant, these were analysed in batches by hand drawn ROI using imaging software ‘Image J’ 
(Abràmoff et al., 2004). Two observers drew ROIs separately around the selected muscle groups 
(Figures 8 and 9) at a single level. The images were separated into fat and water fractions; the fat 
percentage of a voxel was calculated as a percentage of total signal per voxel. Data from the left and 
right legs was combined by averaging, as were the results from the two analysts. 
Mean FF and muscle CSA were calculated using the ROIs. c-CSA was calculated by multiplying the CSA 
by one minus FF; this represents the muscle content of the ROI. 
During movement muscles rarely function in isolation, therefore composite FFs were calculated as 
area-weighted averages. Composite muscle groups were all muscles of the thigh, all muscles of the 
calves, the QUADS (RF, VL, vastus medialis (VM)), HMS (SM, ST, biceps femoris short head (BFSH), 
BFLH), triceps surae (LG, MG, Sol).  
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Figure 8. MRI acquisitions to demonstrate imaging of the left thigh using the Dixon technique. Both images were taken 
at six year follow up. A is a water separated image, B is a fat separated image.  
 
 
Figure 9. Examples of ROI selection from baseline water separated images. Image A left thigh, image B left calf.  
Key: RF, rectus femoris, VL, vastus lateralis, VM, vastus medialis, Sar, Sartorius, Gr, Gracilis, SM, semimembranosus, ST, 
semitendinosus, BFLH, biceps femoris long head, BFSH, biceps femoris short head, TA, tibialis anterior, PL, peroneus 
longus, Sol, Soleus, MG, medial gastrocnemius, LG, lateral gastrocnemius.  
  
A B 
A B 
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3.9.2 Conventional and accelerated cine imaging for cardiac indices  
During breath-holding, steady-state free precession images were acquired in the short axis plane with 
a FOV of 350x315mm, FA 40°, slice thickness 8mm, 0mm gap, cardiac cine 25 phases, with 14 slices. 
Resolution of 1.85 x 1.54mm, zero-filled to 1.37mm, temporal duration 40ms per phase, dependent 
on heart rate.  
For comparison the protocol acquires cardiac cine data using two techniques:  
1) Standard conventional protocol with contiguous slice coverage, 
2) Accelerated protocol with contiguous slice coverage 
In all cases, two chamber and four chamber long axis views were acquired using parameters as 
described below. The accelerated protocols utilise enhanced gradient mode to reduce TR by 20% and 
TE by 24%, making use of a higher SENSE factor 2.1 on the 16 channel coil, and higher turbo 
acceleration factor 23 compared with the previous 17. Due to reduced TR, the TFE shot length is similar 
for the two acquisitions: 61ms (TR x turbo factor – 23 x 2.65 = 61ms) for the accelerated sequence and 
58.5ms (17 x 3.44 = 58.5ms) for conventional images. The short and long axis acquisitions were made 
sequentially, using the parameters as outlined (Table 3).  
To compare inter-rater reliability, two appropriately trained observers reviewed a sample of the 
accelerated images (n=10) for the five cardiac indices studied. Images were reviewed independently 
and results were compared using Bland Altman analysis.    
To qualitatively analyse the images, observers were asked to rate a sample (n=8) of the accelerated 
images in terms of quality based on a five point scoring system (Table 4).  
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Axis Parameter Conventional stack Accelerated stack 
Short axis TR/TE/Turbo factor 3.3ms/1.7ms/17 2.7ms/1.3ms/23 
 SENSE acceleration factor 1.5 2.1 
 Partial Fourier factor (%) 37.5 37.5 
 Phase acquisition factor (%) 55 55 
 Slices per breath-hold 2 4 
 Number of breath-holds 7 4 
 Duration of breath-hold† 7 x 10.3s 3 x 10.3s, 1 x 5s 
Long axis TR/TE/Turbo factor 3.3ms/1.7ms/17 2.7ms/1.3ms/23 
 SENSE acceleration factor 1.5 2.1 
 Partial Fourier factor (%) 37.5 37.5 
 Phase acquisition factor (%) 55 55 
 Slices per breath-hold 1 1 
 Number of breath-holds 1 1 
 Duration of breath-hold† 1 x 5s 1 x 2.6s 
Table 3. A table to show the short-axis parameters of the three techniques of acquisition. The same partial Fourier factor 
and phase acquisition factor is used in all acquisitions (0.625/55% respectively). Slice thickness was the same in all three 
techniques (8mm).  
Key: TR, repetition time, TE, echo time, SENSE, SENSitivity Encoding. 
† at 70 bpm 
 
Score Description 
1 Image quality in conventional is considerably better than that of accelerated 
2 Image quality in conventional is marginally better than that of accelerated 
3 No obvious difference between the image quality in conventional and accelerated 
4 Image quality in accelerated is marginally better than that of conventional 
5 Image quality in accelerated is considerably better than that of conventional 
Table 4. Five point qualitative rating scale of image quality. 
 
3.9.3 Cardiac tagging 
Tagged short-axis images were obtained during the same scan session. Short axis slices of 10 mm 
thickness were prescribed centred at the mid-ventricle, with a spacing of 12mm. The apical and basal 
slices themselves were avoided due to the risk of the grid moving out of the heart during the cardiac 
cycle. Calculation of cardiac tagging indices involved acquisition of tagged images at identical position 
to the slices used in cine imaging. A TFE sequence with acceleration factor 9 was used 
TR/TE/FA/number of excitations 4.9/3.1/108/1, SENSitivity Encoding (SENSE) factor 2, FOV 
350×350mm, voxel size 1.37 × 1.37mm, orthogonal complementary spatial modulation of 
magnetisation (CSPAMM) grid with tag spacing of 7mm. Reconstruction was possible using view 
sharing, 15–27 time frames per cardiac cycle. Breath-holds were requested of participants to reduce 
potential respiratory artefact (Lumens et al., 2006).  
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3.9.4 Imaging pre and post-gadolinium administration 
Pre-contrast T1 map acquisition for ECV calculation used a modified Look Locker (MOLLI) sequence 
(TR/TE/TI/FA = 2.1ms/0.95ms/350ms/20o, FOV 300x300, resolution 2 x 2mm zero-filled to 1.17mm2) 
to acquire at a fixed diastolic cardiac phase using a 5s(3s)3s inversion scheme. This was followed by 
an injection of 0.2mmol/kg Gd contrast agent, Dotarem (Guerbet, France). A LGE short-axis stack and 
orthogonal long-axis planes were acquired using 3D Phase Sensitive Inversion Recovery (PSIR) 
sequence 10 minutes post-Gd. Enhanced post-contrast T1 map acquisition was made at 15 minutes 
post-administration using a 4s(1s)3s(1s)2s inversion scheme. Pre- and post- contrast T1 mapping 
acquisitions were at three short-axis locations (apical, mid-cavity, and basal) during separate breath-
holds (duration 12s), then reconstructed using custom software.  
 
3.9.5 Cardiac magnetic resonance imaging analysis 
Five cardiac indices were obtained from the accelerated and conventional images: LVEF, LVM, left 
ventricular stroke volume (LVSV), left ventricular end diastolic volume (LVEDV), and left ventricular 
end systolic volume (LVESV). Cardiac indices were obtained from the cine images using ViewForum 
workstation (Philips). End-systole and end-diastole were defined with endocardial and epicardial 
boundaries manually traced as described previously (Jones et al., 2010). Five cardiac indices were 
calculated: LVEF, LVSV, LVM, LVEDV, and LVESV. WMA were identified by an experienced observer 
looking for asymmetrical LV wall contraction. 
All tagging data was analysed using the ‘Cardiac Image Modelling package’ (University of Auckland), 
as described in detail previously (Hollingsworth et al., 2013b). In line with previous analyses (Lumens 
et al., 2006) we calculated PT at systole, peak whole wall circumferential strain (PWWS), and peak 
endocardial circumferential strain (PECS). The relationship between torsion and strain was estimated 
using torsion to shortening ratio (TSR = PT/PECS), a constant among age-matched healthy subjects, 
but which increases with healthy ageing (Lumens et al., 2006, Hollingsworth et al., 2012).  
ECV is quantified by selecting a ROI and calculating the average T1 values within the ROI in both 
enhanced and native acquisitions. The difference in the reciprocal of these values (i.e. the relaxation 
rate) is divided by the difference in values of the blood pool to give the partition coefficient; this is 
demonstrated in equation 1. Correction for Hct is achieved by multiplication of one minus the serum 
values (L/L). The concentration of Gd within cardiac tissue is calculated using equation 2.  
Mean T1 values were obtained from the MOLLI images using manually-defined ROI within the LV wall 
using ImageJ (Abràmoff et al., 2004) (Figure 10). Each slice (basal, mid, apical) was divided into four 
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segments modified from the American Heart Association topographical segments (Cerqueira et al., 
2002): the insertion point of the right ventricular wall into the left ventricle was the border of the 
septal and ventricular regions. These were divided to give anterior, posterior, anterior septal, 
posterior septal segments (Figure 11). ECV values are referred to: segmentally, regionally (either: 
basal, mid-cavity or apical), or globally, which is the mean of all segments in all slices. Other studies 
refer to ‘global ECV’ measurement but include only one slice that is analogous to the ‘regional’ values 
in this study (Sado et al., 2012, Ugander et al., 2012, Banypersad et al., 2013, Radunski et al., 2014). 
LGE was confirmed by an experienced observer from the PSIR images with segmental location 
recorded. ROIs were defined on the intraventricular lumen on the pre- and post-contrast images to 
obtain blood pool values, while avoiding papillary muscles and LV trabeculae.  
 
 
Figure 10. An example of T1 maps. The upper image (A) shows pre-contrast enhancement, the lower image (B) shows 
post contrast enhancement. Images were taken from the same point in the cardiac cycle. Intensity map has been applied 
to provide an intensity scale as seen to the left of the image. The lower image demonstrates the reduction in uptake in 
areas of fibrotic tissue (demonstrated by the white arrow).  
B 
A 
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Figure 11. Region of interest (ROI) selection and labelling on a pre-contrast T1 map for extracellular volume (ECV) 
calculation. The blood pool ROI avoids papillary muscles. ‘Regional’ ECV values are taken from a single slice. Left – Basal 
region, centre mid-cavity region, right apical region. Global ECV values are taken from all slices and all segments 
combined. 
Key: Blue, septal anterior, red, septal posterior, green, anterior, yellow, posterior.  
 
3.10 Physical assessments 
The physical function tests were set out in a manual with recording sheets. Teleconferencing enabled 
standardised training of the physiotherapists across the four sites. All assessors were familiar with the 
equipment and tests as set out in the manual.  
Specialist physiotherapists administered tests in a specific order to reduce variability between 
assessors. The order of the testing was: ten metre walk or run (10MWR), spirometry (with hand-held 
device), myometry (hand held assessment of the dominant side), range of ankle movement, timed up 
and go, stair climb, stair descent, chair rise, the NSAA, and finally the 6MWT. If participants were 
unable to complete a test due to being non-ambulant, they were graded as unable and the reason 
recorded.  
 
3.10.1 Standardised functional testing 
The timed tests included a 10MWR in a quiet corridor, with a course pre-measured using a measuring 
tape. Grades indicating how well the participants performed and time taken to complete the course 
were recorded. Similar grading and timing were performed for all the other timed tests. The stair 
climb, and descent were performed on a set of steps, and the height of each step was standardised 
across the four sites at 15cm. Chair rise and timed up and go tests were performed using a chair of a 
standardised 47cm height with arm rests. In the chair rise, the participant was asked to get from a 
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sitting to standing position with their arms by their sides. The timed up and go test involved the 
participants starting in the standing position, then being timed in walking 3 meters from and then back 
to the chair, with the timer stopped once the participant was re-seated. Grades were assigned for all 
of these assessments (with the exception of the timed up and go test) based on the grading scale on 
the physiotherapy data entry forms. The NSAA is a 17 point assessment tool grading ability to perform 
multiple domains, including jumping, climbing a single step, and running as well as timed tests. 
Domains are graded from 0-2 then totalled out of 34; a higher score implies more functional ability. 
The NSAA has been validated for use as a clinical trial outcome measure for DMD (Mazzone et al., 
2010, Mazzone et al., 2009). The 6MWT involves the participants walking for six minutes around a 
25m course marked out with cones on either end. Two assessors are required, both with stop watches. 
One walks closely behind the participant for safety purposes; the second counts how many times the 
course is completed. The final distance is calculated using the number of completed laps added to the 
number of metres the participant had completed on the final lap. Full descriptions of these functional 
assessments are detailed in the physiotherapy manual (Appendix A). 
 
3.11 Statistical analysis 
Statistical analysis was performed using SPSS v23 and Microsoft Excel. All data was checked for 
normality using the Shapiro-Wilk test. In Chapter 4, where data is normally distributed, results are 
presented as mean and standard deviation unless otherwise indicated, with significance tested via 
two tailed paired Student t-test. Where data is non-normally distributed median and range are used, 
with statistical significance calculated using the Wilcoxon signed test. Throughout assessment of 
correlation, strength and significance was performed using Pearson correlation. 
For timed tests a participant may be unable to perform a functional assessment. For the purposes of 
obtaining statistical significance this is recorded as a time greater than all others measured, to permit 
ranking in non-parametric statistical tests: in this case 10,000 seconds. Statistical significance was 
taken to be p<0.05.  
For longitudinal data it is possible to calculate the standardised response mean (SRM) by taking the 
average of the paired difference over the follow up, and dividing by the standard deviation of the 
differences. SRM facilitates comparison between different outcome measures with a high SRM (>0.8) 
implying a high level of responsiveness to changes in value (Cohen, 1988).       
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Chapter 4: Quantification of fibrosis using the novel gadolinium-based 
contrast agent EP3533 
 
4.1 Summary 
Fibrosis is a pathological process in muscular dystrophies. Increased levels of fibrosis in skeletal and 
cardiac muscle have been associated with a worse prognosis in DMD. Anti-fibrotic medications are 
being evaluated for amelioration of DMD. To date, MRI has not been used successfully to image 
fibrosis within skeletal muscle as an outcome measure. EP3533 is a novel Gd-based contrast agent 
using a complex peptide with an affinity to collagen 1. EP3533 has been used successfully to quantify 
fibrosis in pre-clinical trials of several disease models.  
This chapter is a description of experiments on age-matched 40 week old mdx and BL10 mice, using 
EP3533 to detect and quantify fibrosis within skeletal and cardiac muscle. Correlation between ex vivo 
measures of fibrosis and R1 change is compared following both EP3533 and non-collagen specific SGd 
agent. T1 mapping was used to quantify changes in R1 over time in areas of interest. R1 change using 
EP3533 was significantly higher in the mdx than the BL10 mouse group (cardiac muscle p=0.02, GCN 
p=0.04, TA p=0.04). A strong correlation was demonstrated between change in R1 and histological 
quantification of fibrosis in muscle (GCN r=0.83 p=0.0001, TA r=0.73 p=0.01, cardiac muscle r=0.73 
p=0.02). There were no significant correlations between ex vivo quantification and the use of standard 
gadolinium. No differences were seen in LVEF however RVEF was significantly lower in the mdx group, 
and correlated with ex vivo quantification change (MT r=-0.70 p=0.01, hydroxyproline assay r=-0.72 
p=0.008,) and R1 change (r=-0.83 p=0.006).  
EP3533 was further assessed as an outcome measure in quantifying the difference in R1 change 
between treated and untreated mdx mice following a 12 week treatment of an anti-fibrotic. Four age-
matched mouse groups (treated mdx, untreated mdx, treated BL10 and untreated BL10) were scanned 
at baseline using T1 mapping looking at skeletal muscle (TA, GCN, QUADS, HMS). Treated groups were 
administered IP halofuginone three times a week for 12 weeks. Control groups received vehicle 
injections via the same route. All mice underwent grip strength testing (two and four limb assessment) 
prior to a second scan with EP3533; they were then killed for ex vivo quantification of fibrosis. R1 
change was significantly different from baseline to follow up scan in three out of four muscles (GCN 
p=0.04, HMS p=0.009, and TA p=0.01) in the untreated mdx group only. In terms of absolute R1 change 
at follow up, there were no significant differences between the treated and untreated mdx groups 
(P=NS). Treated mdx mice had significantly less fibrosis than untreated mdx mice in all four muscles. 
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Correlation of R1 change was significant but less strong than in the first experiment, and varied 
between the two methods of ex vivo quantification. EP3533-induced R1 change correlated 
significantly but weakly to the functional assessment of grip strength (two r=-0.33 p=0.004, four r=-
0.32 p=0.06). 
In conclusion, EP3533 was used successfully to detect and quantify fibrosis in skeletal muscle and 
cardiac muscle, and detected differences between mdx and BL10 mice. SGd was unable to 
demonstrate the same difference. EP3533 was unable to detect change in response to treatment in 
absolute numbers, but did detect changes in values over the period of follow up, this may be in part 
due to variation in R1 change at baseline. EP3533-induced R1 change correlated significantly to a 
measure of right ventricular heart function and grip strength. Further studies in humans will eventually 
be required to confirm these findings of EP3533 as an outcome measure in DMD.   
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4.2 Results  
The development of this technique involved three separate experiments. The first (Section 1) was to 
find the optimal time for skeletal muscle imaging; the second (Section 2) was to assess the efficacy of 
EP3533 in vivo, and the final stage (Section 3) explored the use of EP3533 as an outcome measure 
following anti-fibrotic treatment. 
 
4.2.1 Section 1 – Pilot study of EP3533 in skeletal muscle 
Both the mdx and BL10 mouse survived the anaesthetic and were killed post-procedure. All muscle 
groups had increased SNR at 5 minutes, which may be due to interference from Gd enhancement in 
blood vessels. Levels of SNR in the mdx mouse reached a plateau at 60-90 minutes, and did not return 
to pre-contrast levels by the end of the scanning period (120 minutes). The BL10 mouse showed an 
initial peak in SNR at 5 minutes, and then plateaued at a much lower level from approximately 10 
minutes onwards (Figure 12). Differences between mdx and BL10 mouse muscles in signal were 
demonstrated most clearly in the TA muscles (Figure 13).  
The mice tolerated injection with EP3533 contrast agent and the prolonged scanning procedure. The 
greatest change in SNR was in the mdx mouse at 60-90 minutes. Due to this the optimal time to 
measure R1 change in lower limb skeletal muscle was taken as 70 minutes.     
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Figure 12. A line graph to display the dynamic changes in signal to noise ratio (SNR) in the mdx mouse (A) and the BL10 
mouse (B). All lines are lower in the BL10 mouse compared to the mdx muscles at the same time point suggesting that 
contrast enhancement was higher in certain mdx muscles compared to the BL10 mouse at these times. Note that the 
SNR increase is at a plateau from approximately 60 minutes onwards in the mdx mouse. In (B) from 60-65 minutes an 
artefact was present in the right TA muscle these points were therefore excluded.  
Key: TA, tibialis anterior, GCN, gastrocnemius, SNR, signal to noise ratio. 
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Figure 13. Comparison of signal to noise ratio (SNR) change in individual muscles between mdx and BL10 mice. The mdx 
tibialis anterior (TA) demonstrated the greatest SNR change compared to the BL10 TA. (A) Left TA, (B) Right TA, (C) Left 
gastrocnemius (GCN), (D) Right GCN. 
Key: SNR, signal to noise ratio, TA, Tibialis anterior, GCN, gastrocnemius. 
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4.2.2 Section 2 - Evaluation of the utility of EP3533 in assessing fibrosis within cardiac and 
skeletal muscle 
One mdx mouse died during the scanning process, most likely due to the stress of the anaesthetic. 
This mouse was therefore excluded from the MRI analysis and dissection. All other mice (BL10 n=5, 
mdx n=8) survived both scans and were included in the analysis. 
Post-contrast using continuous gated-T1w-GRE acquisitions it was possible to show dynamic change 
of signal in cardiac tissue over a one hour period. The peak change in SNR in the mdx using EP3533 
was at 40 minutes, with a smaller peak at 15-20 minutes (Figure 14). SGd scanning also demonstrated 
a small peak at 15 minutes; however after this the difference with BL10 mice was minimal. 
 
 
Figure 14. Line graph to show the results of the dynamic cardiac study. There is an increase in signal in the mdx mice 
during the scan using EP3533 at 10-15 minutes and again at 40 minutes. Each line represents the averaged values. All 
measurements are from ROI measurement of the left ventricle of T1 values from axial slice at the approximate middle 
of the ventricle during diastole. Due to the nature of cardiac gating measurement times are approximate; no 
measurements were taken from 40 minutes to 60 minutes due to T1 mapping acquisition, as highlighted in the grey 
rectangle.  
Key: blue lines, EP3533, red lines, scans with standard gadolinium (SGd).  
* - significant difference (p<0.001) between EP3533 scan and Gd-DOTA.    
 
  
* 
* 
* 
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Four mice (2 BL10, 2 mdx) were excluded from analysis with the T1 mapping data due to movement 
artefact. The remaining images (3 BL10, 6 mdx) were deemed of sufficient quality (Figure 15).  
 
 
Figure 15. Examples of T1 maps acquired pre and post-administration of EP3533 contrast (Murphy et al., 2018). Upper 
row shows lower limb muscles in an mdx mouse, while the lower row shows images at a similar location in a BL10 mouse. 
Contrast binding in muscle reduces the tissue T1 in the mdx mouse in the post-contrast scan (right), compared to the 
pre-contrast scan (centre). Non-homogenous signal increase is demonstrated as an increase in green in mdx lower limb 
muscles in the post-contrast images. These images demonstrate the change in T1 post contrast in the mdx mouse, which 
is evident in the tibialis anterior (TA) and gastrocnemius (GCN), but less obvious in the BL10 mouse where it is more 
homogenous in colour. 
Key: P, posterior, A, anterior, L, left, R, right, S, superior, I, inferior.   
 
  
68 
 
Change in R1 following EP3533 was higher in the muscle of mdx mice compared to BL10 mice, with 
significant differences in all three muscles (cardiac p=0.02, GCN p=0.04, TA p=0.04) (Figure 16Figure 
16).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quantification of fibrosis was performed using two methods: MT and hydroxyproline assay. To identify 
other disease features, sirius red and H&E staining was also performed (Figure 17). Taking all 
measurements from muscles into account, MT quantification and hydroxyproline correlated to a 
highly significant degree (r=0.64, p<0.001) suggesting a level of correlation between the two methods 
of ex vivo quantification. 
BL10 mice had significantly lower mean quantities of fibrosis when quantified with both MT (BL10 
heart 0.5% ±0.4 vs mdx 6.1% ±2, p<0.001, BL10 GCN 2.4% ±0.9 vs mdx 15.2% ±3.99, p<0.001, BL10 TA 
1.3% ±0.8 vs mdx 10% ±3, p<0.001) and hydroxyproline quantification (BL10 heart 2.8µg/mg ±1.5 vs 
Figure 16. Box plot showing R1 change between BL10 and mdx mice using EP3533 broken down by muscle (Murphy et al., 
2018). Cardiac muscle had the greatest change in R1 from baseline scan. All three muscles demonstrated a significant 
difference compared to BL10. Asterisks demonstrate outliers greater than three times the interquartile range (IQR).  
Key: green, BL10, red, mdx, GCN, gastrocnemius, TA, tibialis anterior. 
 
p=0.04 p=0.04 P=0.02 
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mdx 5.2µg/mg ±1.9 p=0.04, BL10 GCN 1.8µg/mg ±0.4 vs mdx 3.9µg/mg ±1.1 p=0.002, BL10 TA 
3.5µg/mg ±1.4 vs mdx 5.3µg/mg ±1.1 p=0.04) (Figures 17 and 18).  
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C 
Figure 2. Examples of transverse sections from gastrocnemius (GCN) muscles. Top row: Haematoxylin and eosin 
(H&E) staining – mdx section shows centrally located nuclei (marked as ‘A’) and evidence of extracellular fibrosis, 
with regenerated myocytes. Middle row: Sirius red stain – fibrosis is shown as areas of dark red (marked as ‘B’). 
Bottom row: Masson’s trichrome (MT) staining – fibrosis is shown as dark blue (marked as ‘C’) or larger focal areas 
appear as white regions. MT staining shows evidence of diffuse fibrosis in the extracellular space throughout, with 
focal fibrosis in some regions of muscle. Magnification of H&E stain is intentionally shown as higher to highlight 
the dystrophic features - x20 magnification, MT and Sirius red stains are shown as x10 magnification to 
demonstrate the extent of extracellular fibrosis (x10 magnification). 
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Figure 18. Bar charts to show ex vivo mean quantification of fibrosis in BL10 and mdx mice: top - Masson’s trichrome 
(MT), bottom - hydroxyproline assay. Both methods of quantification showed significant differences (p<0.05) between 
BL10 and mdx values in all types of muscle.  
Key: green, BL10, red, mdx, MT, Masson’s trichome.  
Error bars display standard error. 
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Change in R1 obtained during scans with EP3533 showed several strong and significant correlations 
(Table 5). The strongest correlation was seen between hydroxyproline and change in R1 using EP3533 
in the GCN muscle (r=0.83, p=0.001).  
 
Method of 
quantification 
Change in R1 GCN Change in R1 TA Change in R1 cardiac 
Masson’s trichrome  0.60 p=0.04* 0.62 p=0.03* 0.76 p=0.01* 
Hydroxyproline assay 0.83 p=0.001* 0.73 p=0.01* 0.73 p=0.02* 
Table 5. A table to demonstrate the calculated Pearson correlation of EP3533-induced R1 change and the two methods 
of ex vivo quantification. In all three muscles change in R1 and ex vivo measures correlated to a significant degree. 
* - p value < 0.05 
 
For measurement of cardiac function one mdx mouse had significant respiratory artefact during the 
cine scanning and was excluded from the analysis. RVEF was the only measure of cardiac function that 
was significantly higher in BL10 (59.9% ±11.3) compared to mdx mice (31.1% ±9.1) (p=0.01). Other 
parameters, LVEF and LVM, were not significantly different between mdx and BL10 mice (Figure 19). 
Heart rate was maintained between 300-400 bpm in both mouse groups.  
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Figure 19. Comparison between cardiac indices in left and right ventricular function in mdx and BL10 mice; no significant 
differences were seen between BL10 and mdx mice except in right ventricular ejection fraction (RVEF) (p=0.04). Asterisks 
demonstrate outliers greater than three times the interquartile range (IQR). Right ventricular mass and left ventricular 
mass were not significantly different between BL10 and mdx mice (p=NS) 
 
 
 
 
RVEF correlated inversely to a significant degree with MT quantification (r=-0.70, p=0.01) and 
hydroxyproline assay values (r=-0.72 p=0.008). Concentration of EP3533 as calculated using T1 
mapping correlated strongly to RVEF (r=-0.83 p=0.006) (Figure 20). LVEF and LVM did not significantly 
correlate to either of the ex vivo methods of fibrosis quantification. These findings demonstrate a 
significant relationship between increases in fibrosis, R1 change using EP3533 and cardiac dysfunction. 
 
 
P=0.01 
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Figure 20. Top row - correlation of right ventricular ejection fraction (RVEF) to ex vivo measures of fibrosis quantification 
(Masson’s Trichome (MT) and hydroxyproline assay).  Bottom row – correlation of RVEF to EP3533 derived R1 change in 
the heart. These graphs demonstrate the strong, significant correlation between RVEF and change in R1 (p=0.006), as 
well as the degree of correlation between ex vivo measures and change in R1. None of the other cardiac indices 
correlated significantly to change in R1 (p=NS).  
Key: green, BL10, red, mdx, RVEF, right ventricular ejection fraction, MT, Masson’s trichrome. 
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4.2.3 Section 3 - Evaluation of EP3533 in monitoring disease progression in response to 
anti-fibrotic treatment 
The final section of this chapter aims to evaluate whether EP3533 is sensitive enough to detect disease 
progression in skeletal muscle of mdx mice following administration of an established anti-fibrotic 
(Halofuginone).   
All mice (mdx n=21, BL10 n=6) tolerated the halofuginone, vehicle and EP3533 administration with no 
side effects attributed to the drug and no significant weight difference was seen between treated and 
untreated groups. There were no significant differences between BL10 mouse groups in terms of 
weight, functional assessment, ex vivo measures of fibrosis or baseline and follow up R1 change; the 
BL10 groups were therefore considered together for comparison with mdx mouse groups.   
 
4.2.3.1 Pharmacokinetics 
Pharmacokinetic results demonstrated that halofuginone was detectable in serum at six of the eight 
time points (5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours and 24 hours). The 
concentration range was from 2.85-21.2ng/ml with the highest peak at 5 minutes post-administration 
(Figure 21). Area under the curve analysis was 913.68ng/ml/min. 
 
Figure 21. A line graph demonstrating the change in serum halofuginone post - intraperitoneal (IP) administration of 
7.5ug (n=4). To allow inclusion of all time points, time is measured in minutes. The last five data points are at 1, 2, 4, 8 
and 24 hours respectively.   
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4.2.3.2 Inter-observer data 
Inter-observer consistency was assessed using Bland-Altman analysis of five randomly chosen scans. 
The observers had a mean difference in R1 change of 0.005s-1 (Figure 22). The 95% limits of agreement 
(LOA) were 0.05s-1, therefore no fixed bias was present. Four of the seven data points outside of the 
95% LOA were from where the two observers disagreed on the positioning of all four muscles at 40 
minutes in one mouse. These findings suggest an overall good, non-biased agreement between 
observers using this technique.  
 
Figure 22. A Bland-Altman plot to show the mean inter-observer differences in ROI analysis between two observers. Two 
observers calculated R1 change in all muscles of five mdx mice chosen at random and included all time points (0-70 
minutes) during the pre-treatment scan. Horizontal lines from top to bottom denote +1.96 standard deviation, the mean 
difference, and -1.96 standard deviation. 
 
 
4.2.3.3 Functional assessment 
All mice tolerated the grip strength testing with no signs of discomfort. Both treated groups had 
significantly lower starting weight than their respective control groups (mdx p=0.02, BL10 p=0.02). 
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Comparison of absolute force values demonstrated a significantly lower force in the two limb 
assessment (treated mouse group 1.3mN versus untreated mdx group 0.8mN, p=0.002). Treated mdx 
mice were not significantly different to BL10 mice (p=0.32); however untreated mdx were significantly 
lower than BL10 (p=0.035). No significant differences were seen when comparing the two BL10 
groups, or comparing all BL10 to all mdx mice. Four limb assessment was not significantly different in 
any of the mouse groups, except for untreated mdx compared to BL10 (p=0.048).   
Normalising force to weight, in the mdx cohort as a whole, there were no significant differences in the 
two or four limb assessments compared to the BL10 groups (p=0.85, p=0.72 respectively). The grip 
assessments were not significantly different between the treated and untreated BL10 groups (p=0.69) 
(Table 6).   
Two and four limb assessments demonstrated significantly larger value of weight normalised-force in 
the treated mdx compared to the untreated mdx (two limb p<0.001, four limb p=0.049) (Table 6). No 
significant differences were seen between the mdx treated group and the ‘all BL10’ group (two p=0.08, 
four p=0.52) (Table 6). The untreated mdx were significantly lower than the ‘all BL10’ group in the two 
limb assessment only (two p=0.04, four p=0.17). These findings lend support to the efficacy of the 
treatment and suggest that the treated mdx groups were able to generate similar force to the BL10 
groups. Furthermore the treated mdx group could generate significantly greater than the untreated 
mdx groups (p=0.002).  
Group Mean two limb weight normalised-
force (mN/g) 
Mean four limb weight normalised-
force (mN/g) 
All mdx 27.9 ±11.4 49.4 ±8.6 
All BL10 28.7 ±7.5 50.7 ±8.1 
mdx untreated 21.5 ±6.8 46.4 ±5.5 
mdx treated 37.0 ±10.6 53.7 ±10.7 
BL10 untreated 29.6 ±9.7 45.9 ±5.9 
BL10 treated 27.2 ±2.1 58.5 ±3.6 
Table 6. The table summarises the differences in force assessment between the four mouse groups. In the two limb 
assessment significantly lower force was demonstrated in the untreated compared to the treated mdx group (p=0.002). 
Significant differences were seen between the untreated mdx group and the BL10 group as a whole in both two (p<0.001) 
and four limb assessments (p=0.049). No difference was seen between the treated mdx and the BL10 groups. These 
findings suggest that the treated mdx were able to generate more force which suggests that the treatment may have 
been efficacious.   
 
4.2.3.4 Dynamic measurement of R1 change in skeletal muscle   
Gd-based contrast agents reduce the relaxation time (denoted as T1) in target tissue. Relaxivity rate, 
(denoted as R1) is the reciprocal of T1. The difference in R1 from baseline is calculated at ten minute 
intervals as a dynamic measurement of the tissue change in response to the contrast agent (Figures 
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23 to 25). In the pre-treatment scans the R1 change of the TA was significantly higher in the mdx 
groups than BL10, at all time points with the exception of 10 and 70 minutes (Table 7). In the GCN and 
the QUADS R1 change was only significantly higher in the mdx group at the 60 and 70 minute time 
points. At post-treatment scan, all muscles at 40, 50 and 60 minutes had significantly higher R1 change 
in the mdx groups (Table 7).  
In the pre-treatment scan, no significant differences were demonstrated between the mdx groups at 
any time points in any muscles, with the exception of the TA at 50 minutes (untreated mdx 0.09s-1 
±0.06 versus treated mdx 0.15s-1 ±0.05 p=0.04), and in the HMS at 70 minutes (untreated mdx 0.08s-1 
±0.05 versus treated mdx 0.12s-1 ±0.03 p=0.04) (Figure 23).  
In the post-treatment scan, there were no significant differences between the untreated and treated 
BL10 groups in any of the muscles at any of the time points (Table 7). Post-treatment R1 change in the 
untreated mdx groups demonstrated significantly higher values compared to the treated mdx in the 
HMS at 10-40 minutes and in the GCN at 20 minutes (Tables 8 to 9 and Figure 24).  These findings 
suggest a degree of variability and dependence on the timing of R1 measurement, 70 minutes was 
retained as the point for correlation and comparison as this had been used in the previous 
experiments (Sections 1 and 2). There was a lack of significant difference in the absolute value using 
the magnitude of R1 change alone in treated versus untreated mdx mouse groups. The following 
section will assess whether the degree of R1 change demonstrates a significant difference between 
the groups when comparing the pre-treatment scan to the post-treatment scan.  
In the halofuginone experiment, mean values of R1 change at follow up scan in the untreated mdx 
group (0.11-0.16s-1) were similar to the skeletal mdx muscle results seen in section 2 (skeletal muscle 
R1 change 0.14-0.15s-1). The similarity in values between separate experiments suggests that EP3533 
R1 change measurement is consistent.  
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 10 20 30 40 50 60 70 
mdx TA 0.08 
±0.04 
0.10 
±0.05* 
0.11 
±0.05* 
0.12 
±0.05* 
0.11 
±0.06* 
0.11 
±0.05* 
0.11 
±0.05 
BL10 TA 0.08 
±0.03 
0.10 
±0.02 
0.11 
±0.01 
0.12 
±0.01 
0.11 
±0.01 
0.11 
±0.02 
0.11 
±0.06 
mdx GCN 0.07 
±0.03 
0.08 
±0.04 
0.10 
±0.04 
0.09 
±0.04 
0.09 
±0.04 
0.10 
±0.04* 
0.09 
±0.04* 
BL10 GCN 0.03 
±0.05 
0.03 
±0.05 
0.04 
±0.06 
0.05 
±0.05 
0.04 
±0.06 
0.04 
±0.05 
0.01 
±0.004 
mdx HMS 0.07 
±0.03* 
0.08 
±0.03* 
0.09 
±0.04* 
0.10 
±0.04* 
0.10 
±0.04* 
0.11 
±0.04* 
0.10 
±0.05 
BL10 
HMS 
0.02 
±0.01 
0.02 
±0.00 
0.001 
±0.05 
0.02 
±0.04 
0.01 
±0.04 
0.03 
±0.04 
0.07 
±0.02 
mdx 
QUADS 
0.06 
±0.04 
0.07 
±0.05 
0.08 
±0.06 
0.08 
±0.06 
0.09 
±0.07 
0.09 
±0.12* 
0.08 
±0.00* 
BL10 
QUADS 
0.03 
±0.04 
0.03 
±0.05 
0.03 
±0.06 
0.04 
±0.06 
0.03 
±0.07 
0.001 
±0.12 
0.01 
±0.001 
Table 7. Comparing dynamic R1 change in mdx and BL10 groups at pre-treatment scan. All measurements were 
significantly higher in the mdx group at 60 minutes, only the gastrocnemius (GCN) and the quadriceps (QUADS) were 
significantly higher at 70 minutes.  
*p value <0.05 compared to contemporaneous control group.  
Key: TA, Tibialis anterior, GCN, Gastrocnemius, HMS, Hamstrings, QUADS, Quadriceps. 
 
 10 20 30 40 50 60 70 
mdx TA 0.09 
±0.04 
0.12 
±0.05 
0.14 
±0.05* 
0.15 
±0.04* 
0.15 
±0.05* 
0.14 
±0.06* 
0.15 
±0.04* 
BL10 TA 0.06 
±0.06 
0.09 
±0.08 
0.09 
±0.07 
0.10 
±0.08 
0.08 
±0.08 
0.07 
±0.01 
0.08 
±0.05 
mdx GCN 0.07 
±0.03* 
0.09 
±0.04* 
0.10 
±0.04* 
0.10 
±0.04* 
0.11 
±0.05* 
0.10 
±0.05*  
0.12 
±0.04* 
BL10 GCN 0.03 
±0.03 
0.03 
±0.04 
0.04 
±0.04 
0.05 
±0.04 
0.04 
±0.05 
0.04 
±0.05 
0.03 
±0.04 
mdx HMS 0.08 
±0.04 
0.10 
±0.04 
0.12 
±0.05 
0.12 
±0.05* 
0.12 
±0.05* 
0.12 
±0.04* 
0.12 
±0.05* 
BL10 
HMS 
0.06 
±0.04 
0.06 
±0.06 
0.08 
±0.06 
0.06 
±0.06 
0.06 
±0.06 
0.06 
±0.06 
0.05 
±0.05 
mdx 
QUADS 
0.05 
±0.03 
0.06 
±0.04 
0.07 
±0.04 
0.08 
±0.04* 
0.08 
±0.04* 
0.09 
±0.05* 
0.10 
±0.06 
BL10 
QUADS 
0.04 
±0.04 
0.05 
±0.04 
0.05 
±0.05 
0.04 
±0.05 
0.03 
±0.05 
0.04 
±0.06 
0.05 
±0.06 
Table 8. Comparing dynamic mean R1 change in mdx and BL10 groups at post-treatment scan. There were significant 
differences between BL10 and mdx mouse groups at 70 minutes during the post-treatment scan in the tibialis anterior 
(TA), gastrocnemius (GCN) and the hamstrings (HMS). 
*p value <0.05 compared to contemporaneous control group. 
Key: TA, Tibialis anterior, GCN, Gastrocnemius, HMS, Hamstrings, QUADS, Quadriceps. 
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 10 20 30 40 50 60 70 
Untreated 
TA 
0.09 
±0.04 
0.13 
±0.05 
0.15 
±0.05 
0.15 
±0.05 
0.15 
±0.06 
0.15 
±0.06 
0.16 
±0.05 
Treated 
TA 
0.08 
±0.04 
0.10 
±0.05 
0.13 
±0.03 
0.14 
±0.03 
0.14 
±0.05 
0.13 
±0.05 
0.15 
±0.04 
Untreated 
GCN 
0.07 
±0.03 
0.10 
±0.03 
0.11 
±0.04 
0.12 
±0.05 
0.12 
±0.05 
0.12 
±0.05 
0.13 
±0.03 
Treated 
GCN 
0.05 
±0.03 
0.07 
±0.04* 
0.08 
±0.04 
0.09 
±0.04 
0.09 
±0.05 
0.08 
±0.05 
0.10 
±0.04 
Untreated 
HMS 
0.08 
±0.04 
0.11 
±0.03 
0.13 
±0.04 
0.14 
±0.05 
0.13 
±0.05 
0.13 
±0.05 
0.13 
±0.04 
Treated 
HMS 
0.05 
±0.03* 
0.07 
±0.04* 
0.09 
±0.04* 
0.09 
±0.04* 
0.10 
±0.04 
0.10 
±0.04 
0.10 
±0.05 
Untreated 
QUADS 
0.06 
±0.03 
0.07 
±0.04 
0.08 
±0.04 
0.08 
±0.04 
0.09 
±0.04 
0.11 
±0.05 
0.11 
±0.06 
Treated 
QUADS 
0.03 
±0.04 
0.04 
±0.04 
0.05 
±0.04 
0.07 
±0.04 
0.06 
±0.04 
0.07 
±0.04 
0.08 
±0.05 
Table 9. Comparing dynamic R1 change in treated and untreated mdx groups at post-treatment scan. No significant 
differences were demonstrated between the untreated and treated mdx groups in terms of absolute R1 change value 
values at 60 or 70 minutes. 
*p value <0.05 compared to untreated contemporaneous mdx group.  
Key: TA, Tibialis anterior, GCN, Gastrocnemius, HMS, Hamstrings, QUADS, Quadriceps. 
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Figure 23. Dynamic R1 change over the period of the pre-treatment acquisition, each graph represents a different muscle: 
(A) Tibialis anterior (TA), (B) Gastrocnemius (GCN), (C) Hamstrings (HMS), (D) Quadriceps muscles (QUADS). Lines 
represent mean values of R1 change. Error bars display standard error for the groups at baseline. Untreated mdx (n=13), 
treated mdx (n=8), BL10 (n=3). One image was not analysable in the BL10 group at 70 minutes, at this time therefore 
n=2. These graphs demonstrate the variability of R1 change from baseline in individual muscles. There was minimal 
difference between the two mdx groups over the period of scanning suggesting that at baseline scan there were no 
significant differences prior to treatment. It is possible to detect a difference between BL10 and mdx mice at this age 
although this is only significant at certain time points and is variable.    
Key: red, untreated mdx, blue, treated mdx, green, BL10.   
0.00
0.05
0.10
0.15
0.20
0 10 20 30 40 50 60 70
C
h
an
ge
 in
 R
1 
fr
o
m
 
b
as
el
in
e 
(s
-1
)
TIme (minutes)
Untreated mdx Treated mdx BL10
0.00
0.05
0.10
0.15
0.20
0 10 20 30 40 50 60 70
C
h
an
ge
 in
 R
1 
fr
o
m
 
b
as
el
in
e 
(s
-1
)
Time (minutes)
Untreated mdx Treated mdx BL10
0.00
0.05
0.10
0.15
0.20
0 10 20 30 40 50 60 70C
h
an
ge
 in
 R
1 
fr
o
m
 
b
as
el
in
e 
(s
-1
)
Time (minutes)
Untreated mdx Treated mdx BL10
0.00
0.05
0.10
0.15
0.20
0 10 20 30 40 50 60 70C
h
an
ge
 in
 R
1 
fr
o
m
 
b
as
el
in
e 
(s
-1
)
Time (minutes)
Untreated mdx Treated mdx BL10
D
A 
 
B 
 
C 
 
82 
 
 
 
 
Figure 24. Dynamic R1 change over the period of the post-treatment acquisition, each graph represents a different 
muscle: (A) Tibialis anterior (TA), (B) Gastrocnemius (GCN), (C) Hamstrings (HMS), (D) Quadriceps muscles (QUADS). Lines 
represent mean values of R1 change. Error bars display standard error for the groups at follow up. Untreated mdx (n=13), 
treated mdx (n=8), Treated BL10 (n=3), Untreated BL10 (n=5). The proximal slices in one of the treated mdx was not 
analysed in the due to an artefact therefore QUADS and HMS are based upon one fewer subject (n=12). There were no 
significant differences in R1 change at 70 minutes comparing the two mdx groups. There were significant differences 
between the BL10 groups and the mdx groups in three out of four muscles.    
Key: red, untreated mdx, blue, treated mdx, green, BL10.  
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4.2.3.5 Comparison of R1 values at 70 minutes between pre-treatment and post-
treatment scans  
Comparison of the R1 change from pre-treatment to post-treatment scan at 70 minutes, in the three 
groups with paired longitudinal data, (mdx treated, mdx untreated, and BL10 groups) demonstrated 
significant increases in R1 values at 70 minutes in the untreated mdx group (GCN p=0.04, HMS 
p=0.009, and TA p=0.01). The QUADS in this group did not demonstrate a significant change (p=0.20). 
There were no significant differences comparing pre-treatment to post-treatment scan values for any 
of the muscles in either of the other two groups (Table 10).  
Comparing R1 values of treated mdx and BL10 groups together demonstrated significantly higher 
values in the former group at post-treatment in the TA p=0.006, and the GCN p=0.009.  
It is possible to calculate the SRM value for the different muscles at 70 minutes; the TA had the highest 
SRM (0.56), then GCN (0.48), with the QUADS and HMS demonstrating the lowest SRM value (both 
0.36). 
 
 
Group Muscle Mean R1 change at 70 
minutes pre-treatment 
(s-1) 
R1 change at 70 
minutes post-
treatment (s-1) 
P value 
Untreated 
mdx 
(n=13) 
TA 
GCN 
HMS 
QUADS 
0.09 ±0.06 
0.08 ±0.04 
0.08 ±0.05 
0.08 ±0.04 
0.16 ±0.05 
0.13 ±0.04 
0.13 ±0.04 
0.11 ±0.07 
0.01* 
0.04* 
0.009* 
0.20 
Treated 
mdx 
(n=8) 
TA 
GCN 
HMS† 
QUADS† 
0.13 ±0.03 
0.10 ±0.04 
0.12 ±0.04 
0.08 ±0.02 
0.15 ±0.04 
0.10 ±0.04 
0.10 ±0.05 
0.08 ±0.05 
0.33 
0.79 
0.23 
0.70 
BL10 
treated 
(n=3) 
TA 
GCN 
HMS 
QUADS 
0.07 ±0.06 
0.01 ±0.00 
0.07 ±0.02 
0.10 ±0.00 
0.05 ±0.05 
0.03 ±0.05 
0.07 ±0.02 
0.07 ±0.05 
0.88 
0.69 
0.50 
0.36 
BL10 
untreated 
(n=5) 
TA~ 
GCN 
HMS 
QUADS 
N/A 
N/A 
N/A 
N/A 
0.08 ±0.05 
0.03 ±0.04 
0.05 ±0.06 
0.04 ±0.07 
N/A 
N/A 
N/A 
N/A 
Table 10. Comparison of R1 changes at 70 minutes at pre-treatment and post-treatment. In the untreated mdx group the 
tibialis anterior (TA), gastrocnemius (GCN) and hamstrings (HMS) all demonstrated a significant difference from pre-
treatment to post-treatment scan. This was not evident in the treated mdx group. 
*p value<0.05 compared to pre-treatment R1 change 
†Linear artefact through proximal slices in two mice, HMS and quads not analysed (n=6).  
~One image removed due to image artefact at 70 minutes (n=4) 
Key: TA, Tibialis anterior, GCN, Gastrocnemius, HMS, Hamstrings, QUADS, Quadriceps, N/A, not applicable. 
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4.2.3.6 Ex vivo measures of fibrosis 
Histological analysis demonstrated the diffuse nature of the fibrotic changes in mdx mouse muscle 
and comparative differences between groups (Figures 25 and 26). All treated mdx muscles 
demonstrated significantly lower mean levels of fibrosis compared to untreated, using hydroxyproline 
assay (Figure Figure 27). Comparing treated to untreated mdx, MT quantification was significantly 
lower in three of the four muscles, except for the QUADS (p=0.06) (Figure 27). These results suggest 
that the levels of fibrosis were lower in the majority of muscles in treated mdx groups. 
BL10 muscles had significantly lower levels of fibrosis compared to untreated mdx using both methods 
of quantification. Hydroxyproline quantification suggested that only the HMS had significantly lower 
levels of fibrosis in BL10 compared to treated mdx (p=0.01). In contrast, MT quantification suggested 
that the treated mdx group had significantly higher levels of fibrosis in the GCN (p=0.001), QUADS 
(p=0.001), and the TA (p=0.003) (Figure 27). 
Pearson correlation between hydroxyproline and MT quantification was significant (r=0.57, p<0.001). 
suggesting a significant correlation between the two methods of ex vivo quantification. 
 
4.2.3.7 Correlation of EP3533 to ex vivo measures of fibrosis 
R1 change at 70 minutes in all muscles at post-treatment scan correlated significantly with Masson’s 
trichrome (Table 11). R1 change at post-treatment correlated in three out of four muscles with 
hydroxyproline. The strongest correlations to ex vivo measures of fibrosis were in the GCN muscle 
(Table 11). 
 
Method of 
quantification 
Change in R1 
TA 
Change in R1 
GCN 
Change in R1 
HMS 
Change in R1 
QUADS 
Masson’s trichrome  0.84** 0.80** 0.59* 0.59* 
Hydroxyproline assay 0.58* 0.59* 0.41* 0.24 
Table 11. Table to show Pearson correlation R values between R1 change at post-treatment scan and ex vivo measures 
of fibrosis.  
* - P value is less than 0.05, ** - P value <0.001. 
Key: TA, Tibialis anterior, GCN, Gastrocnemius, HMS, Hamstrings, QUADS, Quadriceps.
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A B C 
D E F 
Figure 25. Examples of transverse sections from gastrocnemius (GCN) muscles. Top row: collagen 1 immunofluorescent staining with DAPI, areas of red are areas with collagen 1, 
nuclei are highlighted as blue using DAPI. Magnification x10. A) mdx untreated with large highlighted collagen-rich regions. B) Treated mdx mice demonstrating focal areas of 
fibrosis and areas of endomysial collagen 1. C) BL10 group limited fibrosis evident, nuclei are peripherally located. Bottom row - H&E Staining. D) mdx untreated areas of fibrosis 
in white with varying myocyte size and centrally located nuclei. E) Treated mdx – fewer areas of fibrosis, though with similar variation in myocyte size and centrally located nuclei. 
F) BL10 group with regularly sized myocytes and peripheral nuclei.  
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A 
B 
C 
Figure 26. Masson’s trichrome (MT) staining x20 magnification – fibrosis is dark blue. A) mdx treated shows diffuse 
fibrosis in the extracellular space throughout. B) treated mdx fewer areas of blue staining. C) BL10 group 
demonstrating small amounts of blue staining. 
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Figure 27. Bar charts to show the differences in ex vivo quantification of fibrosis within muscle between treated mdx, 
untreated mdx and BL10 groups. A) hydroxyproline quantification, B) MT quantification. Significant differences are seen 
between the all muscles of the untreated mdx mice and the BL10 group using bother measures of fibrosis. Using Masson’s 
trichrome (MT) quantification, all muscles were significantly lower in the treated mdx group compared to the untreated. 
Hydroxyproline quantification identified 3/4 of these muscles as significantly lower in the treated mdx group. Error bars 
represent standard error.  
* p value <0.05 
Key: GCN, Gastrocnemius, HMS, Hamstrings, QUADS, Quadriceps, TA, Tibialis anterior.
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4.2.3.8 Correlation of EP3533 to functional assessment 
None of the two or four limb force assessments significantly correlated to the change in R1 values at 
follow up, in either the individual muscles or all muscles grouped together (p=NS). Considering all 
muscles together, the change in R1 values from baseline to follow up scan correlated significantly, 
albeit weakly, to two limb assessment (two r=-0.33 p=0.004, four r=-0.32 p=0.06) (Figure 28). The 
correlation here may suggest there is an association between R1 change at post treatment and muscle 
function, the lack of a strong correlation may be due to the other compounding factors that influence 
muscle function. 
 
Figure 28. Scatter graph of the relationship of force assessment using two and four limbs to the change in R1 value from 
pre-treatment to post treatment. Demonstrating the weak correlation between the two types of assessment and change 
in R1.  
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Chapter 5: Results of quantitative MRI in the assessment of long term 
changes in skeletal muscle in limb girdle muscular dystrophy type R9 
 
5.1 Summary 
The LGMD are a group of heterogeneous neuromuscular diseases, LGMDR9 is a subtype with a slowly 
progressive and variable phenotype. Few natural history studies have investigated this cohort. With 
the development of several promising putative therapies, there is a real need to develop and validate 
outcome measures for clinical trials. A previous study performed by Willis et al. in 2010 followed up a 
group of 34 participants over a twelve month period (Willis et al., 2013). They compared MRI measures 
(i.e. Dixon technique FF calculation) to standardised functional assessments (i.e. 6MWT, timed up and 
go). Willis et al. found that quantitative MRI using FF calculation was able to detect a significant change 
in 9 of the 14 muscle groups studied. Both semi-quantitative MRI grading of conventional T1-weighted 
imaging using the Mercuri scale and functional muscle assessments were unable to demonstrate 
significant changes over the same period (Willis et al., 2013).  
For this study, participants were recruited six years after their participation in the original study to 
undergo calculation of the FF of upper and lower leg skeletal muscles and standardised functional 
assessments. The aim was to compare these outcome measures and investigate whether they were 
able to detect a significant change over this time period.  
Participants were recruited from the four original sites, in Newcastle upon Tyne, Paris, Copenhagen 
and London. A three point Dixon acquisition was used to calculate the FF in fourteen muscle groups 
of the upper and lower legs for each subject. Participants underwent the following standardised 
functional assessments: myometry of the lower limbs (knee extension and flexion, hip adduction and 
abduction), timed tests (timed up and go, 6MWT, and 10MWR, chair rise, stair ascend and descend), 
and spirometry testing. 
A total of 23/34 participants from the original study were available and recruited into the six year 
follow-up study. All fourteen muscles and selected composite groups demonstrated a significant 
increase in fat content over the six year period. Of the timed tests all functional assessments and FVC 
demonstrated a significant decline over six years. Of all the myometry measurements only hip 
adduction significantly declined over the period of follow up. Significant correlations were seen in 
18/20 muscles at six years with the 6MWT test and the 10MWR.    
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The results of this study suggests that FF measurement using the Dixon technique is sensitive to 
changes over a six year period in all skeletal muscles. Use of the Dixon technique has several 
advantages over standardised functional assessments and can provide useful interim measures of 
disease progression which is not currently possible with functional assessment. The results of this 
study support FF calculation in LGMDR9 clinical trials as a primary outcome measure alongside 
functional assessments. The results suggest the most appropriate target muscles for analysis are the 
VL, Gr, Sar, and the MG and LG.  The 10MWR, 6MWT and spirometry are the selected as the most 
appropriate functional measures that could be used as outcome measures in a therapeutic trial over 
a six year period. 
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5.2 Results 
5.2.1 Recruitment 
Of the 38 participants in the baseline study, 23 participated in the six year follow up reassessment; 
the recruitment rate was overall therefore 60.5% across the four sites. The following reasons were 
given for not taking part in the six year follow up: subject was deceased (n=1), contraindication to MRI 
(implantable cardioverter defibrillator (ICD)) (n=2), undergoing treatment for a comorbidity (n=2), 
uncontactable (n=2) or declined to participate for various personal reasons (such as difficulties in 
travel) (n=8). Recruitment in all four sites took place from June 2015 to February 2017. All 23 
participants completed both the skeletal muscle MRI and the functional assessments. Fourteen 
muscle groups were assessed, 9 in the proximal leg and 5 in the distal leg. Identification of the borders 
of the muscle groups was more difficult in those with higher percentages of fat replacement.   
At baseline assessment the median age of the participants (n=23) was 39.1 years (interquartile range 
(IQR) 27.4-50.6). Median length of follow-up was 6.1 years (IQR 5.8 to 6.1). In the original study by 
Willis et al., participants were required to be ambulant with an ability to walk over 50m (Willis et al., 
2013, Willis et al., 2014): by six years, six participants were non-ambulant. At baseline, no participants 
received NIV, by six years five participants required NIV overnight. Seven participants received cardio-
active medication at baseline and this had increased to thirteen six years later.  
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5.2.2 Inter-observer consistency 
Inter-observer consistency of ROI analysis was assessed using the Bland-Altman analysis (Figure 29). 
The observers reported a mean difference in FF of 0.05%. The muscle with the widest 95% LOA 
between observers was the BFSH at 10.46% (Table 12). ROI analysis of this muscle was difficult 
because of the small size and irregular shape. 
 
Figure 29. A Bland-Altman plot to show the mean inter-observer differences in ROI analysis between two observers. This 
includes all measurements of all participants’ muscles in both left and right legs. Horizontal lines from top to bottom 
denote +1.96 standard deviation, the mean difference, and -1.96 standard deviation. 95% limits of agreement (LOA) were 
-3.92 and 4.02. Eight of the furthest outliers were from inter-observer differences in values for the rectus femoris (RF) in 
two of the participants. This was due to the difficulties in identifying the borders due to large amounts of peripheral fat 
in the muscle. 
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Muscle Bias (%) 95% Limit of 
Agreement (%) 
Biceps femoris short head 0.11 10.46 
Gracilis -0.03 4.44 
Rectus femoris 0.28 3.75 
Vastus medialis 0.45 3.37 
Sartorius 0.09 3.23 
Semitendinosus 0.34 3.21 
Lateral gastrocnemius -0.18 3.11 
Medial gastrocnemius -0.53 3.07 
Semimembranosus 0.09 3.04 
Vastus lateralis 0.14 2.28 
Biceps femoris long head 0.05 2.25 
Peroneus longus 0.04 1.83 
Tibialis anterior -0.84 1.24 
Soleus -0.03 1.12 
 
Table 12. Comparing inter observer differences between muscles in terms of bias and 95% limits of agreement (LOA) for 
fat fraction (FF) between observers in individual muscles. Data presented as bias (mean difference) and LOA (1.96 times 
the standard deviation of the differences between observers). The widest LOA were between different observers 
regarding the BFSH, which was difficult to identify due to the shape of the muscle. The gracilis (Gr) and rectus femoris 
(RF) muscles had the next widest LOA at 4.44 and 3.75 respectively. 
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5.2.3 Functional assessments 
All of the timed assessments of patients demonstrated a significant change over six years (Table 13). 
Of the myometry assessments, only measurement of the hip adduction decreased significantly over 
the period of follow up (median baseline 6.1kg, median six years 4.2kg, p=0.02). FVC measured in both 
positions significantly declined over six years (Table 13).  
Functional assessment Median baseline 
(range) 
Median six 
years (range) 
P value SRM 
Forced vital capacity sitting (%)† 77 (55-94) 64 (31-86) 0.001* -1.29 
Forced vital capacity lying (%)$ 70 (36-90) 54 (21-84) 0.002* -1.06 
Hip flexion (kg) 7.7 (0-36.8) 6.4 (0-24.3) 0.13 -0.35 
Hip adduction (kg) 6.1 (0.7-26.7) 4.2 (0-23.9) 0.02* -0.59 
Hip abduction (kg) 8.3 (0.6-25.0) 7.2 (2.2-25.3) 0.76 -0.01 
Knee extension (kg) 11.1 (2.0-40.3) 12.0 (1.5-39.1) 0.15 -0.26 
Knee flexion (kg) 8.4 (0.9-30.0) 4.8 (0-37.9) 0.21 -0.12 
Ankle dorsiflexion (kg) 14.7 (2.5-38.6) 13.9 (2.4-26.3) 0.07 -0.42 
Six-minute walk (meters) 391 (67-625) 286 (0-750) 0.001* -0.85 
Timed up and go velocity (ms-1)‡ 0.5 (0-1.7) 0.3 (0-1.6) 0.007* -0.48 
Ten-meter walk or run velocity (ms-1)‡ 1.2 (0.5-4.4) 0.8 (0-3.9) <0.001* -1.02 
Stair ascent velocity (steps/s-1)‡ 0.7 (0-4.4) 0.4 (0-3.0) 0.001* -0.46 
Stair descent velocity (steps/s-1)‡ 1.2 (0-4.4) 0.4 (0-3.3) 0.008* -0.47 
Chair rise (s)~ ‡ 
2.6 (0.3 to ∞) 9.8 (0.5 to ∞) 0.001* N/A 
Table 13. The median change in functional assessments over the follow up of six years (n=23). The only myometry 
measurement that was significantly reduced over the follow up period was hip adduction. Both measures of FVC, all 
timed tests significantly changed over the follow up period.   
P values calculated using Wilcoxon non-parametric rank signed test. * P value <0.05. SRM – standardised response mean. 
† Paired values available in 17 participants 
~ Participants unable to perform the chair rise were given a value of 10,000 (effectively infinity) for the purposes of the 
Wilcoxon non-parametric rank signed test. 
$ Paired values available in 16 participants 
‡ Paired values available in 22 participants  
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Several of the functional tests (timed up and go, 10MWR, stair ascend and stair descend, 6MWT test) 
require ambulation for the test to take place. Ability for the participants to complete timed 
assessments is measured in duration to complete the test. Participants are also assigned a grade 
depending on their use of compensatory mechanisms. The grading is from ‘1 - unable’, to ‘6 - with no 
support or normal function’. While the grading scale is not weighted to allow direct statistical 
comparisons, it does take account of compensatory mechanisms that may be employed by a 
participant to maintain their speed in the face of increased weakness. The participants at six years 
showed a significant reduction in all timed assessment grades except for the stair ascend (p=0.06) 
(Table 14). 
 
Test Number 
increased grade 
Number 
decreased grade 
Unchanged grade P 
value~ 
Ten metre walk or run (%) 2 (8.7) 14 (60.9) 7 (30.4) 0.006* 
Chair rise (%) 0 (0) 14 (60.9) 9 (39.1) 0.001* 
Stair ascend (%) 5 (21.7) 11 (47.8) 7 (30.4) 0.06 
Stair descend (%) 4 (17.4) 9 (39.1) 10 (43.5) 0.01* 
Table 14. To show the change in grading of the timed tests over six years: Ten metre walk or run (10MWR), chair rise, 
stair ascend and stair descend. The majority of participants decreased their grade suggesting that more participants were 
using compensatory mechanisms or were unable than at baseline.  
*p value <0.05.  
~ Calculated using Wilcoxon non-parametric signed test. 
 
The 6MWT demonstrated a significant reduction in distance from median baseline of 391 metres (67 
to 625) to 286 metres (0 to 750) at six years (p=0.001) (Table 13). Four participants improved from 
their first assessment at baseline by a mean increase of 68.8 metres ±50.3 at six years (Figure 30). 
These four subjects were from different sites and showed a FF increase of at least 1% in the majority 
of the 20 muscle groups and composite groups studied (15/20 groups for 1 patient, 19/20 groups for 
2 patients and all groups for 1 patient). No significant differences between those that improved were 
seen in terms of age (improved 37.7 years (24.1 to 68.9) versus declined 47.5 years (14.1 to 70.5), 
p=0.49). Median fat content was lower in all muscles at baseline and six year follow up in the 
participants that improved on the 6MWT, however this didn’t reach significance and there was 
significant overlap. There were no significant differences in the rate of fatty transformation in this 
group as detected by MRI over the six years.  
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Figure 30. The line chart shows the individual participant scores on the six minute walk test (6MWT). As demonstrated 
here, four participants improved over the four years. No obvious cut off for loss of ambulation is noted, although half of 
those walking under 300m at baseline were non ambulant at six years. Red lines – participants that declined from 
baseline to year six. Green lines – participants that improved from baseline to year six. 
 
Data from the baseline NSAA was available only from Newcastle site participants (n=10). Participants 
had a significantly higher mean total score of 20 ± 11 at baseline and 10 ± 11 at six year follow up 
(p=0.04). Individual loss of NSAA score is shown in Figure 31. 
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Figure 31. Waterfall plot of loss in North star ambulatory assessment (NSAA) scores. All participants had decline in score 
over six years, a greater number of points were available to lose in those who were more functional at baseline.  Each 
blue bar is an individual assessed over the six year follow up period, values are obtained by taking the total score at 
baseline from the total score at follow up. Numbers in brackets are the percentage of loss of points from baseline.  
 
5.2.4 Quantitative Dixon fat fraction 
Over the six years, all 14 muscle groups demonstrated a significant increase in percentage of fat 
replacement (Table 15 and Figure 32). The highest median percentage of fat replacement at baseline 
was in the BFLH at 69.4%, increasing to 78.6% at six years. The TA muscle was least affected at 
baseline, median 5.2% and at follow-up, median 7.1%. The TA also had the smallest median change 
over the six year period (Table 15). The inter-observer variability in FF demonstrated in the BFLH, ST 
and SM muscles may be caused by high levels of fat replacement at follow-up, making recognition of 
ROI borders difficult. The BFSH had the widest LOA of any of the muscles (Table 12), this is likely due 
to the small size of the muscle in the transverse plane. The RF muscle had one of the next widest LOA 
and had difficult to define borders when replaced by fat (Figure 33). The values of the RF muscle from 
two participants were excluded from analysis due to the high levels of discrepancy between observers 
in ROI placement. 
Following analysis of the FF results, a post-hoc group of potential ‘target muscles’ for use in future 
clinical trials was identified. These muscles demonstrate significant change at one year (Sol was 
excluded as the change was not significant over this time period (Willis et al., 2013)), allowing an 
interim analysis, and demonstrate disease progression with the highest SRM. They are reported as an 
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additional composite group using area-weighted FF averaging (Table 15). The averaged target muscle 
group consisted of the VL, Gr, Sar, MG and LG.  
 
Muscle group Median baseline 
(range), % 
Median six 
years (range), % 
P value SRM 
Rectus femoris† 10.8 (0.9-81.9) 19.9 (0.4-92.2) <0.001* 0.90 
Vastus medialis 21.0 (1.1-86.6) 44.4 (2.5-87.9) <0.001* 0.83 
Vastus lateralis 13.7 (1.5-65.2) 36.1 (2.8-81.7) <0.001* 0.92 
Sartorius 20.9 (1.7-89.8) 34.2 (5.4-88.3) <0.001* 0.98 
Gracilis 18.4 (3.7-81.0) 32.4 (4.5-90.2) <0.001* 1.04 
Biceps femoris long head 69.4 (2.2-97.7) 78.6 (4.8-100) 0.001* 0.81 
Biceps femoris short head 21.3 (3.2-94.5) 32.5 (4.6-84.3) 0.002* 0.53 
Semitendinosus 35.6 (2.1-100) 69.6 (4.1-100) <0.001* 0.83 
Semimembranosus 25.7 (0.5-95.1) 53.4 (4.6-99.2) <0.001* 0.90 
Tibialis anterior 5.2 (0.9-25.3) 7.1 (1.1-27.1) 0.002* 0.67 
Peroneus longus 15.8 (3.0-46.2) 18.0 (4.6-65.2) 0.001* 0.88 
Soleus 7.5 (1.8-67.4) 16.7 (3.1-70.1) <0.001* 1.17 
Lateral gastrocnemius 19.4 (0.9-76.1) 35.8 (3.1-75.2) <0.001* 0.91 
Medial gastrocnemius 19.9 (1.1-91.8) 48.0 (2.8-84.2) <0.001* 0.95 
Averaged thigh† 30.8 (2.1-76.2) 47.3 (4.2-82.1) <0.001* 1.20 
Averaged lower leg 15.4 (1.6-56.1) 26.8 (3.4-55.5) <0.001* 1.28 
Averaged quadriceps† 23.0 (1.3-67.6) 40.4 (2.6-79.8) <0.001* 1.05 
Averaged hamstrings 45.0 (2.8-97.8) 60.4 (4.7-98.7) <0.001* 0.93 
Averaged triceps surae 16.7 (1.4-74.2) 30.3 (3.3-72.6) <0.001* 1.25 
Averaged target muscles 21.5 (1.8-70.8) 43.8 (3.6-76.9) <0.001* 1.23 
Table 15. Median muscle fat fractions (FF) at baseline and six-year follow up. All muscles and composite muscle measures 
of FF were significantly increased over the six years. The measures with the strongest standardised response mean (SRM) 
were the averaged lower leg, triceps surae, and target muscles.   
P values calculated using Wilcoxon non-parametric rank signed test.  
* P value<0.05. SRM – standardised response mean. 
† Due to difficulties in ROI placement in the rectus femoris (RF) muscle the FFs for two of the participants were excluded 
for this muscle group (n=21). As the RF measures are excluded from two participants it is not possible to create composite 
measures (thigh and quadriceps (QUADS)) involving this muscle for these participants. The thigh and QUADS measures 
are based on 21 participants.   
Key: SRM, standardised response mean. 
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Figure 32. Box plot showing the change in fat percentage from baseline to six years. This demonstrates that the muscles 
with the largest median change were the triceps surae, target muscles and the lateral gastrocnemius (GCN).  The blue 
bars show the interquartile range (IQR) and the median. The lines show the range of the data. Outliers that are one to 
three times the IQR are marked as circles. Outliers greater than three times the IQR from the median are shown as 
individual asterisks. The median change is shown for each muscle group on the left side.  
†Due to difficulties in region of interest (ROI) placement in the rectus femoris (RF) muscle the fat fractions (FF) for two 
of the participants were excluded for this muscle group, and no composite results calculated where appropriate (n=21). 
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Figure 33. Images showing the change in fat replacement over six years. Fat fraction (FF) maps acquired from the 
left thigh and lower leg at baseline and six-year follow up. Progression of fat replacement was visible in almost all 
muscles, with changes most noticeable in the muscles relatively spared at baseline, such as the sartorius (Sar) (in 
this participant FF increased from 21.3% to 34.2%) and the Gracilis (Gr) (increased from 40.3% to 58.7%) muscles. 
As indicated by the white arrow (A), fat replacement began at the borders of the rectus femoris (RF) muscle at both 
baseline and six years, which caused difficulties in ROI placement. In this participant, the FF was 78.9% at baseline 
increasing to 81.9% at six years. The shape and size of the biceps femoris short head (BFSH) muscle also caused 
difficulties in ROI placement as demonstrated by the white arrow (B). 
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5.2.5 Cross sectional area and contractile cross sectional area 
The CSA and cCSA results are presented in Table 16Table . The CSA did not significantly decline in any 
of the muscles over the period of the study. The cCSA was significantly decreased in 8 of the 14 
individual muscles and in all of the averaged muscle groupings (Table 16).  
 
Muscle group CSA 
baseline 
(mm2) 
CSA six 
years 
(mm2) 
c-CSA 
baseline 
(mm2) 
c-CSA 
six years 
(mm2) 
P value c-CSA 
SRM 
Rectus femoris† 343 344 260 232 0.009* -0.51 
Vastus medialis 720 932 428 389 0.11 -0.15 
Vastus lateralis 1639 1517 1195 1025 0.003* -0.62 
Sartorius 402 425 346 231 0.06 -0.41 
Gracilis 344 309 168 154 0.003* -0.64 
Biceps femoris long head 1012 911 316 145 0.02* -0.49 
Biceps femoris short head 153 157 110 81 0.63 -0.16 
Semitendinosus 687 679 316 206 0.002* -0.71 
Semimembranosus 685 671 410 301 0.04* -0.37 
Tibialis anterior 568 569 536 537 0.67 -0.20 
Peroneus longus 578 546 464 436 0.09 -0.29 
Soleus 1803 1635 1512 1430 0.09 -0.35 
Lateral gastrocnemius 553 523 435 317 0.04* -0.39 
Medial gastrocnemius 1243 993 879 516 0.02* -0.53 
Averaged thigh† 6024 6071 3288 3087 0.006* -0.55 
Averaged lower leg 4263 4264 3637 3365 0.01* -0.52 
Averaged quadriceps† 3078 3103 2017 1577 0.01* -0.44 
Averaged hamstrings 2322 2347 1101 842 0.007* -0.63 
Averaged triceps surae 3272 3113 2834 2469 0.009* -0.53 
Averaged targeted muscles 4211 3803 2745 2248 0.005* -0.67 
Table 16. Median cross-sectional area (CSA) and contractile cross sectional area (c-CSA) at baseline and at six year follow 
up. All p values quoted refer to c-CSA. There are no significant changes in CSA between baseline and six years. C-CSA are 
shown to be significantly different over the period of follow up in fewer of the muscles than fat fraction (FF) alone. The 
standardised response means (SRM) are highest in the semitendinosus, though not has high as using FF alone (Table 13). 
Key: SRM, Standardised response mean, CSA, cross sectional area, c-CSA, contractile cross sectional area. 
*Denotes a p value <0.05.  
† Due to difficulties in ROI placement in the rectus femoris (RF) muscle the FFs for two of the participants were excluded 
for this muscle group (n=21)  
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5.2.6 Correlation between MRI and functional assessments 
The median increase in FF per year from this study and the 12-month Willis et al. study is given in 
Table 17 (Willis et al., 2013), together with a correlation between the FF change over 12 months and 
six years: correlation indicates where the short-term measurement may be predictive of long-term 
change. The 10MWR velocity and the 6MWT had several significant negative correlations with the FF 
of most muscle groups at baseline and six years. These were particularly strong in the composite 
muscle groups (such as the thigh, HMS and QUADS) (Tables 18 to 19). Changes in FF and the 10MWR 
velocity across six years correlated significantly only in the Sol muscle. Changes in FF and the 6MWT 
across six years correlated significantly in the Sol, rectus femoris (RF) and less strongly in some of the 
composite muscle groups: the thigh, QUADS, and triceps surae. 
The analysis of individuals who had muscle groups with less than 20% fat replacement at baseline, and 
then progressed by less than 20% over six years, showed that there were 5 individuals for whom this 
was true for all 13 muscle groups and 1 further individual for whom this was true for 11/13 groups. 
This group of 6 subjects was significantly younger than the other 17 participants (median 23.5 years 
vs 43.0 years, p<0.001). 
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Muscle group Annual median 
change in FF over 
six years (%) 
(n=23) 
Annual median 
change in FF 
Willis et al. (%) 
(n=32) 
Correlation of change 
in FF over one year 
compared to 
calculated rate of 
annual increase in FF 
over six years (n=20) 
Lateral gastrocnemius 1.7 1.4 NS 
Semitendinosus 1.3 1.6 0.51* 
Gracilis 1.3 1.6 NS 
Vastus lateralis 1.3 0.5 0.41* 
Sartorius 1.2 1.2 NS 
Semimembranosus 1.2 1.8 NS 
Rectus femoris 1.1† 0.8 NS 
Medial gastrocnemius 1.0 1.4 0.63* 
Biceps femoris long head 0.9   1.9 NS 
Biceps femoris short head 0.9 1.2 NS 
Peroneus longus 0.9 0.1 0.45* 
Soleus 0.8 0.3 0.50* 
Vastus medialis 0.5 0.6 0.46* 
Tibialis anterior 0.2 -0.1 NS 
Table 17. Rate of annual median fat fraction (FF) increase derived from the six year data (i.e. total fat fraction increase 
over six years divided by number of years)  compared to the 12 month data presented in Willis et al (Willis et al., 2013). 
The change in FF over one year and six years were correlated – Pearson coefficients for significant correlations are given. 
Significant correlation is only seen in the semitendinosus, vastus lateralis, peroneus longus, soleus (sol) and the vastus 
medialis. Annual median change is similar in the majority of muscle groups, but short term measurement may reduce 
the accuracy of detection of change (as seen in the biceps femoris long head or the lateral gastrocnemius (GCN))  
* p value < 0.05,  
† Due to difficulties in ROI placement in the rectus femoris (RF) muscle the FF for two of the participants were excluded 
for this muscle group (n=21).  
Key: NS, not significant, FF, Fat fraction 
  
 104 
 
Muscle group Correlation between 
FF and 6MWT at 
baseline 
Correlation 
between FF and 
6MWT at six years 
Correlation of 
increase in FF with 
change in 6MWT 
over six years 
Lateral gastrocnemius -0.60* -0.59* NS 
Semitendinosus -0.81** -0.67** NS 
Gracilis -0.68** -0.74** NS 
Vastus lateralis -0.79** -0.73** NS 
Sartorius -0.67** -0.66** NS 
Semimembranosus -0.86** -0.75** NS 
Rectus femoris† -0.70** -0.80** -0.53* 
Medial gastrocnemius -0.58* -0.57* NS 
Biceps femoris long head -0.69** -0.63* NS 
Biceps femoris short head -0.60* -0.69** NS 
Peroneus longus -0.45* NS NS 
Soleus -0.49* -0.56* -0.60* 
Vastus medialis -0.76** -0.73** NS 
Tibialis anterior -0.47* NS NS 
Averaged thigh† -0.88** -0.91** -0.47* 
Averaged lower leg -0.61* -0.59* NS 
Averaged quadriceps† -0.85** -0.87** -0.46* 
Averaged hamstrings -0.81** -0.71** NS 
Averaged triceps surae -0.56* -0.58* -0.45* 
Averaged target muscles -0.75** -0.75** NS 
Table 18.  The correlation between the fat fraction (FF) and 6MWT is shown: at baseline, at six years, and between the 
change in FF and change in 6MWT across the six years. Pearson coefficients for significant correlations are given. The 
most significant group correlations are found in the averaged thigh, hamstrings (HMS) and quadriceps (QUADS). 
*p value < 0.05, **p value < 0.001 
† Due to difficulties in ROI placement in the rectus femoris (RF) muscle the FF for two of the participants were excluded 
for this muscle group (n=21).  
Key: NS, not significant, FF, Fat fraction, 6MWT, six minute walk test, 
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Muscle group Correlation between 
FF and 10MWR 
velocity at baseline~ 
Correlation between 
FF and 10MWR 
velocity at six years 
Correlation of increase in 
FF with change in 10MWR 
velocity over six years~ 
Lateral 
gastrocnemius 
-0.62* -0.64* NS 
Semitendinosus -0.76** -0.77** NS 
Gracilis -0.63* -0.74** NS 
Vastus lateralis -0.70** -0.71** NS 
Sartorius -0.61* -0.67** NS 
Semimembranosus -0.76** -0.77** NS 
Rectus femoris† -0.63* -0.75** NS 
Medial 
gastrocnemius 
-0.59* -0.65* NS 
Biceps femoris long 
head 
-0.78** -0.76** NS 
Biceps femoris 
short head 
-0.61* -0.74** NS 
Peroneus longus NS NS NS 
Soleus -0.49* -0.52* -0.52* 
Vastus medialis -0.69** -0.68** NS 
Tibialis anterior NS NS NS 
Averaged thigh† -0.83** -0.90** NS 
Averaged lower leg -0.60* -0.62* NS 
Averaged 
quadriceps† 
-0.76** -0.80** NS 
Averaged 
hamstrings 
-0.80** -0.80** NS 
Averaged triceps 
surae 
-0.58* -0.62* NS 
Averaged target 
muscles 
-0.71** -0.77** NS 
Table 19. The correlation between the fat fraction (FF) and ten meter walk or run (10MWR) is shown:  at baseline, at six 
years and between the change in FF and change in 10MWR across the six years. Pearson coefficients for significant 
correlations are given. Similar to the 10MWR, the most significant group correlations are found in the averaged thigh, 
hamstrings (HMS) and quadriceps (QUADS). 
*p value < 0.05, **p < 0.001.  
† Due to difficulties in ROI placement in the rectus femoris (RF) muscle the FF for two of the participants were excluded 
for this muscle group (n=21). 
~ Results of the 10MWR test not available for one participant at baseline (n=22).  
Key: NS, not significant, FF, fat fraction, 10MWR, 10 metre walk or run test.  
 106 
 
5.2.7 Subgroup analyses  
Male participants (n=10) had a median age of 48.0 years (range 14.1 to 70.5), females (n=13) who 
participated had a similar median age, but a narrower range of ages (47.2 years range 24.1 to 65.2) 
(p=0.61). Weight was not significantly different between gender groups. The male cohort had a 
significantly higher median percentage of fat in the Sol and the VM (Table 20). Change in median 
percentage over the six year follow up period was similar between genders, with the exception of the 
LG (female 15.9% range 0.1 to 41.8, versus male 3.3% range -8.7 to 19.4, p=0.02) and TA (female 3.1% 
range -2.8 to 12.8, versus male 0.3% range -1.5 to 4.1, p=0.04). In these two muscles the female fat 
percentage rose at a significantly higher rate than the males, this was in spite of no significant 
differences in these muscles at baseline or follow up. 
 
Muscle Male baseline Female 
baseline 
P 
value 
Male six years Female six 
years 
P 
value 
Vastus 
medialis 
68.4 (1.1-86.6) 20.7 (2.7-92.2) 0.01* 77.5 (4.3-70.8) 23.8 (4.3-70.8) 0.03* 
Soleus 21.3 (1.8-67.4) 6.0 (3.3-19.4) 0.01* 27.5 (4.0-70.1) 8.6 (3.1-81.9) 0.01* 
Table 20. Male and female cohorts fat content at baseline and six year follow up. In these two muscles more fat 
replacement was evident at baseline and six year follow up. 
P values calculated using Wilcoxon non-parametric rank signed test.  
*p value <0.05. Muscles not included within the table were not significantly different between genders. 
 
No significant differences were demonstrated between genders using myometry at either baseline, or 
at six year follow up. The only timed assessment that was significantly different between genders was 
the 10MWR. The velocity was significantly smaller median in the male cohort (0.0ms-1 range 0.0 to 
2.1, versus female 1.0ms-1 range 0.0 to 4.0, p=0.02). 
Of the 6 participants that had become non-ambulant, all were male, with a median age of 58.5 years 
(27.9 to 70.5) compared to the ambulant group 44.7 years (14.1 to 65.2) (p=0.11). The non-ambulant 
cohort median weight was significantly higher at final follow up compared to ambulant participants 
(non-ambulant 93.3kg range 59.0 to 111.8, versus ambulant 69kg range 53.6 to 82.4, p=0.02).  
In non-ambulant participants, FF was significantly higher in three muscle groups at baseline and at six 
years: these were the Sol, RF and VM (Table 21). The rate of increase in fat percentage was not 
statistically different in any of the muscles between the two groups over the six years.  
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Muscle Ambulant 
(baseline) 
Non-ambulant 
(baseline) 
P 
value 
Ambulant (six 
years) 
Non-ambulant 
(six years) 
P value 
Rectus 
femoris 
6.9 (0.9-81.9) 43.4 (21.4-78.9) 0.03* 13.7 (0.4-92.2) 64.3 (4.4-81.9) 0.03* 
Vastus 
medialis 
18.7 (1.1-86.6) 74.3 (10.6-79.2) 0.001* 23.8 (2.5-87.9) 79.8 (19.7-84.1) 0.005* 
Soleus 6.1 (1.8-67.4) 30.3 (7.0-43.1 0.03* 8.6 (3.1-70.1) 41.1 (21.4-78.9) 0.008* 
Table 211. Muscles that demonstrated a significant difference between ambulant and non-ambulant at baseline and 6 
year follow up. Participants that were non-ambulant at follow up had significantly higher fat content at baseline and 6 
year follow up in the rectus femoris (RF), vastus medialis and the soleus (sol).  
P values calculated using Wilcoxon non-parametric rank signed test.  
*p value <0.05. Muscles not included within the table were not significantly different between ambulant and non-
ambulant groups. 
 
No significant differences were demonstrated between the non-ambulant and ambulant cohorts in 
any of the muscle groups using myometry. 
Age significantly correlated to the percentage FF in four muscles. The muscles included: BFLH (r=0.57, 
p=0.005), BFSH (r=0.65, p=0.001), the ST (r=0.62, p=0.002), SM (r=0.54, p=0.008). The only functional 
test that inversely correlated weakly to age was the 6MWT (r=-0.43, p=0.04). No significant 
correlations were demonstrated between age and spirometry, other timed tests or myometry. 
  
 108 
 
Chapter 6: Use of cardiac extracellular volume measurement as a biomarker 
of fibrosis in limb girdle and Becker muscular dystrophies 
 
6.1 Summary  
This study pilots ECV quantification in LGMDR9 and BMD. Progressive cardiac fibrosis in muscular 
dystrophies is a cause of morbidity and mortality mostly through LV dysfunction and increased risk of 
arrhythmias. Increased ECV measured with post-Gd MRI has been investigated as a biomarker of 
myocardial fibrosis (Table 1).  
Gd-enhanced MRI examination was performed in participants with LGMDR9 (n=6), BMD (n=7) and 
controls (n=10). T1 maps were taken before and 10 minutes after Gd injection.  ROI analysis and Hct 
correction allowed ECV value calculation.  
 
In BMD and LGMDR9 cohorts, of 20 segments with ECV of ≥0.28 15 were in the lateral wall. ECV 
correlated to measures of cardiac function LVEF, WMA, and LGE. Higher ECV values were found in 
LGE-positive segments. ECV values of ≥0.28 were found in 5 participants without LGE-positive 
segments. Increased ECV correlated with reduced LVEF in LGMDR9 (r=-0.41, p=0.047) and BMD 
cohorts (r=-0.45, p=0.02). Unlike the BMD group, LGMDR9 participants had significantly different 
torsion and strain values compared to controls (PT LGMDR9 3.3 ±1.1, versus control 6.2 ±1.8, p=0.004). 
In the LGMDR9 cohort increased ECV correlated with reduced strain and torsion in the basal region PT 
(r=-0.51 p=0.01). Apical ECV values correlated with measures of strain (PWWS r=0.58 p=0.003) and 
inversely to torsion, PT r=-0.50 p=0.01). Regional and global ECV values were significantly higher in 
participants with evidence of global cardiac dysfunction.   
ECV correlated with measures of cardiac dysfunction: LVEF, LGE, WMA, and abnormal cardiac tagging 
values. ECV may be abnormal where other measures are normal. ECV has potential to quantify diffuse 
fibrosis for use in clinical practice or therapeutic trials.  
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6.2 Results 
Mean age of LGMDR9 participants was 51.0 years ±15.6 and the BMD cohort had a median age of 45.0 
years ±13.1 (Table 22). Mean age of the controls was 45.5 years ±14.2 which was not significantly 
different from the disease cohort (p=0.77). NIV was required by 83.3% (n=5) LGMDR9 participants. 
Angiotensin converting enzyme inhibitors and beta blockers were prescribed to 83.3% (n=5) LGMDR9 
participants and 57.1% (n=4) BMD participants suggesting more severe cardiac involvement in the 
LGMDR9 group (Table 22).  
ECV was analysable in 269/276 segments with 7 segments unanalysable due to artefact. No significant 
correlations were evident between ECV and age in any of the groups.   
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Characteristic LGMD (n=6) BMD (n=7) Controls (n=10) 
Age (years) 51.0 ±15.6 45.0 ±13.1 45.5 ±14.2 
Number of segments analysed 
(%)$ 
67 (93.1) 83 (98.9) 119 (99.2) 
Number of males (%) 4 (66.7) 7 (100.0) 10 (100.0) 
Weight (kg)‡ 93.3 (59.8-111.8) 81.7 (56.7-181.0) 76.7 (66.2-114.6) 
Body surface area (m2) 1.91 ±0.19 2.01 ±0.26 2.02 ±0.21 
Systolic blood pressure (mmHg) 133.4 ±11.5 126.1 ±19.4 122.4 ±10.7 
Diastolic blood pressure 
(mmHg) 
85.0 ±8.7* 73.0 ±14.2 68.7 ±10.9 
Heart rate (bpm) 84.3 ±15.9 73.9 ±7.1 70.3 ±16.1 
Haematocrit (L/L) 0.42 ±0.04 0.42 ±0.02 0.44 ±0.02 
Number receiving cardio-active 
medication (%) 
5 (83.3) 4 (57.1) 0 (0) 
Number with late gadolinium 
enhancement (%) 
1 (16.7) 1 (14.3) 0 (0) 
Number with wall motion 
abnormality (%) 
4 (66.7) 1 (14.3) 0 (0) 
LVEF (%) 43.0 ±5.8* 51.0 ±7.7* 69.5 ±7.2 
LVSV (ml) 39.3 ±13.4* 43.2 ±10.8* 80.5 ±10.4 
LVSV/BSA (ml/m2) 19.3 ±4.9* 22.4 ±4.6* 41.3 ±5.1 
LVM (g) 119.0 ±34.6 117.4 ±15.9 139.9 ±30.5 
LVM/BSA (ml/m2) 54.8 ±13.2* 62.0 ±11.4 71.2 ±12.5 
LVEDV (ml)‡ 72.1 (58.9-151.2) 81.8 (66.6-133.0)* 113.8 (87.7-151.4) 
LVEDV/BSA (ml/m2) 36.1 (29.6-62.9)* 41.4 (34.9-66.6)* 57.3 (50.8-74.1) 
LVESV (ml)‡ 41.6 (28.3-93.6) 34.6 (30.2-70.5) 31.6 (17.9-56.3) 
LVESV/BSA (ml/m2) 22.6 (14.2-39.9) 20.8 (16.5-69.8) 17.3 (9.0-27.5) 
Peak torsion (o) 3.3 ±1.1* 6.1 ±1.2 6.2 ±1.8~ 
Peak whole wall strain (%) 15.4 ±3.4* 16.1 ±3.2 18.2 ±2.7† 
Peak endocardial strain (%) 21.2 ±3.4* 21.1 ±3.2 24.3 ±3.0† 
Torsion to strain ratio (rad/%)‡ 0.31 (0.14-0.38)* 0.46 (0.38-0.97) 0.45 (0.28-0.75) 
Global ECV (-)‡ 0.24 ±0.02 0.24 ±0.02 0.23 ±0.02 
Regional ECV – Basal (-)‡ 0.24 (0.23-0.31)* 0.23 (0.19-0.35) 0.23 (0.18-0.27) 
Regional ECV – Mid cavity (-)‡ 0.24 (0.20-0.30) 0.22 (0.20-0.30) 0.23 (0.18-0.27) 
Regional ECV – Apical (-)‡ 0.24 (0.21-0.32) 0.24 (0.21-0.35)* 0.23 (0.19-0.26) 
Table 22. Comparison of cardiac characteristics between the disease and control groups. Left ventricular ejection fraction 
(LVEF), and all cardiac indices corrected for BSA were significantly different in the disease groups compared to controls. 
Left ventricular stroke volume (LVSV) are significantly lower in the disease groups compared to the control group. Cardiac 
tagging data is significantly different in the LGMDR9 group only. Data is represented as mean ±standard deviation unless 
otherwise stipulated. 
*Significant difference between cohort and controls, p value <0.05. 
†(n=9) Due to a parallel imaging artefact the results from one participant was unanalysable and therefore excluded.  
~(n=8) Due to tracking difficulties in one participant it was not possible to get torsion values. 
$ Excluding all segments where image quality was insufficient due to artefact (in total n=7). 
‡ non-normally distributed – Mann Whitney U test used to calculate significance. Data is presented as median and range. 
Key: LVEF, left ventricular ejection fraction, LVSV, left ventricular stroke volume, LVEDV, left ventricular end diastolic 
volume, LVESV, left ventricular end systolic volume, ECV, extracellular volume. 
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6.2.1 Measures of cardiac dysfunction  
To demonstrate cardiac dysfunction detectable via traditional means within the disease cohorts the 
scans were assessed for signs of LGE and WMA. Two participants had sub-endocardial LGE; one from 
each disease cohort. 4/6 of the LGMDR9 and 1/7 from the BMD cohorts had WMA with LVEF 
significantly lower in those with WMA (43.1% ±7.4) compared to those without WMA (50.2% ±6.9, 
p<0.001) and controls (69.5% ±7.2, p=<0.001) suggesting that the WMA seen were pathological and 
reducing cardiac function. 
Overall mean LVEF was significantly higher in the control group (69.5% ±7.2) compared to LGMDR9 
(43.0% ±5.8, p<0.001) and BMD cohorts (51.0% ±7.7, p<0.001). LVSV/BSA was significantly lower in 
both disease groups (LGMDR9 p<0.001, BMD p<0.001), which was contributed to by a significant 
reduction in LVEDV/BSA (LGMDR9 p<0.001, BMD p=0.03) with no significant difference in LVESV (Table 
22). The reduction in LVEDV may be secondary to an increase in fibrosis leading to restriction of the 
left ventricle’s ability to expand during diastole.  These measures of cardiac indices suggest that there 
was sufficient cardiac dysfunction within the disease groups to significantly reduce average cardiac 
function overall.  
Cardiac tagging revealed that the LGMDR9 cohort had significantly lower PT (p=0.004), PECS (p=0.04), 
PWWS (p=0.03), and TSR (p= 0.04) than controls (Table 22). In spite of the reduced LVEF in the BMD 
group, the BMD and control cohorts were not significantly different in strain or torsion.  
The LGMDR9 group had a significant, strong correlation between reduced LVEF and reduced PT (r=0.93 
p<0.001). Correlation was seen between reduced LVEF of this cohort and reduced TSR (r=0.65 
p<0.001), PWWS (r=0.52 p<0.001) and PECS (r=0.72 p<0.001). The correlations demonstrated 
between cardiac tagging indices may be evidence of the different mechanism of cardiac dysfunction 
in LGMDR9 with subepicardial dysfunction seen, in contrast to dystrophinopathies and normal aging.  
No significant correlations were observed between LVEF and cardiac tagging in BMD or control groups.  
 
6.2.2 ECV correlation to measures of cardiac dysfunction 
The highest ECV segmental value in the controls was 0.27 (2/119 segments). In both disease cohorts 
the highest segmental ECVs (0.28-0.35) were in the basal posterior (BP) segments which correspond 
to the most common areas of LGE. ECV was ≥0.28 in 20 segments, 15/20 of these were lateral wall 
segments the remainder were in the septal wall (5/20). In spite of the cardiac pathology seen within 
the LGMDR9 cohort of the participants with ECV values ≥0.28 the majority (6/7) were BMD 
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participants. There were no significant differences in global ECV between controls and either cohort 
which may reflect the regional nature of the fibrosis with normal areas reducing the global average. 
The highest median regional ECV values were in apical regions of both LGMDR9 (0.25 (0.23-0.30)) and 
BMD groups (0.26 (0.22-0.28) compared to control (0.23 (0.19-0.26)). The LGMDR9 cohort had 
significantly higher median basal ECV values (0.23 (0.22-0.29)) than controls (0.22 (0.20-0.26), p=0.04). 
Assuming that higher ECV values correspond to more fibrosis, this suggests that the basal regions were 
more likely to be affected in the LGMDR9 and BMD groups.  
Reduced LVEF significantly correlated to increased basal ECV in BMD (r=-0.45 p=0.02) and LGMDR9 
(r=-0.41 p=0.047). In the BMD cohort reduced LVEF also correlated significantly to increased ECV in 
the apical (r=-0.42 p=0.03) and mid-cavity regions (r=-0.61 p=0.001). These findings may suggest that 
there is a significant link between reduction in overall function and rises in ECV.   
In the BMD participant with evidence of LGE 7/12 segments were affected these segments 
corresponded to higher ECV values (0.26-0.35) (Figure 34). This participant had a low LVEF of 36%. In 
the LGMDR9 participant with LGE positive segments, 5/11 segments were LGE positive which 
corresponded to modest ECV values (0.24-0.27) LVEF in this participant was also found to be low 
(46.2%). These are mixed results with the LGMDR9 participant having ECV values in the LGE positive 
segments which were similar to corresponding segments in controls. In the participant with LGMDR9 
the ECV values of LGE negative segments did not exceed values of LGE positive segments. This may 
suggest that although ECV didn’t increase to the same degree as seen in the participant with BMD, 
ECV did proportionally rise in the LGE positive areas compared to surrounding LGE negative segments.  
 
 113 
 
 
Figure 34. To compare the values of extracellular volume (ECV) segments in regions with late gadolinium enhancement 
(LGE) in a participant with Becker muscular dystrophy (BMD). Left – 3D phase sensitive inversion recovery (PSIR) 
sequence 10 minutes post-gadolinium (Gd) injection, from top to bottom basal, mid cavity and apical slices. Middle – 
Corresponding post-contrast T1 map slices with colour scale of values of T1 relaxation time (in ms). Right – table with 
ECV values in corresponding segments. These images suggest that in the presence of late gadolinium enhancement (LGE) 
ECV has a corresponding rise in the same segment. 
Key: BP, Basal anterior, BA, Basal anterior, BSA, Basal septal anterior, BSP, Basal septal posterior, MCSA, Mid cavity 
septal anterior, MCSP, Mid cavity septal posterior, MCP, Mid cavity posterior, MCA, Mid cavity anterior, AA, Apical 
anterior, AP, Apical posterior, ASA, Apical septal anterior, ASP, Anterior septal posterior. 
 
  
B
 
 114 
 
There was a significant difference between ECV basal regional values in the five participants with a 
WMA (0.26 (0.21-0.32)) compared to the eight without (0.24 (0.21-0.32) p=0.04) which may suggest 
that WMA are more common in those with basal fibrosis. No significant differences were 
demonstrated between ECV values in apical or mid-cavity regions, stratifying by WMA.  
In the LGMDR9 cohort there were significant correlations between regional ECV values and cardiac 
tagging indices; including increasing basal regional ECV values correlating to both lower TSR (r=-0.42 
p=0.04) and lower PT (r=-0.51 p=0.01). Increased apical values correlated to both increased strain 
(PWWS r=0.58 p=0.003, PECS r=0.56 p=0.04) and decreased torsion (TSR r=-0.637 p=0.03, PT r=-0.50 
p=0.01). As suggested earlier, cardiac tagging indices may be sensitive to cardiac dysfunction in 
LGMDR9, the fact that ECV also correlates significantly to these measures suggests it is reflecting 
cardiac dysfunction. BMD regional ECV values did not correlate significantly to cardiac tagging indices 
which were not significantly different from control values. 
 
6.2.3 ECV and cardiac dysfunction 
To further assess ECV in detection of cardiac dysfunction, participants were compared by creating two 
groups. The first group had clinically diagnosed cardiac dysfunction defined as an LVEF<55% or 
evidence of LGE, (n=7) (LGMDR9 n=5, BMD n=2). The second group were all disease group participants 
without cardiac dysfunction and all controls were grouped together. Segmental, regional and global 
ECV values were significantly higher in those with cardiac dysfunction (Figure 35). Significant increases 
were seen comparing ECV segmental values between these two groups in: the basal anterior (BA), BP 
and mid cavity posterior (MCP) segments (Figure 36). These findings strongly suggest that ECV 
increases in participants with clinically defined cardiac dysfunction. It may also follow that cardiac 
dysfunction and reduced function occurs due to these segments being less able to move due to 
increased fibrosis.    
Using these results it is possible to suggest ways to increase power in future therapeutic studies. 
Although all cardiac segments could be included using ECV calculation, a therapeutic trial should 
consider use of basal segments for an outcome measure; this is due to the higher frequency of high 
ECV values in this region. Using a power analysis, a minimum of 63 participants would be required to 
appropriately power a therapeutic trial using basal region ECV values as an outcome measure in 
LGMDR9 and BMD.    
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Figure 35. Part 1: Box plots to compare between extracellular volume (ECV) with and without cardiac dysfunction (as 
defined as an left ventricular ejection fraction (LVEF) <55% or evidence of late gadolinium enhancement (LGE)). The most 
highly significant increase in ECV was the global measure. Overall ECV was significantly higher in the cardiac dysfunction 
group, providing evidence of sensitivity. P values calculated using Mann-Whitney U test. 
Key: A) Apical ECV, B) Mid cavity ECV, C) Basal ECV, D) Global ECV. 
p=0.02 
p=0.005 A 
 
B 
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Figure 35. Part 2: Box plots to compare between extracellular volume (ECV) with and without cardiac dysfunction (as 
defined as an left ventricular ejection fraction (LVEF) <55% or evidence of late gadolinium enhancement (LGE)). The most 
highly significant increase in ECV was the global measure. Overall ECV was significantly higher in the cardiac dysfunction 
group, providing evidence of sensitivity. P values calculated using Mann-Whitney U test. 
Key: A) Apical ECV, B) Mid cavity ECV, C) Basal ECV, D) Global ECV. 
P<0.001 
p=0.002 C 
 
D 
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Figure 36. Comparing segmental extracellular volume (ECV) values in participants with cardiac dysfunction (n=7) (reduced left ventricular ejection fraction (LVEF) <55%, or late gadolinium 
enhancement (LGE) to those without combined with the control cohort (n=16). Only three segments had significantly higher ECV values in the group with cardiac dysfunction, these were 
the basal anterior (BA), basal posterior (BP) and the mid-cavity posterior (MCP) segments. These significantly higher ECV values here may relate to the fact that cardiac dysfunction is seen 
when these are affected due to restriction of movement, secondary to fibrosis. 
Key: BP, Basal anterior, BA, Basal anterior, BSA, Basal septal anterior, BSP, Basal septal posterior, MCSA, Mid cavity septal anterior, MCSP, Mid cavity septal posterior, MCP, Mid cavity 
posterior, MCA, Mid cavity anterior, AA, Apical anterior, AP, Apical posterior, ASA, Apical septal anterior, ASP, Anterior septal posterior.   
p=0.04 
p=0.03 
p=0.02 
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Chapter 7: The quantification of left ventricular indices in muscular dystrophy 
cohorts: Evaluation of accelerated imaging  
 
7.1 Summary 
CMRI provides highly versatile, detailed information about myocardial function and anatomy. CMRI-
generated functional indices are widely used in clinical practice and as an outcome measure in 
therapeutic trials. Neuromuscular cohorts pose challenges to CMRI assessments due to discomfort in 
lying supine for long periods, scoliosis, and cardiorespiratory compromise. There are clear advantages 
to reducing acquisition times required for cardiac functional indices.  
In spite of the common usage of functional cardiac indices as outcome measures for therapeutic trials, 
few studies have investigated cardiac outcome measures in neuromuscular disease. Long term follow 
up of cardiac indices in LGMDR9 has not been investigated using CMRI. It is therefore not clear 
whether CMRI is an effective tool to monitor long term changes in cardiac indices in this cohort. 
An aim of this chapter is to explore whether accelerated imaging can be used to reduce acquisition 
times whilst maintaining image fidelity and obtaining accurate cardiac indices. This chapter will also 
assess the use of CMRI as an outcome measure in LGMDR9, assessing change in LV indices and cardiac 
tagging over a five year period. 
Three groups of age-matched participants were recruited to undergo CMRI assessment: LGMDR9 
(n=8), BMD (n=7) and healthy volunteers (n=10). Participants from the LGMDR9 group had undergone 
CMRI assessment five years prior to this recruitment as part of their participation in an LGMDR9 
natural history study (Hollingsworth et al., 2013b). Participants were scanned supine within a 3T 
Philips Achieva scanner (Best, NL), a 16-channel torso XL coil (Philips, Best, NL) and VCG gating (Philips 
VCG). The protocol included conventional and accelerated cine imaging, and cardiac tagging.  Cine 
imaging was performed during BH, with steady-state free precession in the short axis plane, cardiac 
cine 25 phases, with 14 slices. Two and four chamber long axis views were also collected using both 
conventional and accelerated cine. The following cardiac indices were obtained using segmentation 
software: LVEF, LVSV, LVEDV, LVESV and LVM. Cardiac tagging indices obtained included: PT, PECS, 
PWWS, and TSR. Two observers separately reviewed 8 images rating image quality and generating 
cardiac indices for comparison.  
Bland Altman analysis of the accelerated versus conventional imaging demonstrated no significant 
bias in any of the cardiac indices with 95% LOA for LVEF at 5.9%. A high degree of inter-observer 
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agreement was found with no significant bias between ratings of cardiac indices. Both observers 
scored the accelerated images on average as either ‘no difference appreciated in quality’ or 
‘marginally improved image quality’ compared to conventional images. Follow up of cardiac indices 
and measures of strain and torsion in the LGMDR9 group demonstrated no significant differences over 
the five year period.  
The accelerated method had comparable 95% LOA to other published accelerated approaches, and 
had high inter-observer reproducibility. The technique does however lead to a 95% LOA in LVEF of 
5.9%, which in a clinical context is a potentially significant degree of uncertainty with values of greater 
than 55% being considered normal. Therefore, although accelerated imaging yields images of a 
visually equivalent quality, variation between measurements of cardiac indices may not be clinically 
acceptable. The results of the five year follow up portion of this study suggest that CMRI generated 
cardiac indices and cardiac tagging may be insufficiently sensitive to detect change in the LGMDR9 
cohort over a five year time period. Limitations of the studies are the small sample size and the 
confounding factor of cardioactive medication administration. 
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7.2 Results 
7.2.1 Recruitment  
Accelerated and conventional CMRI acquisition was performed on three groups of participants: 
LGMDR9 (n=8), BMD (n=7), and healthy volunteers (n=10). For the LGMDR9 five year follow up, cardiac 
tagging was not available in two participants due to artefact (n=6). Breakdown of the demographics 
of participants is given in ‘Table 23’. 
 
7.2.2 Comparing accelerated and conventional imaging  
To compare accelerated and conventional imaging, the three disease groups were considered 
together. Mean LVEF was statistically significantly lower measured from the accelerated imaging 
(54.4% ±13.8), compared to the conventional (56.0% ±13.5) (p=0.01). Mean values for other cardiac 
indices LVSV, LVM, LVEDV and LVESV were not significantly different between the two techniques.  
Bland Altman analysis of the different cardiac indices demonstrated that the 95% LOA for LVEF were 
5.9%, with a positive bias of 1.6%. LOA and bias for LVSV, LVEDV, LVESV and LVM are given in ‘Table 
24’ and ‘Figures 37 to 41’ demonstrate the relationship between the two methods. No significant bias 
was demonstrated between the two imaging techniques for any of the cardiac indices, as all LOA 
straddle zero. 
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Characteristic LGMDR9 (n=8) BMD (n=7) Control (n=10) 
Age (years) 54.5 ±15.0 45.0 ±13.1 45.5 ±14.2 
Number of males (%) 6 (66.7) 7 (100) 10 (100) 
Systolic blood pressure (mmHg) 133.4 ±11.5 126.1 ±19.4 122.4 ±10.7 
Diastolic blood pressure (mmHg) 85.0 ±8.7 73.0 ±14.2 68.7 ±10.9 
Heart rate (bpm) 84.3 ±15.9 73.9 ±7.1 70.3 ±16.1 
Receiving cardio-active 
medication҂ 
5 (83.3) 4 (57.1) 0 (0) 
Left ventricular ejection fraction 
(%)~ 
43.4 ±6.3* 51.0 ±7.7* 69.5 ±7.2 
Left ventricular stroke volume 
(ml)~ 
38.8 ±11.7* 43.2 ±10.8* 80.5 ±10.4 
Left ventricular mass (g)~ 112.3 ±35.0 117.4 ±15.9 139.9 ±30.5 
Left ventricular end diastolic 
volume median (ml) (range) ~ 
72.1 (58.9-151.2) 81.8 (66.6-133.0)* 113.8 (87.7-151.4) 
Left ventricular end systolic volume 
median (ml) (range)~ 
41.6 (28.3-93.6) 34.6 (30.2-70.5) 31.6 (17.9-56.3) 
Peak torsion (o) 3.3 ±1.3$* 6.1 ±1.2† 6.2 ±1.8‡ 
Torsion to strain ratio (rad/%) 
median (range) 
0.31 (0.14-0.38)$* 0.46 (0.38-0.97)† 0.45 (0.28-0.75)‡ 
Peak whole wall strain (%) 14.9 ±2.3$ 16.1 ±3.2† 18.2 ±2.7† 
Peak endocardial strain (%) 20.6 ±3.5$ 21.1 ±3.2† 24.3 ±3.0† 
Table 23. Demographics of the three groups comparing accelerated and conventional acquisitions. Values reported as 
mean and standard deviation unless otherwise stipulated. Demonstrating the significant differences between the 
disease groups and the control group in terms of ejection fraction (EF) and stroke volume (SV). The LGMDR9 had 
significantly different values for cardiac tagging indices.    
*p<0.05 significant difference between group and controls. 
† Due to a parallel imaging artefact the results from one participant was unanalysable and therefore excluded.  
~ Calculated using conventional imaging 
$ Due to a parallel imaging artefact the results from two participants was unanalysable and therefore excluded. 
‡ Torsion values were not obtainable in two participants due to a parallel imaging artefact and a tracking difficulty in 
one other participant. 
҂ Cardioactive medication is defined as either monotherapy or combination therapy with: beta blockers, angiotensin 
converting enzyme inhibitors, or angiotensin receptor blockers. 
 
 
Comparison (n) LVEF (%) LVSV (mls) LVEDV (mls) LVESV (mls) LVM (g) 
Inter-observer n=8 0.4, 0.8 0.4, 0.8 0.04, 0.4 0.4, 0.9 3.2, 9.7 
Conventional vs 
accelerated 
n=25 1.6, 5.9 2.5, 13.1 2.2, 17.3 -1.6, 11.4 -3.3, 17.3 
Table 24. Summary of results from Bland Altman analysis with values presented as: bias, 95% limits of agreement (LOA). 
Although the 95% LOA were small between observers, the calculation of cardiac indices (i.e. ejection fraction (EF)) using 
the accelerated imaging technique led to wide 95% LOA.   
Key: LVEF, left ventricular ejection fraction, LVSV, left ventricular stroke volume, LVEDV, left ventricular diastolic volume, 
LVESV, left ventricular end systolic volume, LVM, left ventricular mass.  
 
 122 
 
 
Figure 37. Left ventricular ejection fraction (LVEF) using accelerated and conventional imaging. This demonstrates the 
close relationship of the two methods of measurement, with minimal differences comparing on a individual basis.  
Key: Solid line, line of best fit, Dotted line, line of equality (y=x). 
 
 
Figure 38. Left ventricular stroke volume (LVSV) using accelerated and conventional imaging. This demonstrates the close 
relationship of the two methods of measurement, higher values had more discrepancy between the two methods. 
Key: Solid line, line of best fit, Dotted line, line of equality (y=x). 
y=0.99x+7.53 
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Figure 39. Left ventricular mass (LVM) using accelerated and conventional imaging. This demonstrates the close 
relationship of the two methods of measurement, varibility between the two methods of measurement was greatest in 
the middle values (100-150g) 
Key: Solid line, line of best fit, Dotted line, line of equality (y=x). 
 
 
Figure 40. Left ventricular end diastolic volume (LVEDV) using accelerated and conventional imaging. This demonstrates 
the close relationship of the two methods of measurement, greater varibility between the two methods was seen at 
higher values. 
Key: Solid line, line of best fit, Dotted line, line of equality (y=x).  
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Figure 41. Left ventricular end systolic (LVESV) volume using accelerated and conventional imaging. This demonstrates 
the close relationship of the two methods of measurement, with minimal differences comparing on a individual basis. 
Key: Solid line, line of best fit, Dotted line, line of equality (y=x). 
 
 
7.2.3 Inter-observer analysis 
Image quality of both imaging techniques was acceptable for analysis for all of the conventional and 
accelerated scans (Figure 42). Qualitative analysis with the five point scoring system (Table 4) with a 
higher score demonstrating better image fidelity, showed that the accelerated images were rated as 
3.8 and 4.1 by observer one and two respectively. This suggests that quality in accelerated images has 
no obvious difference or is marginally better than conventional imaging.  
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Figure 42. Example of 2 chamber long axis view (top row) and mid-ventricular short axis views (bottom row) at approximated points in the cardiac cycle. This is 
a demonstration of the close image fidelity.  
A and C – accelerated images, B and D – conventional images. 
Key: H, head, F, feet, L, left, R, right, A, anterior, P, posterior. 
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Bland Altman analysis of the cardiac indices showed narrow 95% LOA in all cardiac indices (Table 24). 
No significant inter-observer bias was demonstrated, with all 95% LOA bracketing zero.  
 
7.2.4 Comparison of results with previous studies 
Previous work in obtaining cardiac indices using accelerated sensing or free breathing (FB) techniques 
have been summarised in ‘Table 25’. The inter-observer 95% LOA in all cardiac values in this study 
were very narrow compared to other studies (Table 25). 95% LOA in the current study for LVEF were 
narrower (5.9%) than Vincenti et al. (8.6%) and Jaroni et al. (9.5%), but similar to Kido et al. (5.2%) 
(Vincenti et al., 2014, Jaroni et al., 2013, Kido et al., 2016). LOA for LVEF were similar to those reported 
in FB approaches adopted by Liu et al. (6.4%), Usman et al. 2015 (7.0%) and 2017 (6.2%) (Liu et al., 
2017, Usman et al., 2015, Usman et al., 2017). 
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Study (year) Mode Method 
summary 
Cohort (n) LVEF  LVSV LVEDV LVESV LVM Breath holds NAcc/sl 
Current inter-
observer 
BH 3.0T, SENSE, 
PF 
LGMDR9 (8) BMD (7) 
 
0.4, 0.8 0.4, 0.8 0.04, 0.4 0.4, 0.9 3.2, 9.7 3 x 10s, 1 x 
5s 
2.0x, 
2.5s 
Current 
conventional 
vs accelerated 
BH 3.0T, SENSE, 
PF 
LGMDR9 (8) BMD (7) 
Controls (10) 
1.6, 5.9 2.5, 13.1 2.2, 17.3 -1.6, 11.4 -3.3, 17.3 3 x 10s, 1 x 
5s 
2.0x, 
2.5s 
(Hudsmith et 
al., 2005) 
interobserver 
BH 1.5T, view 
sharing, PF 
Controls (12) 1.6, 4.4 NG 0.4, 4.2 NG 5.8, 10.2 7 x 10.3s 1.0x, 5s 
(Greil et al., 
2008) 
BH 1.5T, SENSE, 
BLAST 
Controls (17) 0.5, 6.5 4.0, 8.0 5.0, 9.0 1.0, 11.0 -0.9, 7 2 x 15s 5.0x, 
0.5s 
(Vincenti et 
al., 2014) 
BH 1.5T, SENSE, 
PF, GPM  
Controls (12) LV 
involvement (21) 
1.6, 8.6 8.7, 25.6 9.9, 20.4 2.0, 23.4 -2.5, 19.2 1 x 14s 5.2x, 2s 
(Jaroni et al., 
2013) 
BH 1.5T, BLAST Myocarditis (18) 
cardiomyopathy (22) 
MI (15) 
4.5, 9.5 NG NG -4.0, 19.0 NG 1 x 3.8s, 1 x 
5.5s 
7.5x, 
1.8s 
(Kido et al., 
2016) 
BH 3.0T, SENSE 
PF 
Coronary artery 
disease (44) other 
cardiac conditions (21) 
controls (16) 
0.4, 5.2 1.1, 11.6 1.3, 15.9 0.2, 10.1 1.0, 12.3 1 x 24s 3.0x, 3s 
(Usman et al., 
2015) 
FB 1.5T, SENSE  Controls (8) patients 
(3) 
1.3, 7.0 2.2, 12 1.3, 8.5 -1.0, 8.5 NG FB duration 2 
min 
0.5x, 9s 
(Usman et al., 
2017) 
FB 1.5T, SENSE  Controls (8) patients 
(3) 
-2.0, 6.2 -1.0, 10.4 2.7, 8.3 3.7, 7.3 NG FB duration 5 
min 
0.9x, 
5.5s 
(Liu et al., 
2017) 
FB 3.0T, SENSE 
CIRCUS 
Controls (8)  1.4, 6.4 NG 2.6, 3.3 -0.8, 7.5 NG FB duration 
2.5 min 
0.9x, 
4.7s 
Table 25. Summary of results from current study and previous publications using compressed sensing or free breathing (FB). All figures for cardiac indices are reported as: mean difference, 
95% limits of agreement (LOA). Comparison of the current study results ejection fraction results are similar in terms of the degree of LOA to other compressed sensing techniques.  
Key: MI, myocardial infarction, BMD, Becker muscular dystrophy, LGMDR9, limb girdle muscular dystrophy type R9, LVEF, left ventricular ejection fraction, LVSV, left ventricular stroke 
volume, LVEDV, Left ventricular end diastolic volume, LVESV, left ventricular ends systolic volume, LVM, left ventricular mass, SENSE,  PF, partial Fourier, LV, left ventricular, NAcc/sl, Net 
acceleration per slice, NG, not given, FB, free breathing, BH, breath holding, SENSE,  Sensitivity encoding, CIRCUS, circular cartesian undersampling, GPM, guide point modelling, BLAST, 
Broad-use Linear Acquisition Speed-up Technique.
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7.2.5 Five year follow up of cardiac dysfunction   
8 participants from the LGMDR9 group had undergone measurement of cardiac indices over the 
five year period. 2 participants did not have baseline cardiac tagging; therefore averages for tagging 
indices are based upon 6 participants.  
 
Characteristic Baseline (n=8) Five years (n=8) P value 
Age (years) 47.7 ±15.2 53.5 ±15.4 N/A 
Number of males (%) 6 (75) 6 (75) N/A 
Systolic blood pressure (mmHg) 134.6 ±13.4 133.4 ±11.5 0.76 
Diastolic blood pressure (mmHg) 83.6 ±9.9 85.0 ±8.7 0.54 
Heart rate (bpm) 73.8 ±13.6 84.3 ±15.9 0.09 
Receiving cardio-active medication 5 (62.5) 7 (87.5) N/A 
Left ventricular ejection fraction (%) 45.6 ±5.7 43.4 ±6.3 0.48 
Left ventricular stroke volume (ml) 46.9 ±12.6 38.8 ±11.7 0.21 
Left ventricular mass (g) 121.2 ±41.4 112.3 ±35.0 0.65 
Left ventricular  end diastolic volume (ml) 106.0 ±38.0 93.3 ±38.6 0.52 
Left ventricular end systolic volume (ml) 59.2 ±26.0 54.5 ±27.3 0.73 
Peak torsion (°)† 3.6 ±0.8 3.3 ±1.3 0.60 
Torsion to strain ratio (rad/%)† 0.3 ±0.1 0.3 ±0.0 0.58 
Peak whole wall strain (%)† 15.8 ±2.6 14.9 ±2.3 0.53 
Peak endocardial strain (%)† 20.7 ±3.2 20.6 ±3.5 0.96 
Table 26. Summary of participant demographics over five years  
† n=6 as two participants did not have baseline cardiac tagging measurements.  
 
None of the cardiac indices derived from cine imaging declined significantly over the five year 
period (Table 26 and Figures 43-44). Measures of strain and torsion did not decrease significantly. 
LVEF strongly correlated to a significant degree to PT (r=0.81, p=0.01 at follow up). PT and TSR 
demonstrated individual variation (Figure 45). 
The only participant not to receive cardio-active medication over the five year follow up had an 
LVEF of 45.0% at five year follow up, which had not changed from baseline measurement. Cardiac 
indices such as LVM, LVSV, LVEDV, and LVESV were not different from other participants over the 
five years.  
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Figure 43. Line graphs to show individual trajectories in cardiac indices over five year follow up: A) Left ventricular 
ejection fraction (LVEF), B) left ventricular stroke volume (LVSV), C) left ventricular mass (LVM). No significant 
differences in any of the cardiac indices over the five years. This may be due to small sample size or due to the 
confounding factor of cardioactive treatment. 
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Figure 44. Line graphs to show individual trajectories in cardiac indices over five year follow up: A) Left ventricular 
end diastolic volume (LVEDV), B) left ventricular end systolic volume (LVESV). No significant differences were 
demonstrated in any of the cardiac indices over the five years, this may be due to small sample size or due to the 
confounding factor of cardioactive treatment.  
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Figure 45. Line graphs to show individual trajectories in cardiac tagging indices over five year follow up: A) Torsion to 
strain ratio (TSR), B) Peak torsion (PT), C) Peak whole wall circumferential strain (PWWS), D) Peak endocardial 
circumferential strain (PECS). No significant differences were demonstrated in any of the cardiac indices over time, 
this may be due to insensitivity as an outcome measure, small sample size, or confounding factors such as 
cardioactive treatment.  
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Chapter 8: Discussion 
 
8.1 Discussion 
The work contained in this thesis has advanced the knowledge of how quantitative MRI can be used 
to examine different aspects of the pathology of muscular dystrophies. This thesis has expanded 
upon existing knowledge by applying the established quantitative measures of Dixon FF, ECV and 
cardiac tagging to muscular dystrophy cohorts over an extended period. A novel method of 
quantifying dystrophic muscle fibrosis in vivo was also investigated, as well as exploring 
acceleration of acquisition of cardiac indices. For outcome measures of early-stage pathology in 
muscular dystrophies (i.e. fibrosis, fatty transformation) to be utilised in future therapeutic trials, 
they must be compared to existing functional assessments. A particular focus of this work has been 
comparing existing outcome measures and demonstrating where new techniques are more 
sensitive to disease progression.    
 
8.2 Quantification of fibrosis - Use of EP3533-enhanced magnetic resonance imaging to 
quantify fibrosis  
EP3533 has been utilised to accurately stage fibrotic disease in several non-muscle studies (Helm 
et al., 2008, Caravan et al., 2013, Fuchs et al., 2013, Polasek et al., 2012). Experiments described in 
Chapter 4 are the first to use this agent for the quantification of fibrosis in skeletal muscle, and to 
take this further to assess EP3533 as an outcome measure after deployment of therapy. Although 
a promising therapeutic avenue, clinical trials of anti-fibrotics in muscular dystrophies have had 
mixed results (Buyse et al., 2015, Kirschner et al., 2010, Raman et al., 2015, Udelson et al., 2010). A 
reliable, sensitive, and non-invasive outcome measure which can directly quantify fibrosis within 
skeletal muscle has great potential to fully assess therapeutic response in both animal experiments 
and ideally human clinical trials. In muscular dystrophies, native T1 and T2 weighted scans 
demonstrate increases in signal intensity in areas of disease activity without use of contrast 
enhancement, though this largely reflects oedema and fat replacement, and distinction between 
these and fibrosis is not readily possible and currently unreliable (McCully et al., 1992, McIntosh et 
al., 1998, Dunn and Zaim-Wadghiri, 1999). In this study, no significant differences were detected 
between mdx and BL10 groups using pre-contrast (baseline) R1 values in any of the muscles (p=NS). 
However EP3533 was able to demonstrate significant differences between mdx and BL10 groups, 
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which correlated strongly with fibrosis, as opposed to other disease processes. The specificity of 
EP3533 to collagen would be a particular strength when evaluating an anti-fibrotic treatment. 
8.2.1 EP3533 and quantification of fibrosis in muscle 
In Chapter 4 the degree of correlation of EP3533-based R1 change to histological measures of 
fibrosis was lower than some of the results seen in previous studies using EP3533 (Fuchs et al. 
r=0.89, p=NG), (Caravan et al. SNR to hydroxyproline r=0.72, p=NG). Previous studies showed 
strong linear correlation between signal change using EP3533 and ex vivo measures of fibrosis 
(Helm et al., 2008, Caravan et al., 2013, Farrar et al., 2015, Fuchs et al., 2013, Polasek et al., 2012). 
In both experiments in Chapter 4 measuring fibrosis via ex vivo quantification, the strongest 
correlation was seen between ex vivo measures and R1 change in the GCN muscle (Chapter 4 - 
Section 2 r=0.83 p=0.001, Section 3 r=0.84 p<0.001). Although GCN showed the strongest 
correlation it did not have the greatest level of fibrosis in ex vivo quantification. This may be 
explained by ROI positioning or slightly higher blood flow to this muscle during the scan.  
Previous studies have compared their findings using EP3533 using an isomer of EP3533 which does 
not display the same degree of affinity to collagen (EP3612) (Helm et al., 2008, Polasek et al., 
2017b). Gd-DOTA was selected as a control in the second of the experiments in Chapter 4 as it is 
currently used to prognosticate and delineate fibrosis in clinical practice thereby giving the 
experiment greater external validity (Kim et al., 2000, Wu et al., 2008a). Unlike EP3533, Gd-DOTA 
was unable to show any significant differences in R1 change between mdx and control groups, or 
any significant correlation to ex vivo measures of fibrosis (p=NS); EP3533 can quantify fibrosis 
where the probe currently used in clinical practice cannot. Non-specific gadolinium probes are 
extracellular and only taken up into muscle fibres when muscle damage has occurred (Amthor et 
al., 2004). A non-specific gadolinium probe has been investigated before in dystrophic human 
skeletal muscle with only the TA showing significant enhancement post-exercise (Garrood et al., 
2009). A control probe would ideally be structurally similar to EP3533 to prove the signal change 
demonstrated is due to the affinity of EP3533 to fibrosis. If the probes are not structurally similar 
then bias is introduced. Comparing to a non-structurally similar probe means that a change in signal 
intensity may be due to delayed washout time of the peptide-based probe rather than true affinity 
to a target molecule. The contrast probe EP3612 would be better a control to prove the signal 
change demonstrated was due to affinity to fibrosis however this was not available for use in these 
experiments.  
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8.2.2 Fibrosis in mdx mice  
Prior studies have identified that the most fibrotic muscle in mdx mice is the diaphragm, however 
it is not possible to accurately image this muscle quantitatively due to its size and shape (van Putten 
et al., 2012, Carlson, 2014, Turgeman et al., 2008). Ex vivo measurements of fibrosis in all three 
experiments confirmed a significant difference between all muscles in the older BL10 and untreated 
mdx mice. Taking all measurements of the extent of fibrosis from muscles into account, MT 
quantification and hydroxyproline correlated to a significant degree (Chapter 4 - Section 2 r=0.64 
p=0.00004, section 3 r=0.57 p<0.001). An exact correlation is not expected, as Masson’s trichrome 
averages cross sections of muscle, and may exclude focal fibrosis. The levels of fibrosis seen in these 
experiments were comparable to values reported by others (Pistilli et al., 2011, Graham et al., 2010, 
Cohn et al., 2007), although mdx mice can vary widely in subject age and disease severity. Other 
studies using MT to assess fibrosis have suggested results similar to our findings in cardiac fibrosis; 
values range from 0-2% in BL10 and 5-8% in mdx mice (Cohn et al., 2007, Au et al., 2011). The 
hydroxyproline assay has been criticised for insufficient specificity, sensitivity, reproducibility and 
accuracy (Caetano et al., 2016). The hydroxyproline assay is time consuming and involves a multi-
step laborious method through which errors can occur (Ignat’eva et al., 2007, Caetano et al., 2016). 
In both section 2 and 3, quantification of fibrosis through MT staining was shown to correlate 
significantly and strongly with the amount of hydroxyproline in cardiac, GCN and TA muscles in 40 
week old mice (Table 5). In the halofuginone experiment, R1 change at post-treatment scan 
demonstrated weak correlation to hydroxyproline quantification, this was however statistically 
significant in three out of the four muscles (Table 10).  Issues with the hydroxyproline assay may 
have led to a weaker correlation with R1 change in the third experiment. More accurate, and less 
laborious, methods of fibrosis quantification should be considered in the future, such as computer-
assisted histomorphometric analysis (Perini et al., 2015, Caetano et al., 2016) or image intensity 
analysis of Western blot (Taylor et al., 2013, Huebner et al., 2008). 
 
8.2.3 R1 change following EP3533 administration  
Timing of R1 change was selected based upon the results of the dynamic SNR change in cardiac 
muscle with the greatest change in EP3533 seen at forty minutes (Figure 14). The timing of this 
increase correlated well with previous cardiac-related EP3533 experiments (Caravan et al., 2007). 
No previous studies have investigated EP3533 in skeletal muscle therefore the timing of 
measurements of R1 change was taken as the point of signal plateau in the pilot experiment at 
seventy minutes (Figures 12 and 13).  
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Comparing the findings of Chapter 4 to other previous studies in terms of the magnitude of R1 
change demonstrates that the difference in R1 value from pre-treatment to post-treatment scans 
was smaller than was reported in studies using EP3533 in other disease models (Fuchs et al., 2013, 
Polasek et al., 2012). Suggesting there may be a linear relationship between the amount of fibrosis 
in tissue and the degree of EP3533-R1 change. In order for a contrast agent to exhibit visually 
observable contrast, it is estimated that a change in relaxation time of at least 0.5s-1 is required 
(Caravan, 2006). EP3533 did not demonstrate this degree of change in the mdx mouse in these 
experiments so the difference was not visually evident. A greater change in R1 may have been seen 
in older mice although these were not selected as previous studies using younger mice had shown 
a more significant treatment effect (Turgeman et al., 2008).  
Considering the potential for use of EP3533 in clinical trials, humans exhibit a greater degree of 
fibrosis and this may lead to an increase in R1 change which may be more readily visualised (Pessina 
et al., 2014a). While gadolinium-based contrast probes are widely used in clinical practice, to date 
no peptide-enhanced gadolinium probes have been licenced by either the European Medicines 
Agency or the Food and Drug Administration in the United States. Gadolinium-based probes are 
associated with complications such as local tissue toxicity and nephrogenic systemic fibrosis. 
Studies have also shown accumulation of gadolinium in the brain (Neeley et al., 2016). The 
European Medicines Agency have approved the use of certain non-specific gadolinium agents at 
the lowest possible dose to provide enhancement and when unenhanced scans could not be used 
instead (European Medicines Agency, 2018). Due to the delays in washout time and potential for 
gadolinium toxicity in different tissues, targeted gadolinium agents will need extensive preclinical 
and subsequent clinical studies to demonstrate their safety profile prior to use in humans. In 
muscular dystrophies there are no specific contraindications to gadolinium enhancement, there 
are issues limiting MRI use in this cohort such as scoliosis and reduced respiratory reserve on lying 
supine. 
 
8.2.4 Validity of the halofuginone experiment 
Previous murine studies have established the efficacy of halofuginone in reducing fibrosis in mdx 
mice, with clinical trials of halofuginone ongoing (Clinical Trials.gov, 2018c, Huebner et al., 2008, 
Turgeman et al., 2008). Turgeman et al. demonstrated a reduction in collagen as shown by 
quantification of sirius red staining, the number of central nuclei, and areas of degeneration in 
treated mice; suggesting less muscle fibre damage (Turgeman et al., 2008). Turgeman et al. also 
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suggested that there was enhanced motor coordination, balance and cardiac muscle function seen 
in treated mice, suggesting significant reduction in muscle injury (Turgeman et al., 2008). Huebner 
et al. used two treatment lengths of up to 10 weeks in mdx mice of an advanced age (32-36 weeks) 
(Huebner et al., 2008). Both studies suggested that there was a significant reduction of collagen in 
the halofuginone receiving groups (Huebner et al., 2008, Turgeman et al., 2008). The efficacy of 
halofuginone in reducing fibrosis and improving function was reflected in the halofuginone 
experiment in Chapter 4, with significant differences in ex vivo measures of fibrosis in the majority 
of muscles, and a significant difference between untreated and treated mdx mice (Figure 27).  
One of the most important aspects of the halofuginone experiment was the PK study; these were 
performed to provide evidence that halofuginone dose was sufficient to produce a change in 
fibrosis as expected. The results suggest that the halofuginone administered via the IP route was at 
detectable levels similar or higher than reported in other studies (Stecklair et al., 2001, de Jonge et 
al., 2006). The dose of halofuginone (7.5ug/kg) used in this study was selected based on the positive 
results of previous studies in skeletal muscle (Turgeman et al., 2008). To date, no studies of 
halofuginone treated mdx mice have published PK data. Previous murine studies looking at 
halofuginone have suggested that doses above 1.5mg/kg were toxic to mice, and that oral routes 
of administration may not have sufficient bioavailability for detectable serum levels of 
halofuginone (Stecklair et al., 2001). Stecklair et al. reported that mean peak concentration was 
386ng/ml using a 1.5mg/kg dose (Stecklair et al., 2001). In this experiment, using a dose 200 times 
smaller, the peak PK was proportionally higher at 21.2ng/ml after 15 minutes (for comparison this 
would have been 1.93ng/ml reported by Stecklair et al., assuming a linear dose to serum PK 
relationship). Taking into account the lower administered dose, the area under the curve for this 
experiment was proportionally almost ten times higher, at 913.68ng/ml/min compared to 
99.37ng/ml/min (Stecklair et al., 2001). Serum PK levels of halofuginone were not detectable after 
8 hours (Figure 21), which is longer than the 3 hours reported by Stecklair et al. (Stecklair et al., 
2001). Although not the remit of this study, organ PK studies would give more definitive evidence 
of the concentration of halofuginone in tissue, and are therefore likely to have the previously 
described effect (Turgeman et al., 2008, Huebner et al., 2008). The significant differences in muscle 
fibrosis on ex vivo quantification between treated and untreated mdx mice provides further 
evidence of efficacy of the halofuginone administered in this experiment.  
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8.2.5 Use of EP3533 to measure longitudinal disease progression  
Currently the only validated way to quantify fibrosis in human skeletal muscle is via muscle biopsy 
(Sardone et al., 2018). Muscle biopsy is invasive, risks sampling error and includes the risk of a 
general anaesthetic in patients with reduced respiratory function. EP3533, by contrast, is able to 
measure change in skeletal muscle fibrosis over time in a relatively non-invasive manner. Previous 
studies have focussed on whether EP3533 can stage or quantify progression of induced disease 
(Caravan et al., 2013, Fuchs et al., 2013). Farrar et al. looked at response to Rapamycin post-bile 
duct ligation, their findings suggested that EP3533 was able to distinguish between treated and 
untreated groups (p<0.001) (Farrar et al., 2015). In contrast to the halofuginone experiment, they 
found that the magnitude of EP3533-induced signal change was significantly different between 
these groups. Magnitude of R1 change was not significantly different between the treated and 
untreated mdx groups (Tables 8 to 9); however the difference between R1 change in the pre-
treatment to post-treatment scan was significantly different (Table 10). As seen in humans with 
muscular dystrophy, mdx mice demonstrate individual variation in fibrosis. This may explain why it 
was the change in R1 value from pre-treatment to post-treatment which demonstrated a significant 
difference between the treated and untreated groups (Spurney et al., 2009, Grounds et al., 2008).  
Automated segmentation of skeletal muscle boundaries has been attempted in computerised 
tomography (van Vugt et al., 2017), but there are no software programs currently validated for use 
in MRI. Difficulties in automated ROI imaging are due, in part, to the small degree of difference in 
signal between muscles and their surrounding fascia. Automated cardiac analysis is possible due to 
the signal difference between the intraventricular blood and cardiac tissue (Huang et al., 2018). In 
the EP3533 studies, ROIs were drawn by hand using software programs. This can introduce a small 
degree of subjectivity to muscle analysis, particularly when comparing highly fat replaced muscles 
or small muscles in cross section. In the halofuginone experiment, inter-muscular and inter-
observer variation was seen in R1 change at all time points. ROI analysis was more difficult in the 
quadriceps and the hamstrings, as these are composite muscle groups with the external borders 
less defined. ROIs of composite muscle groups include fascia and blood supplies, which may also 
have contributed to variability within the results. Difficulties in drawing ROIs to encompass these 
muscles may have led to a less significant correlation to MT and hydroxyproline quantification 
(Table 11), compared to the GCN and TA muscles.  
Efforts to standardise preclinical trials using mdx mice have suggested several standardised 
methods of assessing treatment response. Spurney et al. compared several potential treatment 
outcome measures in female mdx mice, first comparing mdx to control, then assessing the degree 
 138 
 
of change required to reach statistical significance of various outcome measures. The results 
suggested several measures demonstrated unacceptable variability or were insufficiently sensitive 
to disease change. In the Halofuginone experiment, EP3533-enhanced R1 change was assessed for 
responsiveness with the TA and GCN, giving mid-range SRM values (0.56, 0.48 respectively). The 
SRM was lower in the HMS and quadriceps (both 0.36). This suggests that there is a reasonable 
level of responsiveness to change in value in response to treatment, in at least two of the muscles, 
using this method.  
 
8.2.6 Correlation of EP3533-enhanced R1 change to functional measures 
MRI-based studies have suggested that there are no significant differences between mdx and BL10 
mice in LV indices (LVEF and LVM) even at two years of age (Cohn et al., 2007). Opposing studies 
using echocardiogram have suggested that LV indices (LVM and fractional shortening) can be 
significantly different in mdx mice as early as 42 weeks of age (Quinlan et al., 2004). These 
differences could be due to many factors, such as amount of exercise, and heterogeneity of mdx 
mice. Right ventricular dysfunction in mdx mice has been reported by Quinlan et al., who reported 
that mdx mice had increased right ventricular fibrosis and that progression of fibrosis was similar 
to the left ventricle (Quinlan et al., 2004). A study looking at the effect of beta blockers on mdx 
heart function showed that there was no difference between control and mdx groups in LV indices 
at 24 weeks, but that right ventricular ejection fraction was significantly lower in the latter group 
(Blain et al., 2013). Our results showed that RVEF was the only cardiac functional measure 
significantly lower in the mdx mouse and that the RVEF correlated inversely to a significant degree 
with both ex vivo measures of fibrosis (MT quantification r=-0.70, p=0.01, hydroxyproline assay r=-
0.72 p=0.008 (Figures 19 and 20). Further to this, EP3533-derived R1 change correlated strongly to 
RVEF (r=-0.83 p=0.006). Measurement of the R1 change is based upon ROI selection within the left 
ventricle, as the size and shape of the right ventricle make this impracticable. The strength of the 
correlation between R1 change and RVEF lends support to the possibility of a proportional increase 
in fibrosis between left and right ventricles in mdx mice, as suggested by Quinlan et al (Quinlan et 
al., 2004). It was unclear why LVEF was not significantly different in spite of the EP3533-derived 
signal increase, suggesting an increase in fibrosis; this may be due to compensatory mechanisms. 
Alternatively, right ventricular dysfunction may be disproportionally affected by the increase in 
fibrosis of the diaphragm affecting venous return to the heart and increase right ventricular 
afterload due to hypoxia-induced pulmonary arteriolar vasoconstriction.   
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In murine experiments several standardised assessments have been developed to measure motor 
function and strength in a reliable way (Tinsley et al., 2014, Spurney et al., 2009, Treat NMD, 2016). 
Existing experimental measures of force may be subjective, and musculature is significantly 
different from humans in terms of mechanism of movement; external validity may be reduced due 
to different compensatory mechanisms employed by both species (Hu et al., 2017). Previous 
studies looking at halofuginone in mdx mice have suggested that there were significant 
improvements in functional assessment, including exercise endurance and exercise-induced 
damage repair (Huebner et al., 2008, Turgeman et al., 2008). In Chapter 4, skeletal muscle function 
was assessed using two and four limb myometery (grip strength testing) (Table 6). Grip strength 
tests are most akin to quantitative muscle assessment in humans (McDonald et al., 2013). Grip 
assessments have shown significant differences between control and mdx mice (Spurney et al., 
2009). In the results of Chapter 4, the weight-adjusted two limb assessment results correlated more 
significantly to R1 change (r=-0.33 p=0.004), and demonstrated a significant difference between 
untreated and treated mdx groups (Figure 28). The four limb assessment was unable to 
demonstrate a significant difference between the untreated mdx and the BL10 groups. In contrast 
to these results, Huebner et al. did not report a significant difference between halofuginone treated 
mdx mice and controls in grip assessment (Huebner et al., 2008). This difference may be due to the 
smaller group sizes used by Huebner et al. (n=5) (Huebner et al., 2008). As with functional outcome 
measures in humans, other factors such as cognition, stress and motivation can be confounding 
variables (Grounds et al., 2008). In humans with DMD, quantitative MRI such as Dixon FF 
measurement has been shown to have high levels of correlation to the 6MWT (r=-0.65, p<0.001), 
as well as other functional assessments (Fischer et al., 2016, Wokke et al., 2014b, Willcocks et al., 
2016a, Willcocks et al., 2017). The correlations seen in this experiment were lower than that of 
Dixon FF in humans. Any future evaluation of efficacy of EP3533-induced R1 change in clinical trials 
should therefore be compared with Dixon FF and other MRI measures such as cCSA (Fischer et al., 
2016, Akima et al., 2012). The four limb assessment was expected to correlate more strongly than 
the two limb to MRI measures of fibrosis, as it included the hind muscles in the assessment. The 
weak correlation seen here may be due to the assessment taking into account strength from other 
muscles not selected as regions of interest. The two limb assessment was only able to assess 
forelimb skeletal muscle, and was therefore only an indirect measure of fibrosis in hind limb 
skeletal muscle. The relatively weak correlation between function and EP3533-induced R1 change 
may be due to the non-linear development of fibrosis throughout muscle, as seen in other human 
and murine studies (Vohra et al., 2017, Arpan et al., 2012, Gutpell et al., 2015).  
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8.2.7 Conclusions: EP3533-induced R1 change as an outcome measure in muscle of mdx 
mice 
The experiments performed in Chapter 4 have been the first to examine use of EP3533 in muscle 
of mdx mice. The results support several conclusions: firstly, that EP3533-induced R1 change at 70 
minutes can be used to reliably detect differences between older age-matched mdx and control 
mice in the TA, GCN, hamstrings and the heart. Secondly, that EP3533-induced R1 change 
correlated to a significant degree with ex vivo measures of fibrosis in the same muscles. Finally, 
there was a significant overall correlation between EP3533-induced R1 change in both measures of 
heart and skeletal muscle function.  
Less clear was whether EP3533 can be used to successfully quantify disease progression over time. 
Absolute R1 change values were not significantly different between groups at either pre-treatment 
or post-treatment. Comparison of the difference in R1 change at 70 minutes from baseline to follow 
up scan did show significant increases in the untreated mdx, which were not evident in the treated 
mdx group.  
There is therefore potential for EP3533 to be used as an outcome measure for clinical trials, though 
little is known of the safety profile of peptide-based gadolinium agents. Further preclinical studies 
are required to provide safety data findings used to inform a future application for registration of 
potential human trials before this agent can be used as an outcome measure or in clinical practice.  
 
8.2.8 Limitations of EP3533-induced R1 change as an outcome measure in muscle of 
mdx mice 
As with all animal studies, there are questions over the detailed translation of findings to the clinical 
disease, which relies on imperfect animal models. A serious flaw in the mdx mouse is the absence 
of one of the hallmarks of muscular dystrophies, fatty transformation of skeletal muscles. It is not 
possible to ascertain how other measures of disease progression, such as FF, relate to EP3533-
induced R1 change; which is particularly important in light of the high levels of fatty transformation 
in human dystrophic muscle. Compared to other animal models that have investigated EP3533, 
there are relatively small amounts of fibrosis present in skeletal mdx mouse muscle. The mild 
phenotype of mdx mice may have contributed to a relatively small treatment effect and reduced 
the significance of our findings; larger scale murine or other animal model studies with treatment 
over prolonged periods may be required. Humans with DMD have larger volumes of collagen and 
may be more likely to have proportionally higher signal using this probe. Alongside FF 
 141 
 
measurement, using EP3533 as an outcome measure could provide significant and sensitive insight 
into disease progression. 
Little is known about the potential safety profile of EP3533, this needs to be explored extensively 
prior to registration for human trials and subsequent licencing application. 
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8.3 Quantification of adipose tissue - quantitative MRI in skeletal muscle in limb girdle 
muscular dystrophy type R9 
Whilst EP3533 has shown promise in quantification of fibrosis in skeletal and cardiac muscle, it is 
important to consider that this is only on aspect of the pathology of muscular dystrophy. In humans, 
adipose replacement of skeletal muscle is an important aspect of pathology in muscular 
dystrophies. Non-invasive imaging of muscle fat replacement has been shown to correlate to 
disease progression and functional assessments in conditions such as the LGMD (Willis et al., 2014, 
Willis et al., 2013, Diaz-Manera et al., 2018), DMD (Schmidt et al., 2018, Ricotti et al., 2016) and 
BMD (Fischer et al., 2016).  
Research into LGMDR9 has been increasing, with several putative therapies showing promise in 
ameliorating LGMDR9 in vivo and in vitro (Qiao et al., 2014, Stevens et al., 2013, Richard et al., 2016, 
Svahn et al., 2015). Due to the likelihood of upcoming human trials of various promising agents, a 
European neuromuscular centre workshop addressed the trial readiness of LGMDR9 (Richard et al., 
2016), highlighting the need for a large scale longitudinal study, with an array of outcome measures 
(Richard et al., 2016). The results of the study detailed represent the longest multicentre natural 
history study of LGMDR9 to date. The results have several important findings which are relevant to 
developing outcome measures for clinical trials into treatments for LGMDR9. These results provide 
support for the Dixon technique as an early outcome measure to show effects on disease 
progression. The results also identified the standardised physical outcome measures which 
significantly changed over a six year period.  
 
8.3.1 Dixon fat fraction and quantitative MRI in skeletal muscle in LGMDR9 
The Dixon technique has been established as a sensitive measure of skeletal muscle disease 
progression in muscular dystrophies (Fischmann et al., 2013, Ricotti et al., 2016, Wren et al., 2008, 
Gaur et al., 2016, Hollingsworth et al., 2013a, Willcocks et al., 2016b, Willis et al., 2013, Fischer et 
al., 2016). In a slowly progressive condition such as LGMDR9, a highly sensitive outcome measure 
is required for clinical trials, unless the effect size of an intervention is very high. Functional 
measures may not significantly change except over prohibitively long periods. In Chapter 5, the use 
of FF calculation demonstrated that over six years, all muscle groups significantly increased in 
percentage of fat replacement (Table 15). Comparing individual muscles, the TA (median 7.1%) was 
relatively spared, with the most fat infiltrated muscle being BFLH (median 78.6%) (Table 15). The 
median fat replacement per year was greatest in the lateral GCN (1.7%), ST (1.3%), Gr (1.3%) and 
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VL (1.3%) muscles (Table 15). The highest composite muscle changes over six years were in the 
triceps surae (12.5%). Comparable rates of fat replacement were seen in several muscles, including 
TA (Willis et al. -0.1%, six year follow up 0.2%) and lateral GCN (Willis et al. 1.4%, six year follow up 
1.7%) (Table 17).  
The Dixon technique for FF calculation had a high degree of inter-rater reliability, as shown by Bland 
Altman analysis (Figure 29). Wide range of fat replacement was demonstrated in several muscles 
and muscle groups; this may be a sign of variable involvement between participants, or due to ROI 
placement because of difficulty in identification of the borders of the muscle, in those heavily fat 
replaced (Figure 32 and Table 12). 
To increase the power and reliability of the Dixon technique as a biomarker, muscles can be 
selected for analysis over the follow up period. Such muscles need to be easy to identify, with high 
levels of interrater reliability. Muscles also need to be progressively affected from baseline to follow 
up, and it is important to consider the variability of involvement of the muscle between 
participants. Following a database lock therapeutic trials plan to release interim results during a 
long term trial after a year or more of follow up. Such publications may be used to justify further 
studies into a treatment. Ideally any selected muscle should demonstrate a significant change over 
a short period. Willis et al. identified nine muscles demonstrating significant change over one year; 
four were suggested to be appropriate targets for analysis (Willis et al., 2013). The muscles selected 
were, proximally, the RF, VL, Gr, and, distally, the medial GCN. Over a six year period, the RF was 
not appropriate as this muscle had the most outliers, which may be due to difficulties in ROI 
placement. SRM values were above 0.8 in all muscles, with the exception of the BFSH (0.53), and 
the TA (0.67). There were several highly significant p values coupled with high SRM values, which 
suggests that to maximise power the following muscles should be targeted for analysis: the VL 
(0.92), Gr (1.04), and Sar (0.98). In the lower leg both of the gastrocnemii muscles should be 
included (lateral 0.91, medial 0.95). Other thigh muscles, including the BFLH, ST and SM, were not 
suitable in spite of high SRM values (0.81, 0.83, and 0.90 respectively). These muscles showed high 
fat fractions at baseline; therefore it is likely that therapeutic effects would be reduced. High levels 
of fat content at baseline increased difficulty and reliability of ROI placement (Figure 33). The VM, 
BFSH, and remaining calf muscles (PL, Sol, and TA) were less suitable endpoints due to the lack of 
significant difference at one year, thereby excluding interim analysis. Other composite muscle 
groups such as the averaged thigh (1.20), averaged lower leg (1.28) and averaged triceps surae 
(1.25) had high SRM values, similar to the value of the target muscle group (1.23). Therefore, these 
composite measures may also have utility as a powerful outcome measure.  
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Lokken et al. suggested that in LGMDR9, a lower cCSA is found compared to controls, but with 
preserved ratio between the cCSA and force (Lokken et al., 2016). Chapter 5 did not aim to evaluate 
this relationship, and is unable to, due to the physical function tests which were based on those 
done six years previously to allow for long term comparison. For each muscle group the SRM for 
the cCSA was smaller, with a less significant p value than the FF, which may indicate that variability 
in the CSA within the group outweighed the smaller changes in FF (Table 16). cCSA has been 
previously shown to correlate to measures of strength in muscular dystrophies (Lokken et al., 2016, 
Wokke et al., 2014b); however our results suggest that cCSA is a less sensitive endpoint than FF 
quantification in the LGMDR9 cohort. 
 
8.3.2 Functional outcome measures in LGMDR9 over six years 
Compared to functional assessment, MRI is criticised as not being as clinically relevant to the 
patient. If MRI results were used in isolation as an outcome measure, there is a risk that 
improvements may not necessarily benefit the patient in terms of desirable functional ability or 
measures of health. The European Medicines Agency has stipulated that therapeutic trials into 
neuromuscular diseases include measurements of movement that affect quality of life (Richard et 
al., 2016). For quantitative MRI to be accepted as a primary outcome measure, it is important for 
the measurements to provide an extra dimension that isn’t provided by other cheaper, quicker 
tests. The advantage of using FF progression as an outcome measure is that it is more sensitive to 
slowly progressive disease changes, as seen in LGMDR9 (Richard et al., 2016, Willis et al., 2013). 
The results of this thesis and that of Willis et al. suggested that the Dixon technique can reliably 
detect changes in leg muscles over one and six years in LGMDR9. None of the skeletal muscle 
functional assessments demonstrated a significant difference over one year (Willis et al., 2013). 
Over six years all of the timed muscle function tests demonstrated disease progression (Table 13). 
Of the hand-held myometry tests, only hip adduction significantly declined. The 6MWT and the 
10MWR assessments had high SRMs (-0.85 and -1.02 respectively); other timed assessments had 
lower SRM values <0.5. Two participants improved their speed for the 10MWR assessment over six 
years, though both had a reduction in their 6MWT distance. Willis et al. found that in one year, the 
median 6MWT distance improved from 312m to 353m – possibly due to learning effects, patient 
motivation or motor strategy adaptations (Hamilton and Haennel, 2000, Guyatt et al., 1985, Wu et 
al., 2003, Willis et al., 2013, Alfano et al., 2014). Over six years, the 6MWT distance significantly 
declined; six participants became non-ambulant. All timed functional assessments demonstrated a 
significant decline but only the 6MWT and the 10MWR velocity had SRM values of >0.5 (Table 13). 
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Four participants improved their distance (mean increase 68.8m ±50.3). These participants 
demonstrated FF increase of at least 1% in the majority of the 20 muscle groups and of the 
composite groups studied (15/20 groups for 1 participant, 19/20 groups for 2 participants and all 
groups for 1 participant). This shows that quantitative MRI can demonstrate disease progression in 
individuals where a physical function test cannot. Looking at the increase in FF of the two 
participants that improved in their 10MWR test velocity, one had >1% increase in all muscles, and 
the other had only one muscle with >1% increase. The differences in the FF increase and between 
the results of the two functional tests (6MWT and the 10MWR) may further highlight the 
participant dependent factors of the functional tests, i.e. effort or fatigue. In contrast to DMD 
studies (McDonald et al., 2013), there was no clear cut-off in distance walked at baseline, which 
could predict non-ambulation in the LGMDR9 cohort at six years (Figure 30). This is likely due to 
the variability in rate of progression of weakness.  
The only myometry measurement which demonstrated a significant decline over six years was hip 
adduction. In DMD, myometry measurements may be predictive of decline, though they are not 
always significant even over two years (McDonald et al., 2013). The timed tests lack the sensitivity 
to detect the slowly progressive weakness of LGMDR9 over one year (Willis et al., 2013). 
Forced vital capacity (FVC) was the only functional assessment significantly reduced over both one 
and six-year time periods (Table 13) (Willis et al., 2013). The annual median FVC decline in the 
sitting position was -2.6% annually, with -1.9% median annual decline when in the supine position. 
This is less than reported elsewhere, which is perhaps explained by the differing cohort ages (Poppe 
et al., 2003, Willis et al., 2013). Respiratory muscle involvement was only indirectly linked to skeletal 
muscle involvement, but as a comorbidity may have led to a reduction in functional assessments.  
As a potential clinical trial outcome measure, the 6MWT and the 10MWR were the only functional 
timed assessments relating to skeletal muscle, demonstrating a significant difference over six years 
which included all participants at baseline. The 6MWT, 10MWR, chair rise, stair ascend, and stair 
descend tests are important to include as outcome measures in future trials investigating LGMDR9 
cohorts. These tests were also graded to show whether participants were relying on compensatory 
methods to assist with the test. In all assessments except the stair ascend, the grading had 
significantly decreased over six years, implying an increase in compensatory measures to perform 
the test (Table 14). Such tests of leg function rely on ambulation; upper limb measures and multi-
domain tools may be able to show disease progression after this point (Mazzone et al., 2009, 
Mayhew et al., 2013a).  
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The NSAA demonstrated a significant reduction in total score over six years (p=0.04). As only ten 
participants underwent NSAA, this precludes definitive conclusions or more detailed analysis. The 
results of the ten participants who underwent the NSAA did demonstrate wide differences in loss 
of function over six years. This variability may have been due to the heterogeneity of disease 
progression, or merely to higher losses recorded in those with more function at baseline; i.e. more 
function to lose (Figure 31).   
 
8.3.3 Subgroup analyses 
Gender differences in affected muscles have been identified in the LGMDR9 cohort. Willis et al. 
reported that the Gr was more preserved in males, though there was more fat replacement in the 
VM compared to females (Willis et al., 2014). At six years the VM continued to have a significantly 
higher percentage of fat content (Table 20). Timed assessments and myometry results were similar 
between genders, with females only performing significantly better on the 10MWR (p=0.02). The 
6MWT results were not significantly different between genders. Due to the small numbers in each 
group, our results may lend evidence to gender difference, particularly in fat replacement of the 
VM; however definitive conclusions cannot be drawn. The overall effect of such gender differences 
on functional assessments is also not certain. Based on previous studies and results of this PhD 
future clinical trials should not stratify according to gender but a larger scale clinical trial would 
confirm whether gender differences exist (Willis et al., 2014, Willis et al., 2013).     
Non-ambulant patients (n=6) were not significantly different in terms of age, but did have 
significantly increased fat replacement at both baseline and follow up in the Sol, RF, and VM (Table 
21) - three of the most important muscles for walking. It is unclear whether this was causative of 
loss of ambulation; there was a significant overlap in terms of FF in the muscles of non-ambulant 
and ambulant participants. One participant had a higher fat fraction in all three muscles than the 
highest FF of the non-ambulant participants, yet remained ambulant. The increase in fat 
replacement in these muscles may merely be an effect of the reduced use of these muscles as the 
patient became less ambulant. However it is important to consider the significant heterogeneity 
between individuals in this condition, co-morbidities may be a factor in reduced ambulation, with 
reduced respiratory or cardiovascular drive reducing individual walking abilities (Siciliano et al., 
2015). Other compensatory mechanisms such as changes in gait, may be employed by individuals 
to aid ambulation. Alternatively other muscles may compensate for weakness in the more affected 
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muscles, heterogeneity in individual muscle weakness can be controlled for using composite 
muscle measures.      
Age correlated significantly with the four hamstring muscles, though not strongly; the 6MWT was 
the only functional assessment which correlated significantly (p=0.04). The lack of strong, 
significant correlations suggests that the loss of function may be independent to age and, as seen 
in other studies, there is heterogeneity in terms of phenotypic progression within participants with 
the same mutation (Harel et al., 2003, Rivas et al., 2014, Bourteel et al., 2007).   
 
8.3.4 Correlation of fat fraction to functional assessments   
Strong significant correlations were seen between the 10MWR, the 6MWT, and FF at both baseline 
and follow up (Tables 18 and 19). Change in FF over time did not correlate strongly to change in 
6MWT or the 10MWR, which suggests a non-linear relationship. The lack of strong correlation to 
change in FF may be due to the existence of confounding factors such as co-morbidities and 
compensatory mechanisms. Other functional assessments did not demonstrate strong correlations 
with FF at baseline and follow up, which may be related to their insensitivity to disease progression, 
with the majority of assessments unable to demonstrate disease progression over this time period.    
 
8.3.5 Conclusions 
The results of Chapter 5 constitute the longest follow up into a LGMDR9 cohort to date, and suggest 
that FF calculation using the Dixon technique is sensitive to changes over a six year period in all 
muscle groups. Use of the Dixon technique has several advantages over standardised functional 
assessments, and can provide useful interim measures of disease progression – not currently 
possible with functional testing. The results of this study support FF calculation in LGMDR9 clinical 
trials as a primary outcome measure alongside functional assessments. The results suggested the 
most appropriate target muscles for analysis alongside composite muscle groups were the vastus 
lateralis, gracilis, sartorius, and the medial and lateral gastrocnemii. The results suggested that the 
6MWT and the 10MWR were the most appropriate functional assessments over six years, and 
correlated reasonably strongly to FF in individual muscles. Measures of trophicity were unlikely to 
be useful as outcome measures in the LGMDR9 cohort, even over six years.    
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8.3.6 Limitations  
It is important to acknowledge that these results may underestimate progression of the disease 
process; the most severely affected individuals were less likely to have returned at six years due to 
the difficulties in travel. Other limitations included the fact that only one slice was analysed in each 
subject at a predefined level. Multi-slice analysis could take account of heterogeneity in disease 
progression. While there were many possible correlations between FF calculations and functional 
measures, this work concentrates principally on the sensitivity of outcome measures to detect 
change over time. The studies performed only included participants with homozygous mutations, 
rather than the more severe form of the condition caused by compound heterozygous mutation. 
The results of this study is useful to inform clinical trials of LGMDR9 with a homozygous mutation 
and are not valid for the compound heterozygous cohort.      
A drawback of quantitative FF analysis is that it is unable to identify the other main pathology of 
muscular dystrophies, namely fibrosis. The Dixon technique is able to sensitively and non-invasively 
detect disease progression; however it is possible that patients may have intra-subject variability 
in the percentage of fat replacement to fibrosis ratio. Potentially FF calculation could be used 
alongside contrast agents (i.e. EP3533) to allow quantification of both fibrosis and fat replacement. 
Although the development of use of contrast agents in this fashion is not expected for a long time 
due to the need for regulatory approval, use of these non-invasive biomarkers could be especially 
important in assessing anti-fibrotic therapeutic agents in clinical trials of muscular dystrophy. 
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8.4 Quantification of fibrosis - Use of extracellular volume in muscular dystrophies 
The focus of the studies within this thesis have been quantification of fibrosis and adipose 
replacement of skeletal muscle. Although EP3533 was considered in mice to quantify overall 
cardiac fibrosis, comparing this to global measures of function and ex vivo measures, the focus was 
on the heart as a whole. In humans, cardiac dysfunction in muscular dystrophies can be insidious, 
with regional cardiac dysfunction and fibrosis difficult to detect. Chapter 6 aimed to assess how 
ECV could be used to quantify fibrosis and demonstrate cardiac dysfunction non-invasively within 
BMD and LGMDR9 cohorts, comparing this to traditional measures of cardiac pathology.    
ECV has been investigated as a biomarker in both muscular dystrophy and other conditions causing 
dilated cardiomyopathy (Florian et al., 2014b, aus dem Siepen et al., 2015, White et al., 2013, 
Olivieri et al., 2017). This study is the first to investigate use of ECV in a LGMD cohort and to report 
use of cardiac tagging in BMD. The cardiac phenotype of BMD and LGMDR9 shows slowly 
progressive regional and global cardiac dysfunction. The slow progression requires a quantifiable, 
sensitive, and non-invasive biomarker for interventional trials and clinical practice. ECV may be 
useful in predicting regional cardiac dysfunction, though no large longitudinal studies have been 
undertaken to date. Florian et al. performed ECV quantification on two patients with BMD, finding 
no difference in ECV values over a short follow up of one year (Florian et al., 2014b). The findings 
of Chapter 6 suggest that ECV may provide quantification on disease progression and regional 
changes which are not evident with other measures of cardiac dysfunction. Further to this, cardiac 
studies often consider BMD and LGMDR9 together due to their similar cardiac phenotype (Sveen 
et al., 2008a, Petri et al., 2015). Differences in torsion and strain measurements between these 
groups highlight potential mechanistic differences in cardiac dysfunction that may be relevant for 
future therapy development. 
 
8.4.1 ECV in quantification of segmental fibrosis 
Comparing ECV in individuals with cardiac dysfunction to those without demonstrated that ECV 
was significantly higher in all regions, and globally (Figures 35 and 36). The findings of Chapter 6 
were similar to these, with higher average ECV values in lateral segments. A study of a BMD cohort 
by Florian et al. reported that ECV measures were highest in lateral wall segments, ranging from 
0.26-0.35 in those with cardiac dysfunction (Florian et al., 2014b). Soslow et al. found high ECV 
values in lateral wall and anterior segments in a DMD cohort (Soslow et al., 2016).  The magnitude 
 150 
 
of our average regional ECV was lower than these studies, possibly due to the cohorts studied 
previously being more severely affected (Soslow et al., 2016, Florian et al., 2014b).  
 
8.4.2 Relationship between extracellular volume to late gadolinium enhancement and 
wall motion abnormalities 
Presence of late gadolinium enhancement (LGE) is a negative prognostic factor in muscular 
dystrophies (Florian et al., 2014a, Hor et al., 2013). Myocardial fibrosis develops diffusely in early-
stage disease, potentially lacking the required visible contrast for LGE recognition. Generally, 
studies have shown a positive correlation between higher ECV values and LGE-positive regions 
(Collins et al., 2015, Flett et al., 2010, Ugander et al., 2012). Two participants in our study were LGE-
positive with corresponding high ECV values (Figure 34). The highest ECV values were found in the 
basal posterior, basal anterior and the mid-cavity posterior regions. In BMD, the most common 
LGE-positive areas were the basal region and lateral walls (Florian et al., 2016, Yilmaz et al., 2008, 
Becker et al., 2016). These LGE-positive areas map to higher ECV values seen in our study in 
participants with cardiac dysfunction.  
Other studies suggest ECV may be raised in LGE-negative segments, suggesting advancing disease 
progression not detectable by LGE (Florian et al., 2014b, Soslow et al., 2016, Hong et al., 2015). In 
5 participants without LGE, there were 22 segments with ECV values ≥0.28 with a corresponding 
reduced LVEF (<55%).  
WMAs are associated with focal fibrosis, restricting regional movement (Cicala et al., 2007). In the 
general population, WMAs are associated with increased risk of morbidity, and may be present 
with normal global function (i.e. LVEF) (Cicala et al., 2007). In this study, 5 participants had WMA 
with a significantly reduced LVEF (43.1% ±7.4), compared to both of those without (50.2% ±6.9, 
p<0.001). Participants with WMA had a significantly higher basal ECV (0.26 range 0.21 to 0.32), 
compared to those without (0.24 range 0.21-0.32) (p=0.04). None of those with WMA had LGE-
positive segments, suggesting that WMAs may be associated with diffuse rather than focal fibrosis. 
Four participants without WMA had ECV ≥0.28 in 7 segments. ECV may be able to demonstrate 
areas of diffuse fibrosis not yet causing WMAs.    
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8.4.3 Correlation of ECV to measures of cardiac dysfunction 
LVEF is the most commonly used measurement of global cardiac function in clinical practice, and 
as an outcome measure in clinical trials (Florea et al., 2016, Duboc et al., 2005, Bushby et al., 2010b). 
We observed significant correlation between reduced LVEF and increased ECV in our disease 
groups. Other studies have observed this in BMD and DCM (aus dem Siepen et al., 2015, Florian et 
al., 2014b). In 2/6 of the participants with LGMDR9 and an LVEF >55%, 3/24 segments had ECV 
values ≥0.28. Higher segmental ECV values were found in segments in spite of a normal global 
function.    
Cardiac tagging provides sensitive quantification of regional cardiac dysfunction in muscular 
dystrophies (Hollingsworth et al., 2013b, Hor et al., 2009). The complicated nature of cardiac 
muscular architecture means that the tissues contract in multiple planes, allowing compensation 
for loss of contractility in layers of muscle fibre. Studies have used cardiac tagging with the most 
common pattern of dysfunction increased PT with reduction in PECS (Hollingsworth et al., 2012, 
Van Der Toorn et al., 2002, Young et al., 1994). By contrast, Hollingsworth et al. demonstrated 
lowered PT in a LGMDR9 cohort compared to controls (Hollingsworth et al., 2013b). The reduction 
in PT reflects epicardial dysfunction leading to abnormal transmission of mechanical forces from 
endocardium to epicardium (Hollingsworth et al., 2013b). Chapter 6 demonstrated significant 
differences between LGMDR9 and control groups in all measures of strain and torsion (Table 22). 
Reduced PT correlated strongly with reduced LVEF in the LGMDR9 cohort, suggesting this reduction 
in PT is directly linked with systolic performance. As demonstrated by Hollingsworth et al., these 
results suggest that the sub-epicardium is affected in the LGMDR9 cohort (Hollingsworth et al., 
2013b). These findings are consistent with Rosales et al. who found in a LGMDR9 cohort that LGE 
is most commonly identified in the epicardium and midwall (Rosales et al., 2011). Increased apical 
and basal ECV correlated with reduced torsion in both regions in this LGMDR9 cohort. Cardiac 
tagging is able to demonstrate cardiac dysfunction in the LGMDR9 cohort, with strong correlation 
to LVEF and ECV values.   
To date, no previous studies have reported cardiac tagging in BMD cohorts. Studies of DMD cohorts 
have suggested that abnormalities of strain and torsion exist and may be present in those with 
normal LVEF (Hagenbuch et al., 2010a, Hor et al., 2009). In the BMD group, no significant 
correlations were demonstrated between measures of strain and torsion, ECV values or LVEF. 
Furthermore, there were no significant differences between control and BMD cohorts in PT, PWWS 
or PECS (Table 22). However, several indicators of cardiac dysfunction (i.e. reduced LVEF, WMA, 
and LGE-positivity) were present within the BMD cohort. The differences between the strain and 
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torsion in BMD and LGMDR9 cohorts suggest that the mechanism of cardiac dysfunction differs 
between these groups.  
 
8.4.4 ECV in detecting cardiac dysfunction 
For the purposes of this thesis, cardiac dysfunction was defined as LVEF <55%, or presence of LGE. 
Comparison of ECV values between groups demonstrated that global and regional values were 
significantly higher in the group with cardiac dysfunction (Figures 35 to 36). Segmental analysis 
revealed that basal posterior, basal anterior and mid-cavity posterior segments were significantly 
higher in those with cardiac dysfunction. Florian et al. suggested that basal segments were 
significantly higher in those with cardiac dysfunction, defined as being LGE-positive (Florian et al., 
2014b). These results suggest a clear increase in ECV values in participants with cardiac dysfunction, 
providing further evidence of correlation between ECV and disease progression.      
 
8.4.5 Conclusions 
The findings of Chapter 6 support ECV as a measure in the assessment of cardiac disease in LGMDR9 
and BMD cohorts, alongside traditional measures. ECV was most frequently higher in the basal 
region. Measures of PT, TSR, PWWS and PECS correlate to cardiac measures in the LGMDR9 cohort, 
but may have limited utility in the BMD cohort. ECV correlated well with traditional measures of 
cardiac dysfunction such as LVEF, LGE, and WMA. Additionally, ECV shows high values in segments 
of participants that would otherwise be considered normal by traditional measures. Alongside 
other measures, ECV is a potentially useful tool in quantification of fibrosis in muscular dystrophy. 
Although ECV will not replace traditional measures of global cardiac function, our findings suggest 
that there is potential for delineation of regional cardiac wall dysfunction.   
 
8.4.6 Limitations 
As an initial study of ECV measurement in LGMDR9 and BMD participants requiring intravenous 
gadolinium administration, the number of participants was small, precluding definitive conclusions, 
but suggesting further lines of inquiry. Another limitation was the lack of longitudinal data on how 
ECV varies in the natural history of these diseases, or in response to therapy. Whilst ECV has been 
shown to correlate histologically to cardiac fibrosis (Flett et al., 2010, Miller et al., 2013, White et 
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al., 2013, Fontana et al., 2012), potentially ECV may be increased by oedema and inflammation as 
seen in muscular dystrophies, which may vary over time. ECV therefore should not be used in 
isolation, but should be used alongside other measures of cardiac dysfunction such as: LGE, cardiac 
indices calculation, and cardiac tagging. 
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8.5 Quantification of function - Evaluation of accelerated imaging in quantification of 
left ventricular indices in the muscular dystrophy cohorts 
This thesis has presented a number of studies into how MRI can be used to quantify different 
aspects of the pathology of muscular dystrophies. It is important to consider the individuals with 
the conditions and the burden that is placed upon them whilst undergoing these investigations. 
Due to their difficulties in lying supine and poor respiratory function there are clear reasons for 
reduction of acquisition times.   
Accelerated imaging is one of a number of techniques that have the potential to speed up MRI 
acquisition and reduce scan burden on participants. The accelerated approach described within 
Chapter 7 was successful in providing high quality images (Figure 42), which for the purposes of 
generating cardiac indices demonstrated no significant bias compared to conventional cine 
imaging. The accelerated method had comparable 95% LOA to other published approaches using 
forms of compressed sensing (Tables 24 and 25), and was highly reproducible between observers 
(Table 24). The results of this study provided evidence for this approach in obtaining cardiac indices 
with high levels of image fidelity and potential to speed up acquisition by a net factor of two. 
Chapter 7 is the first to report longitudinal data on torsion and strain in a LGMDR9 cohort. The 
results of the five year follow up portion of this study suggest that CMRI generated cardiac indices 
and cardiac tagging may be insufficiently sensitive to detect change over this time period, although 
the small sample size and the confounding factor of the effects of cardio-active medications 
precludes any definitive conclusions. There were no significant differences detected between the 
LGMDR9 and BMD cohorts in terms of LVEF or age (Table 23). 
 
8.5.1 Accelerated versus conventional imaging  
Using Bland Altman analysis to compare accelerated to conventional images, none of the 
parameters demonstrated significant or consistent bias. In contrast to this, consistent bias was 
reported in LVEDV by Vincenti et al.; their method underestimating measurement by 9.9mls 
(Vincenti et al., 2014). Although the lack of significant bias may be considered to be in support of 
our approach, consistent bias can be corrected prior to reporting, which is not the case with our 
results.  
Bland Altman analysis is unable to indicate whether LOA are clinically significant for a particular 
test; the clinical significance is dictated by the wider context. For CMRI, arguably the most 
important measure of function is LVEF. Studies investigating cardiac disease have used 
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measurements of global function, such as LVEF and fractional shortening, alongside presence of 
LGE and measurements of cardiac strain, as primary and secondary outcome measures in assessing 
response to treatments (Duboc et al., 2005, Duboc et al., 2007, Raman et al., 2015, Witting et al., 
2014, Leung et al., 2014). In clinical practice the most commonly used measure of function is LVEF. 
In muscular dystrophies, LVEF has been shown to be most predictive of increased mortality 
alongside the presence of LGE (Tandon et al., 2015). It is therefore important for any technique 
aiming to improve the speed of acquisition of cardiac indices using CMRI to be as accurate as 
possible in reporting LVEF. 95% LOA between the two approaches for LVEF was 5.9%; clinically this 
may be considered a significant degree of error. Patients could therefore be under or over 
estimated by 5.9% using the accelerated approach. Comparing accelerated CMRI against 
echocardiogram in the measurement of LVEF has been suggested to have much wider LOA (95% 
LOA 12.3%) compared to CMRI (Bellenger et al., 2000). Echocardiogram has several advantages 
over accelerated CMRI, and in the event of an equivocal result a CMRI would be organised to 
confirm findings. If this also risked over or underestimating LVEF by 5.9%, it would be introducing 
further uncertainty as to the validity of the test. Studies looking at investigation of the variability of 
LVEF have estimated beat to beat variability to be as high as 5.8% (Wood et al., 2014). As it is not 
possible to take the conventional and accelerated acquisitions simultaneously the LOA found when 
comparing these methods could be wholly or partially due to natural variation which may be more 
profound in disease states (Wood et al., 2014).    
These findings should be considered, too, in the context of other acceleration approaches, including 
compressed sensing, as shown in ‘Table 25’. One of the most recently published articles into this 
field, Kido et al., used a comparable net acceleration of three (Kido et al., 2016). Kido et al. reported 
bias and LOA for their technique (LVEF 5.2%) which were similar to our study. The other cardiac 
indices reportedly had similar or slightly narrower LOA (Table 25). Other compressed sensing 
approaches using k-t Broad-use Linear Acquisition Speed-up Technique (BLAST) and guide-point 
modelling had wider LOA in cardiac indices, which is likely to reflect the higher net acceleration 5.2-
7.5-fold increase (Vincenti et al., 2014, Jaroni et al., 2013).   
An alternative approach to reducing subject burden is to not require breath holding during 
acquisition. Free breathing techniques incorporate motion correction algorithms to allow high 
quality image acquisition without breath-holding. To date, there have been three studies 
attempting to clinically validate the use of this technique in obtaining cardiac indices (Usman et al., 
2015, Usman et al., 2017, Liu et al., 2017). The results of Chapter 7 provided narrower LOA for LVEF; 
however wider LOA were present when comparing other cardiac indices such as LVEDV and LVM 
(Table 25). Free breathing techniques are considered less efficient, with data discarded as a result 
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of the breathing motion. When combined with compressed sensing, this technique has been able 
to acquire the full series of short axis slices in approximately two minutes without breath holding. 
Therefore, free breathing may have an advantage over accelerated imaging as described in this 
study, but with comparable 95% LOA (Usman et al., 2015, Usman et al., 2017).  
Comparison of the results of Chapter 7 with other studies using similar degrees of net acceleration 
(two fold) showed similar negligible bias between observers (this study: LVEF mean difference 0.4, 
LOA 0.8 versus Mann et al.: mean difference 0.2% LOA 0.8) (Louis et al., 2016). Overall, using 
compressed sensing with parallel imaging, as described in both of these studies, at net acceleration 
of two leads to a high degree of agreement between observers (Louis et al., 2016).  
 
8.5.2 Cardiac indices and tagging in LGMDR9 over a five year follow up period 
Follow up of CMRI in the LGMDR9 group did not show any significant changes in any of the cardiac 
indices over the five years (Figures 43 and 44). Sveen et al. reported that in their group 
cardiomyopathy was present in 29% of those with LGMDR9; previously this figure has been 
reported to be between 10-55%, with a preponderance toward men with the condition (Sveen et 
al., 2008b, Poppe et al., 2004). At the beginning of our study, 6/8 participants were receiving 
cardioactive treatments; over the five years this increased to 7/8. This suggests that 
cardiomyopathy was more prevalent within our group than that found in other studies. Petri et al. 
published the longest follow up study of individuals, with LGMDR9 cohort reporting results from 
echocardiogram over a nine year period. Over the nine year period, Petri et al. reported an annual 
decline in LVEF of 0.4%, which was statistically significant (p=0.03). This is in line with our results, 
which had a lower baseline (45.6% versus 59% (Petri et al., 2015)) but declined at a similar rate of 
0.44% annually (43.4% after five years, 55% after nine years (Petri et al., 2015)). The reason for lack 
of a significant change over the five year period could be due to the test being insensitive to small 
changes over five years, compared to nine years in Petri et al. (Petri et al., 2015). More likely, the 
reason for no significant difference being detected is the small sample size.  
Hollingsworth et al. (2013) investigated measures of strain and torsion in a LGMDR9 cohort, 
demonstrating significant decrease in peak torsion compared to controls (3.9° ±1.3), with torsion 
to strain ratio significantly lower (0.31rad/% ±0.1) (Hollingsworth et al., 2013b). In Chapter 7, over 
a five year period these measures were not significantly different (Figure 45). The reasons for this 
may be that these changes were non-progressive or too slowly progressive to detect with these 
measures. Another reason could be that the study number here was too small to show a significant 
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change over the five year period. Hollingsworth et al. suggested that these measures correlated to 
LVEF (r=0.93, P<0.001) (Hollingsworth et al., 2013b), which was also seen in this study with LVEF 
correlating strongly to PT (r=0.81, p=0.01).  
None of the cardiac indices demonstrated significant changes over five years, which may be in part 
explained by using cardio-active treatments. Treatments such as angiotensin converting enzyme 
inhibitors, beta blockers and angiotensin receptor antagonists reduce afterload, and have been 
shown to induce ventricular remodelling (Khalil et al., 2001, Yusuf et al., 1992). These medications 
are recommended in the treatment of dilated cardiomyopathy and cardiac manifestations of 
muscular dystrophy (Feingold et al., 2017). Duboc et al. used angiotensin converting enzyme 
inhibitors in prophylactic treatment of DMD, finding that these can increase or stabilise LVEF over 
time (Duboc et al., 2007). As all but one of our participants were receiving cardioactive treatment 
by the end of the five year follow up, it is likely that these medications had a similar effect of 
increasing or stabilising the measures of cardiac function. Based on the results of this study, CMRI 
functional measures and cardiac tagging measures are unlikely to be a useful outcome measure for 
cardiac disease over a five year time period in this cohort. Potentially, a larger sample, a longer 
follow up period, or exclusion of participants taking cardioactive medications may have led to 
significant results. 
 
8.5.3 Conclusions 
The technique of accelerated imaging described here demonstrated that it is possible to reduce the 
time for acquisition and produce images with comparable image fidelity. The technique does lead 
to a 5.9% limit of agreement in LVEF, which for clinical work may not be acceptable. In the context 
of other imaging modalities and other approaches to speed up CMRI acquisition, this method was 
similar in terms of bias and width of the 95% LOA. The accelerated imaging approach may have a 
role in reducing patient burden during MRI scans in clinical practice, and may potentially be of use 
in clinical trials detecting disease progression of other neuromuscular conditions. Other techniques, 
such as free-breathing acquisitions, may provide an alternative way of reducing patient burden 
during CMRI.    
In contrast to DMD, cardiac indices and cardiac tagging measures did not significantly change over 
a five year period in a LGMDR9 cohort, and may therefore be insensitive to disease progression 
(Hagenbuch et al., 2010a).  
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Chapter 9: Conclusions 
9.1 Conclusions 
This thesis examined how MRI techniques can be applied to quantify aspects of pathology and 
disease progression in muscular dystrophies. Each chapter looked at how MRI could be used to 
examine different hallmarks of disease progression. The findings demonstrated that quantitative 
MRI can be used to show progression of early muscle pathology such as fat replacement, and 
fibrosis. The most promising method of demonstrating disease progression in humans with 
muscular dystrophies was using Dixon FF calculation to quantify fat replacement of muscle in 
LGMDR9. In animal models of muscular dystrophy, imaging of fibrosis with EP3533 also showed 
promise in demonstrating disease progression. ECV was explored in two types of muscular 
dystrophy and its’ use may show some benefits over conventional outcome measures.  
EP3533-enhanced R1 change was shown to be: significantly higher in dystrophic muscles compared 
to in controls, correlating significantly to functional measures and ex vivo quantification of fibrosis. 
The widely clinically used gadolinium-based probe was unable to demonstrate any difference 
between disease and control groups. EP3533-enhanced R1 change was able to show response to 
an anti-fibrotic treatment, relying on the difference in R1 change from baseline to follow up, rather 
than absolute R1 values. The degree of R1 change was less than seen in other studies probably due 
to the mild phenotype of mdx mice. Human studies of EP3533 will eventually be required to confirm 
utility of this contrast agent in quantifying fibrosis in muscular dystrophies; more animal studies 
are required to confirm the safety profile of this contrast agent prior to registration with the 
relevant regulatory body (i.e. Food and Drug Administration or the European Medicines Agency). 
The Dixon FF calculation is well established in imaging of muscular dystrophies, however the 
knowledge gained here in terms of how this applies to LGMDR9, can now be used to inform power 
calculations in future clinical trials. FF calculation over a six year time period can be used alongside 
functional assessments to show disease change and allows for interim analyses. 
Regarding cardiac muscle fibrosis, ECV was explored in LGMDR9 and BMD cohorts for the first time. 
There were significantly higher values for ECV regionally and globally, which was evident in patients 
with demonstrable cardiac dysfunction and in some without. This suggested that ECV may be able 
to provide information on areas of regional cardiac dysfunction not evident using other measures 
i.e. global cardiac function and late gadolinium enhancement. ECV should be examined 
longitudinally to explore whether it can predict cardiac dysfunction in muscular dystrophies and 
therefore be used as an outcome measure. 
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The major challenge to therapeutic trials in muscular dystrophies and a recurrent theme of this 
thesis, is how difficult it is to demonstrate disease progression over short time periods. Functional 
assessments have been shown to be relatively insensitive to change. This was reflected in this thesis 
by the lack of significant difference in CMRI-generated measures of cardiac function and cardiac 
tagging indices in LGMDR9 over a five year period. The method of accelerating acquisition of cardiac 
indices demonstrated a lesser degree of variation compared to previous studies comparing 
echocardiography and a similar degree compared to other reported compressed sensing methods, 
with a qualitatively good image fidelity.  
Quantification of fat replacement, and fibrosis in skeletal and cardiac muscle using MRI as described 
has been shown to have several advantages over other conventional measures of disease 
progression.  
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1. ORDER OF TESTS:  RECOMMENDED SEQUENCE OF STUDY PROCEDURES 
 
Study procedures should be performed in the same order and at approximately the same time of day for 
each subject. All procedures should be conducted by a trained physiotherapist. 
 
Test order 
 
a) Timed 10 m walk / run (in shoes) 
b) Respiratory Function Test 
c) Hand-‐held Myometry: The dominant side only will be tested 
d) Ankle Range of Movement 
e) North Star Assessment for Dysferlinopathy (NSAD)  (with Timed 10m walk / run and Rise from floor 
without shoes) 
f) Functional and timed tests (Timed UP and Go, Four Stair climb, Four stair descend, Rise from chair) 
g) PUL 1.3 Proximal module (optional) 
h) 6 minute walk test – ambulant only 
 6 
 
2. EQUIPMENT AND SPACE REQUIREMENTS FOR EVALUATIONS 
 
Use your own local equipment. Please let us know if you have any queries. Worksheets are required for all 
tests. 
Spirometry Local spirometry system and bacterial filters 
Strength testing Hand held myometer, MicroFET if available 
North Star Assessment for 
Dysferlinopathy and timed 
tests 
15 cm step 
A sturdy chair for sit to stand, timed up and go, and stand from 
sitting on floor. 
Digital stopwatch 
A quiet hallway with at least 12 meters of straight, uninterrupted 
walking space, with a starting line and finish line exactly 10 
metres apart. 
Four step set with hand rails 
PUL 1.3 Proximal module Selection of metric weights. 200g, 500g and 1000g. 
Plastic cup (vending cup) 
Six Minute Walk Test A quiet hallway of 30m length 
Small orange cones (12 inch or 20 cm): 2 
One 25 metre tape measures 
Stop watch: 2 
Tape 
Clip board 
A chair or wheelchair that can be easily moved along the walking 
course 
6MWT worksheet with checklist 
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3. INTRODUCTION TO PROCEDURES FOR EVALUATIONS 
 
Clinical evaluation will include respiratory testing, muscle strength testing, timed tests including the 6 
minute walk test, timed up and go, timed 10 metre / walk, rise from chair, rise from the floor and stairs, 
functional scales including North Star Assessment for Dysferlinoapthy (NSAD) and PUL 1.3 – Proximal 
module 
Ideally the same evaluator should perform evaluations at subsequent assessments. The evaluator and back 
up should perform at least the first assessments in pairs. 
Tests should be performed at approximately the same time of day and after similar pre-‐test activities and 
routines. 
Tests should be performed in the order provided in this manual. 
To avoid bias, the clinical evaluator (CE) should not review any previous testing results. The testing 
environment should be standardised. 
It is recommended that family members or friends not be present in the room during testing, unless test 
compliance is affected. 
A second CE or staff member may be in the room during testing. 
The subject should wear loose clothing. It is preferable for the subject to wear a short-‐sleeved shirt and 
shorts. 
 
 
4. TIMED 10 METRE WALK / RUN (IN SHOES) 
 
Prior to all tests perform a 10 m walk / run following the guidelines within the NSAD (Item 29) but 
with the patient wearing shoes and if required orthotics. Record whether they used orthoses and 
aids on the worksheet, grade the test and record the time. 
 
 
10 m Walk / Run (in shoes) 
Grade 1 2 3 4 5 6 Time 
(seconds) 
10 metre 
walk / run 
Please circle 
Unable Walk with 
aids 
Walk No 
extra 
speed 
Walk extra 
speed 
Nearly 
running 
No flight 
Running  
_ _ . _  s 
 
 
 
 
Definition of ambulation: If a patient is able to walk 10 metres with aids and with assistive devices 
(orthotics) they are defined as ambulant. They should then attempt all other tests. If they are unable to 
complete 10m walk even with aids the patient is defined as non-ambulant. Do not perform TUG, stair climb 
and descend and 6MWT. 
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5. PULMONARY FUNCTION TEST (FVC -‐ SITTING AND LYING) 
Pulmonary function tests are Forced Vital Capacity (FVC) and Forced Expiratory Volume in 1 second (FEV1). 
They are performed using the same manoeuvre in sitting and in lying. 
 
 
 
 
The patient should be sitting comfortably in a chair. The evaluator explains /demonstrates the procedure 
to the subject and explains that they will be performing the test at least 3 times. The specific wording of 
instructions should be followed closely. These are then repeated in lying. A pillow may be used. 
 
 
 
 
Ask the patient to ‘take as big a breath in as possible and then blow out through the mouth as hard 
and as long as you can’. The evaluator should verbally encourage the subject to keep going for as long as 
possible. ATS criteria state a 6 second plateau is required. 
The test should be repeated three times making sure that the patient has recovered between 
attempts. If at each attempt there is an improvement in the results further tests can be conducted until 
the subject has achieved his best result. 
The subject can place the mouthpiece in his own mouth unless he is unable to reach his mouth with 
his hands or flexes his head and shoulders to reach the tube. In this case the evaluator should place the 
tube into the subject’s mouth. 
The tube can be placed in the mouth either before the beginning of inspiration (closed circuit 
technique) or at the end of inspiration just prior to expiration (open circuit technique) whichever the 
subject finds most comfortable. 
Whichever technique is used the same method should be used at each evaluation and documented 
on the worksheets. 
A nose clip should be applied just prior to expiration. If a tight seal cannot be made around the tube 
then a mask may be used 
The subject should not be allowed to flex forward during expiration. 
Calibrate the system on the day of testing 
Height calculation: For patients able to stand take a height measurement in centimetres in order to 
calculate percentage predicted FVC and FEV1. For patients unable to stand use an arm span measurement. 
Use a tape measure from the tip of the longest finger, across each joint (wrist, elbow and shoulder) to the 
sternal notch. Double this measurement to give an estimated height in centimetres. 
Please make a note on the worksheet of the type of system you are using to perform the pulmonary 
function test 
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6. MYOMETRY 
Testing Guidelines 
 
• Tests should be performed in the order listed on the myometry worksheet. 
• The myometer is a very sensitive measuring tool therefore care must be taken to be consistent with test 
method. 
• Allow at least 5 seconds of rest between trials. 
• Repeat the test if the subject moves out of the testing position during a trial. 
• The subject should be vigorously coached to push or pull in the desired direction while the myometer is 
held stable by the CE (“make” test). 
• If the CE encounters problems during a trial, the trial must be repeated. Three “valid” trials will be 
performed, and the value from the myometer will be recorded after each trial. The unit of measurement 
should be the pound, and values should be recorded with 1 decimal place (eg, 1.0 lbs). The test is 
explained to the patient in a way that they understand. The intent is to build a maximum isometric hold, so 
the command is effectively ‘HOLD’ or ‘Keep still/don’t let me move you’. The words push or pull should not 
be used. 
• The subject will be encouraged verbally to build to and maintain a maximum hold over a period of 
approximately 5 seconds, to allow for full physiological recruitment of muscle. 
• Following one ‘trial’ test to allow for learning, the best of 3 tests shall be noted. Test results should be 
fairly closely grouped – a 10% variation is not unusual, e.g. 30lbs +/-‐ 3 
• Any discomfort will limit the patient’s ability to offer maximum resistance. As much as is possible, ensure 
comfort when applying the myometer. The applicator can be padded to allow for comfort. 
• If the evaluator does not feel that they have been able to gain compliance from the patient for any reason 
(e.g. understanding or poor concentration), this should be noted. 
• All myometry is performed with the MICROFET2 myometer except for grip and pinch which are performed 
with the CITEC. 
• Calibrate system on the day of testing 
Order of Tests 
 
Supine 
 
If it is possible to move a non-‐ambulant subject then attempt all tests if not then document on the 
worksheet why the test was not performed 
• Hip flexors 
• Hip abduction 
• Hip adduction 
• Ankle dorsiflexion 
 
• Ankle dorsiflexion ROM 
 
Sitting 
• Knee extension 
• Knee flexion 
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Supine – Position 1 
 
 
 
Hip Flexion (supine) 
 
 
 
 
Stabilisation Under knee and calf to support weight of leg and prevent unwanted hip 
movement 
The subject is instructed and encouraged to bring his knee up to his chest 
pulling into the transducer pad as hard as he can, ‘Keep still, don’t let me 
move you’ 
Myometer Position 
Anterior aspect of lower thigh, just proximal to condyles 
Therapist position. At 
side of, sitting or 
kneeling on plinth. May 
vary according to 
weight of leg. Facing 
the subject. Apply force 
to resist hip flexion. 
 
 
 
 
 
 
Patient position Supine on firm adjustable height plinth with hip and knee at 90º. Femur in 
neutral rotation. Subject is asked to concentrate on keeping knee steady,
not to move foot, as this discourages hamstring involvement 
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Hip Abduction (supine) 
 
 
 
 
Stabilisation Around heel if necessary or lower leg to prevent excessive rotation from 
the hip 
 
Myometer Position 
Above the knee joint on the lateral aspect of the thigh 
Therapist position. 
Either at end of plinth 
or standing at edge of 
plinth on side which is 
to be tested 
 
 
 
Patient position Supine,  arms  by  side,  leg  straight  and  abducted,  knee  caps  pointing 
towards  the  ceiling.  Patient  is  asked  to  concentrate  on  keeping  knee
steady, not to move foot. 
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Hip Adduction 
 
 
 
Stabilisation Around heel if necessary  or lower leg to prevent excessive rotation 
from the hip 
 
Myometer Position 
Above the knee joint on medial surface of thigh 
 
Therapist Position 
Standing at edge of 
plinth on side which is 
to be tested 
 
 
 
 
 
 
 
 
 
 
Ankle Dorsiflexion (supine) 
 
 
 
Stabilisation If needed on lower limb / over knee joint to monitor for trick 
movements. Watch for: hip external rotation, knee flexion, ankle 
eversion and inversion 
 
 
Patient position Supine,  arms  by  side,  leg  straight,  knee  caps  pointing  towards  the 
ceiling. Test leg in adduction, Other leg in abduction. Patient is asked to 
concentrate on keeping knee steady, not to move foot. 
Patient position Patient in supine. Legs straight with femur in neutral rotation / knee 
caps pointing to ceiling. 
Myometer Position 
Anterior surface of foot, just in front of the ankle joint 
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Sitting – position 2 
 
 
 
Knee Extension 
 
 
 
Stabilisation If needed, given by therapist over lower third of thigh, just above knee 
 
Myometer Position Anterior surface of tibia, at junction between middle and lower third of 
tibia, place myometer on the lower third of the tibia 
Therapist position 
Sitting in front of 
subject, on a chair or on 
floor 
 
 
 
 
 
 
Knee Flexion 
 
 
 
Stabilisation If needed, given by therapist over lower third of thigh, just above knee 
Watch for: hip external rotation, trunk flexion 
 
 
  
Therapist Position 
At end of plinth Or 
at side of subject 
Patient position Patient sitting with thigh supported and hip and knee at 90º, on plinth, 
chair or in wheelchair. Feet must be clear of the floor. Femur in neutral 
rotation. Patient can hold onto front of plinth or chair to stabilise himself 
Patient position Patient sitting with thigh supported and hip and knee at 90º, on plinth, 
chair or in wheelchair. Feet must be clear of the floor. Femur in neutral 
rotation. Patient can hold onto front of plinth or chair to stabilise himself 
Myometer Position 
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Therapist Position 
Sitting in front of 
subject, on a chair or on 
floor 
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7. GONIOMETRY 
1.1 GENERAL ISSUES 
Wherever possible the same clinical evaluator should assess and reassess the subject as intra-‐rater 
reliability has been found to be better than inter-‐rater (Pandya et al, 1985). 
Use an appropriately sized goniometer and measure to the nearest degree. 
Passive range is being measured so the subject needs to relax whilst the clinical evaluator ranges the 
joint. 
 
Measurements should be taken with a ‘moderate’ degree of stretch applied and with the patient trying 
to dorsiflex the foot at the same time. Ask the patient to count to 10 whilst measuring range. 
Variations in manual pressure applied have been identified as one of the key factors in inter-‐rater 
variability when passive ROM is being monitored (Gajdosik & Bohannon, 1987). 
 
1.2 METHOD: ANKLE DORSIFLEXION 
Subject position: Supine. As we are interested in the effects of gastrocnemius shortening on ankle 
dorsiflexion, this test is undertaken with the knee in full extension. The calcaneum is held in neutral 
alignment whilst pressure is applied over the mid-‐section of the foot to dorsiflex the ankle as much as 
possible, preventing inversion. 
Goniometer position:. Stationary arm aligned with the fibular head, along the lateral aspect of the 
lower leg. “Moving arm” held parallel to the lateral aspect of the 5th metatarsal, aligned with the 
posterior third of the foot (this is to ensure that gastrocnemius range is being monitored and not that 
of the planter structures of the foot). Note range of dorsiflexion past plantargrade as +xº’s, range 
lacking from plantargrade as -‐xº’s 
 
Normal range: 20º dorsiflexion to 50º plantarflexion. 
End feel: firm due to joint capsule, Achilles tendon and ligaments. 
Assess bilateral ankle dorsiflexion range of movement 
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8. NORTH STAR ASSESSMENT FOR DYSFERLINOPATHY (NSAD) 
The original North Star Ambulatory Assessment was developed for DMD by the Physiotherapy 
Assessment and Evaluation Group of the North Star Clinical Network in conjunction with Elaine 
Scott. The North Star Project is supported by Muscular Dystrophy Campaign. The revised NSAD for 
adults with dysferlinopathy is based on clinical expertise and modern psychometric analysis and has 
been conducted by Michelle Eagle, Meredith James and Anna Mayhew. It incorporates useful items 
from the MFM 20 which have been modified to be disease specific. In this manual we have included 
this revision as it is considered a good approximation of a scale suitable for use in LGMD. 
Clear explanations of the methods employed to achieve motor goals are given but it is not possible 
to be exhaustive in the descriptions, particularly of modifications to activity. One of the goals of this 
project is to further define common adaptations to movement in people with dysferlinopathy. 
Generally however activities are graded in the following manner: 
2 -‐ ‘Normal’ – no obvious modification of activity 
1 -‐ Modified method but achieves goal independent of physical assistance from another 
0 -‐ Unable to achieve independently 
 
General test instructions 
• If you think that the subject is capable of a better performance, it is acceptable to ask for the item 
to be repeated. Re-‐score if appropriate. You should attempt all activities at each assessment. 
• Do not use a mat unless it is required to gain co-‐operation. If a mat must be used, make sure it is 
not heavily padded. Note in comments and do so for all subsequent evaluations 
• Shoes and socks should be removed for all items 
 
NOTE: Timed rise from the floor, timed run 10 metres are graded 0-‐2 for the NSAA but are also further 
differentiated (see section ‘timed graded functional activities’). The items only need to be performed 
during the NSAD. 
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Test item 1: Lifts head from supine 
Starting position Supine on a plinth or floor, arms folded across chest. No pillow should be used. 
Instruction Can you lift your head to look at your toes keeping your arms folded? 
Scoring detail Ask subject to keep arms crossed over chest during the activity to avoid self-‐ 
assist. Also ask to look at toes to ensure neck is flexed ‘lift your head and look at 
your toes’ 
Activity 1 0 
Lifts   head   from In supine, head must be Unable. No clearance of 
supine lifted in mid-‐line. Chin head from surface or 
moves towards chest only partially achieved 
movement 
Photographs / 
Notes 
 
 
 
 
Score 0 -‐ Didn’t achieve 
full range of flexion 
Score 1 – Chin on chest 
 
 
 
 
 
Test item 2: Hand to opposite shoulder 
Starting position Supine on a plinth or floor, arms by side. Pillow may be situ. 
Instruction Can you bring one hand to the opposite shoulder 
Scoring detail Score best effort R or L and mark on worksheet which arm was used. 
Activity 2 1 0 
Hand to opposite Raises hand and moves it 
shoulder 
Raises hands and moves it to 
to opposite shoulder using Unable 
 opposite shoulder compensatory movements 
Photographs /  
Notes  
  
 
 
Score 2 no compensation 
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Test item 3: Hip flexion in supine 
Starting position Supine on a plinth or floor, arms by side. Pillow may be situ. 
Instruction Can you bend one hip and knee up towards your chest? 
Scoring detail 
Activity 2 1  0 
Hip flexion In supine flexes hip and Partially flexes hip and  
supine knee more than 90° by knee (<90°, > 20°) or foot Unable 
 raising foot through remains in contact with  
 whole movement mat  
Photographs / 
Notes 
 
 
 
 
 
 
Score 2 
 
Score 1 Partial hip flexion 
 
Score 1 Foot in contact with 
bed 
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Test item 4: Bridging in supine 
Starting position Supine on a plinth or floor, arms by side. Pillow may be situ. 
Instruction Can you bend both hips and knees so your kneecaps point up to the ceiling and 
your feet stay on the floor? 
Scoring detail You can help them achieve the crook-‐lying position. 
Score 2 – clear lift of bottom off bed with kneecaps pointing up, feet slightly apart 
and knees not touching. 
Score 1 – Some wobble is allowed of the legs as they partially raise pelvis but they 
must not clamp their knees together in order to lift their pelvis off. 
Activity 2 1 0 
Bridging in Maintains position of 
supine bottom off bed for count 
Maintains the starting
 
of 5, kneecaps pointing 
position for 5 seconds 
Unable 
up, feet slightly apart, 
then partially raises the 
knees not touching 
pelvis
 
Photographs / 
Notes 
 
 
 
 
Score 2 Full bridge Score 1 Partial elevation of 
position pelvis 
 
 
 
 
 
Test item 5: Rolling supine to prone 
Starting position Supine on a plinth or floor, arms by side. No pillow 
Instruction Can roll onto your tummy? 
Scoring detail This item can be observed as they perform the MMT part of the assessment. 
Activity 2 1 0 
Rolling supine to Turns over into prone and 
prone frees both arms from Rolls partially / to side Unable 
under trunk 
Photographs / 
Notes 
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Test item 6: Gets to sitting 
Starting Starting position supine on the floor, with arms by side. No pillow should be used 
position under head. 
Instruction Can you get from lying into sitting? 
Scoring Aim is to move into long sitting rather than sitting over the edge of a plinth. Use of 
detail one 
hand or arm is acceptable to achieve a score of 2. Score 1 if subject turns into prone 
or towards the floor/plinth to work their way into sitting or if uses two arms. 
Activity 2 1 0 
Gets to Starts in supine – may use Uses two arms / pulls on Unable 
sitting  one hand / arm to push up legs or turns towards floor. 
Photographs 
/notes 
 
 
 
 
 
 
 
Score 1 -‐ Pulls with both 
hands on legs 
Score 2 – Uses no hands 
 
 
 
Score 2 -‐ Only needs one 
arm to sit up 
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Test item 7: Reaches forward 
Starting Sitting on floor or plinth in long sitting. Knees may be flexed to accommodate tight 
position hamstrings. 
 Ball placed on plinth far forward enough so they have to use 30 degrees of trunk 
 flexion to touch ball. 
Instruction Can you reach forward and touch this ball with both hands? 
Scoring Score 2 – uses both hands to reach forward and touch ball and return to upright 
detail sitting 
 Score 1 – uses one hand for balance and one hand to touch ball and also returns to 
 upright sitting. 
Activity 2 1 0 
Reaches Without upper limb With upper limb support, 
forward support, leans forward, leans forward, touches ball Unable 
 touches ball and sits back and sits back again 
 again 
Photographs  
/notes  
  
 
Score 2 Reaches forward 30° Score 1 Needs hand on bed 
 knees flexed for support 
  
 
 
 
Score 2 Reaches forward 30° 
 legs extended 
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Test item 8: Stand up from chair 
Starting Sitting in chair or on plinth with arms folded across chest and with feet able to reach 
position floor or supported on secure box. Starting position 90º hips and knees. 
Instruction Can you stand up from the chair keeping your arms folded if you can? 
Scoring detail A size-‐appropriate chair (without armrests) or height adjustable plinth should be used. 
Alternatively a box step under the feet to achieve the correct starting position could be 
used. Score 2 -‐ Arms should be kept crossed throughout the activity to score 2 
Activity 2 1 0 
Stand up Able to stand up keeping Pushes on thighs or chair Unable 
from chair arms folded using one or two hands /  
  prone turn or alters  
  starting position by  
  widening base  
Photographs/ 
notes 
 
Score 2 – keeps arms 
folded 
 
 
Score 1 – pushes with 
hands 
 
 
Score 0 -‐Needs to use 
furniture 
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Test item 9: Stand to sit on chair 
Starting Standing with chair / plinth behind patient (close to or touching legs and secure so 
position chair wont slip) Chair should be at a height so that when patient sits in it their hips 
 and knees are at 90 degrees. 
Instruction Can you sit down in a controlled way? 
Scoring Score 2 – Does not use hands on chair or body and able to sit down in a controlled 
detail fashion 
 Score 1 – uses one or two hands on body or chair to sit down safely 
Activity 2 1 0 
Stand  to  sit Able to sit down without 
on chair 
using arm support in a 
With arm support, able to Unable to sit down 
 
controlled way 
sit down in chair safely without assistance 
Photographs 
/notes 
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Test item 10: Stand 
Starting Feet should be no further than 10cm apart and heels on the ground if possible. 
position Arms by sides. NO shoes should be worn. 
Instruction Can you stand up tall for me for as long as you can and as still as you can for 
 three seconds with your heels flat on the ground? 
Scoring detail When counting to 3 – Use “And 1 -‐ and 2 -‐ and 3” so that three seconds is 
achieved on the word of 3. 
Best done on the floor rather than on a mat. Whichever is chosen maintain 
consistency through repeated testing sessions. 
Score 2 -‐ Minimum count of 3 seconds. 
Activity 2 1 0 
Standing Stands upright, still, Stands but with Cannot stand 
 symmetrical, compensation independently, or needs support 
 without  (even minimal) 
 compensation   
 (heels flat legs in   
 neutral) for   
 minimum count of 3   
 seconds   
Photographs/ 
notes 
 
 
 
 
 
 
 
 
 
 
 
Score 2 -‐ 
Symmetrical heels 
flat 
Score 1 -‐ 
Asymmetrical, heel 
up, everted 
 
 
 
 
 
 
 
 
 
 
 
Score 1 -‐postural 
adaptation 
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Test item 11: Wa lk 
Starting position Standing. Observe walk for at least 10 steps in both sagittal and coronal planes. 
Instruction Can you walk from A to B (state to and where from) for me? 
Scoring detail Walk without shoes/socks on. 
Activity 2 1 0 
Walk 10m Walks consistently with Adapted walking pattern Loss of independent 
heel-‐toe or flat-‐footed e.g. wide base, altered foot ambulation or walk 
gait pattern posture, other please define in short distances with 
comments assistance 
Score 1 – Externally rotated hips 
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Test item 12 & 13: Stand on one leg R & L 
Starting Standing. NO Shoes should be worn. 
position  
Instruction Can you stand on your right / left leg for as long as you can? 
Scoring Do not use mat. 
detail Score 2 – Minimum count of 3 seconds required 
Activity 2 1 0 
Stand on one 
leg 
Able to stand in a Stands but momentarily Unable 
relaxed manner (no or with trunk side-‐ 
fixation) for count of 3 flexion or needs fixation 
seconds e.g. by thighs adducted 
or other trick 
Photographs 
/ notes 
Score 0 -‐If needs to hold onto a 
table or person for support or 
unable to clear foot from the 
floor 
 
 
 
Score 1 -‐Hooks leg 
behind 
standing leg 
 
 
 
 
Score 2 – Relaxed and 
no fixation 
 
 
 
 
 
 
 
 
 
Score 1 -‐Postural 
compensation / leaning 
to side 
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Test item 14 & 16: Climb box step R &L 
Starting A box step 15cm high is used to assess single step climb and descend. Standing in front 
position of box step, toes no more than 20cm away from box step 
Instruction Can you step onto the top of the box using your right /left leg first? 
Scoring Box step should be approximately 15 cm high. Support may be provided by the use of a 
detail height adjustable plinth, or, if not available one ‘neutral’ hand from the therapist (no 
 taking “weight” of subject). 
Activity 2 1 0 
Climbs box Faces step – no support Goes up sideways / rotates Unable 
step needed trunk / circumducts hip or 
 needs support 
Photographs 
/ notes 
                   Score 1 – Needs 
support Score 2 – Faces step  
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Test item 15 & 17: Descend box step R & L 
Starting Standing on box step 
position 
Instruction Can you step down from the box using your right / left leg first? 
Scoring detail Box step should be approximately 15 cm high. 
Support may be provided by the use of a height adjustable plinth, or, if not available 
one ‘neutral’ hand from the therapist 
Activity 2 1 0 
Descends box Faces forward, steps Sideways, skips down, Unable 
step down controlling weight Pushes on leg, or needs 
bearing leg. No support support or uses method 
needed that avoids flexing 
supporting knee (one on 
the box step) 
   
 28 
 
 
 
 
Test item 18: Touches floor from standing 
Starting position Standing upright. Arms by sides. Near plinth or chair for support if required. 
Instruction Can you reach down and touch the floor? 
Scoring detail Score 2 – If they are unable to touch the floor due a lack of flexibility in their 
 spine and hips it is acceptable to score 2 if they are short by no more than 
 20cm off the ground 
 Score 1 – support can be hand(s) on body or plinth or chair 
Activity 2 1 0 
Touches floor from 
standing 
Without support, With support (arm on floor, Unable, able to 
touches floor with one body, plinth) touches floor touch floor but 
hand and stands up again with one hand and stands cannot get back up 
up again again 
Photographs/  
notes  
  
 
 
Score 2 – Touches floor 
Score 1 – Uses arm on leg 
 without using hands or 
for support
 
 hands on legs 
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Test item 19: Rise from floor 
Starting position 
 
Starting position in long sitting on floor with 
arms by sides, legs straight if possible 
Instruction Give the following verbal instructions to the subject: “When I say GO can you 
get up as fast as you can and stand up straight with your arms by your side 
using as little support as possible”. Give the command “Ready steady – GO” 
and start the stopwatch when saying “GO”. Stop the timer when the subject 
assumes an upright position with his arms by his side. 
Scoring  detail  / Activity should be attempted without use of furniture in the first instance. 
Diagram Score 1: If  the person gets  to standing independently  of any furniture  but 
demonstrates any part of the manoeuvre described below. 
Components of Gower’s manoeuvre: 
 
• Turns towards the floor (into a four-‐point kneeling position or rolls to prone) 
• Places hands on the floor to assist rising and walks hands back in towards him 
• Uses one or both arms to push up on legs to achieve upright standing. 
• Large base of support by abducting hips and extending knees 
 30 
 
 
 
 
 
 
 
 
Test item 19: Rise from floor 
Activity 2 1 0 
Rise from floor No evidence of Gower’s 
maneuver. 
Exhibits at least one of the (a) NEEDS to use 
components described external support 
above – in particular rolls object e.g. chair OR 
towards floor, and/or use (b) Unable   
hand(s) on legs 
Photographs / Score 2 -‐ Doesn’t roll. Uses Score 1 -‐ Rolled over used Score 0 – Uses chair 
Note only 1 hand on floor 
 
 
 
 
 
 
 
hands on floor 
 Score 1 -‐ Didn’t roll but 
 used hands 
 
 
 
 
Score 2 No hands on legs 
 
to rise  
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Test item 20: Stands on heels 
Starting Standing on the floor. No shoes to be worn. 
position 
Instruction Can you stand on your heels? 
Scoring detail Must clear both feet at the same time to score 2. Watch for inversion. If substantial 
inversion but forefeet are still lifted – score 1. If only inversion with lateral border 
of foot still on the ground score 0. 
Activity 2 1 0 
Stand on Both feet at the same Only raises forefeet or only Unable 
heels  time, clearly standing on manages to dorsiflex one 
heels only (acceptable to foot or can only evert. 
move a few steps to keep 
balance) for count of 3 
Photographs 
/ Notes Score 0 –inversion and 
feet remain on floor 
 
 
 
 
Score 1 -‐ Both feet raised 
but only forefoot, everting 
 
Score 2 – Both feet raised  
Score 1 Raised forefoot 
only 
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Test item 21: Jump 
Starting Standing on the floor, feet comfortably close together 
position  
Instruction How high can you jump? 
Scoring Want height, not forward movement. Small amount of forward movement acceptable 
detail Score 0 – If unable to leave floor or of they skip jump (one foot then the other) 
Activity 1 0 
Jump Both feet at the same Unable 
 time, clear the ground 
 simultaneously 
Photographs Score 1 clears floor, both Score 0 -‐ Feet do not leave 
/ Notes feet at the same time floor 
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Test item 22 & 23: Hop R & L leg 
Starting Starting position standing on floor on right / left leg. No shoes should be worn. 
position  
Instruction Can you hop on your right / left leg? 
Scoring detail Score 1 -‐ Needs obvious floor clearance. 
Activity 1 0 
Hop Clears forefoot and heel Unable 
 off floor 
Photographs  / Score 2 – Clears foot off Score 0 – not leaving the 
Notes floor floor 
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Test item 24: Squat down 
Starting Standing 
position  
Instruction Can  you  bend  down  to  the  floor  bending  your  knees  like  this?  (show  them  the 
 manoeuvre) 
Scoring For score 1 please tick whether they used the floor or their hands on their thigh. 
detail One tick for one hand, two ticks for two hands. They would score 0 is they used 
 furniture. 
Activity 2 1 0 
Squat Squats down fully with Uses one or two hands on Unable 
arms free (more than 90° thighs or floor to assist 
of hip and knee flexion) full squat 
On thigh 
On floor 
Photographs 
/ Notes 
 
     
Score 2 – full squat – no  Score 0 – Unable to squat 
hands ˚ Score 1 – uses hands on 
floor to assist full squat 
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Test item 25: Rise from squat 
Starting Squatting 
position  
Instruction Can you now stand up from that position? 
Scoring For score 1 please tick the boxes to indicate whether they used a hand on the floor 
detail or on their thigh. Tick both boxes if they used one hand on the floor and one hand 
 on their thigh. 
 They would score 0 if they first went onto all fours or onto their knees to rise from 
 squat or if they used furniture. 
Activity 2 1 0 
 
 
Rise from 
squat 
Stands up from full squat Uses one or two hands to Unable to get back up 
without using arms / rise from squat to stand from squat without 
hands on floor or legs  assistance or uses 
On thigh furniture 
On floor 
 
 
 
 
 
 
Photographs 
Notes 
 
 
 
 
 
 
/ 
 
 
 
 
Score 2 -‐No use of arms Score 1 – Uses hands on 
floor to rise from squat 
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Test item 26: High kneeling to stand through right leg (leading with left leg) 
Starting High kneeling, arms free 
position  
Instruction Can you stand up from this position starting with your left leg without using your 
 hands? 
 May need demonstration 
 Have a bench nearby in case the subject requires support for balance or strength 
Scoring Scores 2: The subject independently transitions from high kneeling to standing via 
detail / right half kneel without arm support. Half kneeling on the right knee must be used 
Diagram in the transition from high kneeling to stand. 
 Scores 1: Able to stand through R leg (leading with left leg) using hand(s) on body or 
 floor. 
 Scores 0: The subject is unable to achieve standing though half kneel or uses 
 furniture to do so. 
Activity 2 1 0 
High kneel Able with arms free Able to stand up through R Unable 
to stand half kneeling using hands 
through on floor or legs (Furniture 
right half NOT allowed) 
kneel  
Photographs Score 2– Able to rise Score 1 -‐ Subject uses 
/ Notes through half kneeling arms to initiate standing 
 without using hands and can stand up 
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Test item 27: High kneeling to stand through left leg (leading with right leg) 
Starting High kneeling, arms free 
position  
Instruction Can you stand up from this position starting with your right leg without using your 
 hands? 
 May need demonstration 
 Have a bench nearby in case the subject requires support for balance or strength 
Scoring Scores 2: The subject independently transitions from high kneeling to standing via 
detail / right half kneel without arm support. Half kneeling on the left knee must be used in 
Diagram the transition from high kneeling to stand. 
 Scores 1: Able to stand through L leg (leading with right leg) using hand(s) on body or 
 floor. 
 Scores 0: The subject is unable to achieve standing though half kneel or uses 
 furniture to do so. 
Activity 2 1 0 
High kneel Able with arms free Able to stand up through L Unable 
to stand half kneeling using hands 
through on floor or legs (Furniture 
right half NOT allowed) 
kneel  
Photographs Score 1 Subject moves 
/ Notes 
Score 2 Subject stands from from high kneel to left half 
 high kneeling through left kneel and uses arm 
 half kneel without the use of support to stand. 
 arm support (is not using 
 elbow) 
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Test item 28: Stand on tiptoes 
Starting Standing 
position  
Instruction Can you stand on your tiptoes? 
Scoring For a score 2, it is possible for the subject to use furniture for balance but not 
detail support or weight bearing 
2 1 0 
Stand on tip Both feet at the same 
toes Tiptoes on one foot, clearly 
time, clearly on toes for 
Unable / momentarily / 
 on toes for count of 3, 
count of 3, knees straight 
knees flexed 
 knee straight 
Photographs 
/ Notes 
 
 
Score 2 Single heel raise,        Score  0:  Knees  
flexed Knee straight Score 1 – Up on toes of to lift heels 
both feet for count of 3, 
knees straight 
 
 
 
 
 
 
 
 
Score 2 Single heel raise, 
rail for balance only 
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Test item 29: Run (10 metres) 
Starting Standing 
position  
Instruction Give the following verbal instructions to the subject: “When I say GO you go as fast as 
 you safely can all the way to me.” Give the command “ready steady – GO” and start the 
 stopwatch when saying “GO”. Give encouragement as necessary. Stop the timer when 
 the second foot clears the finish line. 
Scoring A straight 10m walkway should be clearly marked in a quiet department or corridor. 
detail A stopwatch should be used to time the walk. Preferably no shoes to be worn. 
 Ensure safety of subject. They should self select speed after being asked to go ‘as fast 
 as they can’. Score 1 – Faster than a walk but no time in ‘flight’ Both feet are never 
 off the ground at the same time. May use excessive use of arms, trunk rotation, 
 substantial ’waddle’. No real ‘push-‐off’ 
Activity 2 1 0 
Run Both  feet  off  the  ground Faster than a walk. Walk 
 (no   double   stance   phase 
 during running) 
Photographs 
/ Notes 
 
 
 
Score 2 -‐ Both feet off the 
ground 
Definite ‘run’ 
 
 
 
Score 1 -‐ Picks up speed 
but waddles and always 
has double stance 
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9. TIMED FUNCTIONAL TESTS 
Order of Tests 
 
WITHIN NSAD WITHOUT SHOES 
 
• Timed Rise from floor 
• Timed 10 metre walk /run 
 
WITH SHOES 
 
• Timed up and go (TUG) 
• Stair Ascend 
• Stair Descend 
• Timed rise from chair 
 
 
Rise from floor (NSAD Item 19) 
 
• No shoes or socks to be worn 
• Place the subject in a long sitting position on the floor with his arms by his sides and his legs in front of 
him. 
• Give the following verbal instructions to the subject: “When I say GO you get up as fast as you can 
and stand up straight with your arms by your side”. 
• Give the command “Ready steady – GO” and start the stopwatch when saying “GO”. 
• Stop the timer when the subject assumes an upright position with his arms by his side. 
• Only provide a chair after the subject has attempted to stand from the floor for 30 seconds and failed. 
• Time recorded to the nearest 1/10th of a second? _ _. _ seconds 
Grading Rise from floor 
 
Assign 1 of the following grades: 
 
1= Unable to stand from supine, even with use of a chair 
2= Assisted Gower’s – requires furniture for assist in arising from supine to full upright posture 
3= Rolls over, stands up with both hands “climbing up” the legs to achieve full upright posture. 
4= Rolls over, stands up with 1 hand support on leg 
5=  Rolls to the side and stands up with one or both hands on the floor to start to rise but does not touch 
legs 
6= Stands up without rolling over or using hands on legs 
 41 
 
 
 
10 metre walk/run without shoes (NSAD Item 29) 
 
 
Preparation • No shoes, socks or orthoses should not be worn for this test 
 
 
• NOTE: An additional timed walk/run is performed to determine ambulatory status at the 
beginning of the assessment in shoes and using any orthotics and walking aids. 
 
 
Mark out 10m distance in quiet area if possible 
Starting position Standing at start of marked distance 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Instructions On the word “GO” go as fast as you can to “x”. Define point x. 
 
Timing Start timing on the word go and stop when the second foot passes the 10 metre mark. 
 
 
Grading 
Timing-‐ to the nearest 1/10th of second 
 
 
10 m Walk / Run (in shoes) 
Grade 1 2 3 4 5 6 Time 
(seconds) 
10 metre 
walk / run 
Please circle 
Unable Walk with 
aids 
Walk No 
extra 
speed 
Walk extra 
speed 
Nearly 
running 
no flight 
Running  
_ _ . _   s 
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Timed up and go 
 
 
 
 
 
Preparation Shoes to be worn. Place a piece of tape or other marker on the floor 3 metres away 
from the chair so that it is easily seen by the subject. The chair should be stable and 
positioned such that it will not move when the subject moves from sitting to standing. 
 
The subject wears their regular footwear, may use any gait aid that they normally use 
during ambulation, but may not be assisted by another person. There is no time limit. 
They may stop and rest (but not sit down) if they need to. Please mark on the worksheet 
what orthotics and aids they use. 
 
Normal healthy elderly usually complete the task in ten seconds or less. 
The subject should be given a practice trial that is not timed before testing 
 
Starting 
position 
Subject sitting in a chair with arms. The subject’s back should rest on the back of the 
chair. 
 
Instructions On the word “GO” you will stand up, go as fast as you safely can to the line on the floor, 
turn around and come back to the chair and sit down. 
 
Timing Start timing on the word “GO” and stop timing when the subject is seated again 
correctly in the chair with their back resting on the back of the chair. Time taken 
recorded to the 1/10th second 
 43 
 
Stair Climb 
 
Preparation Shoes to be worn. Use standard steps four steps with handrail where 
possible 
 
Starting position Standing upright at bottom of steps. Arms by side 
  
 
Grading 1.  Unable to climb 4 standard stairs 
 
2. Climbs 4 standard stairs “marking time” (climbs one foot at a 
time, with both feet on a step before moving to next step), 
uses both arms on one or both handrails or uses 1 handrail 
and the other arm pushes on the leg. 
3. Climbs 4 standard stairs “marking time” (climbs one foot at a time, 
with both feet on a step before moving to next step), using one arm 
on one handrail or one arm on a leg or body 
4. Climbs 4 standard stairs “marking time” (climbs one foot at a time, 
with both feet on a step before moving to next step), not needing 
handrail 
5.  Climbs 4 standard stairs alternating feet, needs handrail for support 
or uses arms on body or legs. 
 
6.   Climbs 4 standard stairs alternating feet, not needing handrail 
support 
 
 
  
 
Instructions 
When I say “GO” climb the stairs as quickly as you can,
safely and stand up straight with your arms by your
side when you get to the top 
 
Timing Start the watch on the word go and stop it
when they are standing straight with their arms by
their side. Time recorded to 1/10th second 
 
Grade 5 
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Stair Descend 
 
 
Preparation Shoes to be worn. As stair ascend 
Starting position Standing at the top of the stairs with arms by side (not hands in pockets) 
 
Instructions 
When I say “GO” go as fast as you can down the stairs safely and at the 
bottom, stand up straight with your arms by your side 
 
 
 
Timing 
Start the watch on the word go and stop it when they are standing 
straight with their arms by their side. 
Time taken recorded to the nearest 1/10th second 
 
 
Grading 1.   Unable to descend 4 standard stairs 
2.  Descends 4 standard stairs “marking time” (descends one foot at a time, 
with both feet on a step before moving to next step), requires both arms 
on one or both handrails or uses 1 handrail and the other arm pushes 
on the leg. 
3. Descends 4 standard stairs “marking time” (descends one foot at a time, 
with both feet on a step before moving to next step), requires one arm 
on a handrail or one arm on a leg or body 
 
4. Descends 4 standard stairs “marking time” (descends one foot at a time, 
with both feet on a step before moving to next step), not needing 
handrail 
 
5. Descends 4 standard stairs alternating feet in both directions, needs 
handrail for support or uses arms on body or legs 
 
6. Descends 4 standard stairs alternating feet, not needing handrail support 
 
 
  
 
 
Grade 5 
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Rise from chair 
 
 
Preparation Shoes to be worn. The chair should be stable and positioned such that it will not move 
when the subject moves from sitting to standing. 
 
The subject wears their regular footwear, may use any gait aid that they normally use 
during ambulation, but may not be assisted by another person. 
 
Starting 
position 
Subject sitting in a chair without arms. The subject’s back should rest on the back of the 
chair. 
 
Instructions On the word “GO” you will stand up, go as fast as you can. 
 
Timing Start timing on the word “GO” and stop timing when the subject is standing fully 
upright. 
 
 
Rise from Chair  Record height of chair from floor to middle of cushion or pad  ……………..cm 
Timed rise 
from chair 
Please circle 
Standard 
chair with no 
arms 
Unable Stand up 
using 
additional 
furniture or 
person 
Uses two 
hands to 
stand up 
Uses one 
hand to 
stand up 
Adapts 
standing 
position to 
stand 
Gets up 
normally 
 
_ _ . _ s 
 46 
 
10. PERFORMANCE OF UPPER LIMB SCALE PUL 1.3 –PROXIMAL MODULE 
ONLY 
Relationship of Entry Item A to Brooke score. 
 
The Brooke Upper Extremity Functional Rating Scale was developed specifically for use in DMD [Brooke 
1989] and has been used frequently as an outcome measure in the disease [Lue 2006]. The original 
instrument grades arm and shoulder function from to 1 to 6, with higher values indicating less function. 
The adapted version is reversed to reflect the majority of functional rating scales where a higher score 
means higher function. An additional score of 4 has been added in 
 
 
Adapted 
Brooke 
Score 
0 1 2 3 4 5 6 
 No useful 
function 
of hands. 
Can use 
hands to 
hold pen 
or pick 
up a 
coin or 
drive a 
powered 
chair 
Can raise 
1 or 2 
hands to 
mouth 
but 
cannot 
raise a 
cup with 
a 200g 
weight in 
it to 
mouth 
Can raise 
standardized 
plastic cup 
with 200g 
weight in it 
to mouth 
using both 
hands if 
necessary. 
Can raise both 
arms (elbows to 
shoulder height 
with or without 
compensation. 
Elbow bent or in 
extension 
Can raise both 
arms 
simultaneously 
above head 
only by flexing 
the elbow 
shortening 
circumference 
of the 
movement 
/using 
accessory 
muscles) 
Can abduct 
both arms 
simultaneously 
elbows in 
extension in a 
full circle until 
they touch 
above the 
head. 
Original 
Brooke 
Score 
6 
 
 
 
 
5 
 
 
 
 
4 
 
 
 
3 
 
 
 
 
3 
 
 
 
 
2 
 
 
 
 
1 
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Introduction to PUL 1.3 (Proximal module only) 
 
The Performance of the Upper Limb (PUL) Scale has been devised to assess motor 
performance in the upper limb for individuals with dystrophinopathies (Becker and Duchenne 
muscular dystrophy). Details of the conceptual framework of the scale are detailed in the manual 
and elsewhere (Mayhew et al. Dev Med Child Neurol. 2013 Nov;55(11):1038-45). PUL has been 
devised by the PUL Physiotherapy Working Group (Anna Mayhew, Michelle Eagle, Elena 
Mazzone, Marion Main, Maria Ash, Meredith James, Marlene Vandenhauwe, Katrijn Klingels, Tina 
Duong, Julaine Florence, Valerie Decostre). Work is on-going to improve the content, validity and 
reliability of the scale. This version (1.3) has been updated to reflect on-going psychometric 
analysis of the scale properties. 
Conceptual Framework of PUL 
Intended population 
Ambulant and non-ambulant individuals with dystrophinopathies from childhood to adulthood. The 
scale is recommended from 7 years of age onwards. This has been included to assess proximal 
arm function in LGMD2I. 
The purpose of an upper limb scale for use in dystrophinopathy is to assess change that occurs in 
motor performance of the upper limb over time from when a boy is still ambulant to the time he 
loses all arm function when non-ambulant. Motor performance in dystrophinopathy is defined as a 
demonstrated ability to perform a skill under certain test conditions. This performance changes 
with disease progression and /or intervention (including surgery) and is based on the observed 
response on the day. Motor performance will be impacted by muscle strength, contractures and 
maturational development (puberty) and the scale aims to incorporate performance of shoulder, 
elbow, wrist and hand function. Specific domains have yet to be established precisely but domains 
may relate to functional workspace. I.e. high level shoulder dimension, mid-level elbow dimension, 
distal wrist and hand dimension. These may however lie on a continuum of ability. Items 
measuring motor performance will relate to meaningful functional activities (as detailed in a related 
Patient Reported Outcome measure (PROM) developed through patient focus groups) 
 
Proposed Conceptual framework for Performance of Upper Limb Scale 
 
Muscle strength 
 
Maturation development Motor Performance 
Contractures 
Equipment Required 
General Instructions 
• In general items are scored without compensation, if there is compensation score lower 
• Ideally the same evaluator should perform evaluations at subsequent assessments 
• Items should be performed in the order provided in this manual 
• The subject should wear loose clothing, T shirt etc. 
• For ambulant individuals and those still able to transfer with minimal assistance use a chair 
with a backrest but no armrests and ensure their feet are supported / on the floor 
• For individuals in a powered chair unable to transfer easily ensure their chair has the seat 
positioned as horizontally as possible, the backrest in an upright position if tolerated and 
 48 
 
that the feet are supported, no armrests if possible 
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• No assistive devices are to be used for any of the tests 
• We recommend that a plinth / adjustable table is not used to sit on for the tests (as there is 
no back support) 
• On the worksheet, mark whether the right or left were chosen to perform the test. The same 
hand must be used throughout and at successive visits unless both hands are used 
together 
• If starting position cannot be maintained because of contractures, score is 0 unless stated 
that starting position can be adapted. 
 
 
 
 
 
In the worksheet, indicate: 
• Preferred arm is defined as the one used to draw or write or, if unable, the arm most 
frequently used to perform tasks. 
Items of the PUL scale can be performed by the preferred arm (dominant or not) but 
must be the same one throughout and at successive visits. 
• Make a note of significant elbow contractures and mark on the worksheet if the score was 
limited by these. Elbow contracture should be expressed as its degrees from full elbow 
extension e.g. -10 
• Ambulant is defined as able to walk 10m without any kind of support and non ambulant as 
unable to walk 10m without any kind of support 
 50 
 
 
Entry item – Adapted Brooke Score 
Equipment: 200g weight and plastic cup. Coin and a pencil if necessary. 
Starting position: Sitting, start with hands on lap, no table in front of them. 
If ambulant use a chair with a back rest but with no armrests. If they 
are non-ambulant and it’s not practical to transfer them they can 
remain in their wheelchair with seat as horizontal as possible and 
backrest upright as possible. 
Instruction: “Lift your hands and arms as high as you can.” Trunk side flexion 
can be up to 20°. If they bend their head to their hands instruct them 
to keep their head up if they can. 
For individuals less able you can start by asking them: “Can you 
bring your hands to your mouth?” 
For the most able individuals, demonstrate abduction of both arms 
simultaneously with elbows in extension. 
Scoring details Score 4: Defined as elbow to shoulder height. 
Score 2 and 3. They should not do this by bringing their mouth 
to their hands. If they use significant head and trunk flexion in 
order to complete the task means they cannot score 2 or 3 for 
this item. 
1. Shoulder abduction arms above head (scored from Entry item A) 
Equipment: Seated in chair, no arm rests 
Starting position: Sitting, Preferably with no arm rests on chair. Start with their 
hands in their lap and elbows unsupported. 
Final position Both arms extended above head through abduction 
Instruction: “Raise your arms above your head out to the side – try and 
keep straight elbows” 
Scoring details This item is scored from the entry item above. A score of 2 is 
the equivalent of a score 6 in the entry item and a score 1 is 
equal to a score of 5 in the entry item. 4 or below in the entry 
item scores 0 in this item. 
Item Description 0 1 2 
1 
Score 
from 
Entry 
item 
above 
Shoulder abduction 
both arms above head 
“Raise your arms above 
your head out to the side 
– try and keep straight 
elbows” 
Unable Can raise both arms 
simultaneously above 
head only by flexing 
the elbow (using 
compensation) 
Can abduct both arms 
simultaneously elbows 
in extension in a full 
circle until they touch 
above the head 
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2. Shoulder flexion above shoulder height (no weight) 
3. Shoulder flexion above shoulder with 500g weight 
4. Shoulder flexion above shoulder with 1 kg weight 
Equipment: Weights 
Starting position: Sitting, preferably with no arm rests on chair. Start with their hands in their 
lap. And elbows unsupported, ask them to use a full palmar grasp to hold 
the weight. 
NO table in front. Position yourself to make sure that trunk is not assisting 
e.g at the side of the subject. 
Finish position Arm extended in front  (elbow to eye level) – through flexion 
Note: the arm should be in neutral not pronated or supinated. The 
movement is a combination of almost simultaneous forward flexion and 
elbow extension 
Testing sequence Test using no weight first – Item 2. Proceed to both additional items as 
they may be able to complete the task using compensation. 
Instruction: Item 2:“Reach out and touch my hand” –elbow to eye level 
Item 3 and 4: “Hand on lap – give me the weight” 
Always take weight from them once they have reached maximum height 
(to avoid eccentric muscle work). 
Scoring details The proper movement without compensation is a simultaneous 
combination of shoulder flexion and elbow extension. Absence or 
asynchrony of one of these components or additional movement is 
considered as compensation. They score 2 if they do not use 
compensation. They score 1 if they use compensation but still achieve the 
correct end position. 
Other arm must remain in the individuals lap 
Item Description 0 1 2 
2 Shoulder flexion above 
shoulder height (no 
weights) 
“Reach out and touch 
my hand” –elbow to eye 
level 
Unable Able with compensation Able without 
compensation 
3 Shoulder flexion above 
shoulder height with 
500 g weight 
Hand on lap – “give me 
the weight” –elbow to 
eye level 
Unable Able to lift 500g weight 
with compensation 
Able to lift 500g weight 
without compensation 
4 Shoulder flexion above 
shoulder with 1 kg 
weight 
Hand on lap – “give me 
the weight” –elbow to 
eye level 
Unable Able to lift 1 kg weight 
with compensation 
Able to lift 1 kg weight 
without compensation 
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5. Shoulder abduction above shoulder height (no weight) 
6. Shoulder abduction above shoulder with 500g weight 
7. Shoulder abduction above shoulder with 1 kg weight 
Equipment: Weights 
Starting position: Sitting, preferably with no arm rests on chair. Start with their hands in their 
lap. And elbows unsupported, ask them to use a full palmar grasp to hold 
the weight. 
NO table in front. Position yourself to make sure that trunk is not assisting 
e.g at the side of the subject. 
Finish position Arm extended too side  (elbow to eye level) – through abduction 
Note: the arm should be in neutral not pronated or supinated. The 
Movement is a combination of almost simultaneous abduction and 
elbow extension 
Testing sequence Test using no weight first – Item 5. Proceed to both additional items as 
they may be able to complete the task using compensation. 
Instruction: Item 5:“Reach out and touch my hand” –elbow to eye level 
Item 6 and 7: “Hand on lap – give me the weight” 
Always take weight from them once they have reached maximum height 
(to avoid eccentric muscle work). 
Scoring details The proper movement without compensation is a simultaneous 
combination of shoulder abduction and elbow extension. Absence or 
asynchrony of one of these components or additional movement is 
considered as compensation. They score 2 if they do not use 
compensation. They score 1 if they use compensation but still achieve the 
correct end position. 
Other arm must remain in the individuals lap 
 
 
Item Description 0 1 2 
5 Shoulder abduction 
above shoulder height 
(no weights) 
“Reach out and touch 
my hand” –elbow to eye 
level 
Unable Able with compensation Able without 
compensation 
6 Shoulder abduction 
above shoulder height 
with 500 g weight 
Hand on lap – “give me 
the weight” –elbow to 
eye level 
Unable Able to lift 500g weight 
with compensation 
Able to lift 500g weight 
without compensation 
7 Shoulder abduction 
above shoulder with 1 
kg weight 
Hand on lap – “give me 
the weight” –elbow to 
eye level 
Unable Able to lift 1 kg weight 
with compensation 
Able to lift 1 kg weight 
without compensation 
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11.6-‐MINUTE WALK TEST 
This evaluation is a modified version of the 6MWT adapted from the protocol specifically designed for 
DMD in the PTC 124 2b trial (ATS, 2002, Ref Henriksen, Mc Donald). 
 
Testing Guidelines 
• Subjects should wear comfortable clothing and appropriate shoes for walking (ie, trainers, tennis 
shoes, etc). Since subjects will be tested at multiple time points, they should make an effort to wear 
the same type of shoes each time. 
• A light meal or snack is permissible at least 1 hour before testing. 
• A walking stick or aid may be used if the patient feels this is required for safety. Please mark use of a 
walking aid or orthotics clearly on the worksheet. 
 
Course Set up 
• The test should be performed indoors, along a flat, straight, enclosed, and seldom travelled corridor at 
least 6 feet wide with a hard surface. The test area will be marked with a 25-‐metre tape line. The tape 
line should be placed in the middle of the corridor. Arrows indicating the counterclockwise direction 
and path of movement should be placed in a half-‐circle at the ends of the course. Note that due to the 
possibility of subject falls, the course should be within easy access of appropriate medical assistance. 
 
Testing Directions 
• Set the stopwatch to zero. 
• Ask the subject to stand quietly with his toes at the starting line, immediately adjacent to axis of the 
“home” cone. 
• The following information should be imparted to the subject in a way they will understand 
“Remember, you will be walking back and forth around these cones without crossing the line in the 
middle. You will walk around the cone in a half circle without slowing down. Then you will go back the 
other way. Remember that the object of this test is to walk as fast and as far as you can for six minutes 
without running.” 
• The clinical evaluator should follow the subject whilst he is walking around the 
course. 
• When the subject is ready, say “Ready, set, go!”, and start the stopwatch. 
• Every time the subject reaches the each end of the course, mark the worksheet 
to record the time at each 25 metres completed. 
• Give positive verbal encouragement as appropriate. 
• Let the subject know how long he has been walking. For example “three 
minutes done, only three to go, you are half way there, one minute left” 
• If the subject stops to rest, say: 
• “You can lean on the wall or stand to rest. Just start walking again as soon as 
you feel like you can.” 
24   23   22   21  20   19 
1 
2    3     4    5    6    7    8     9   10   11   12   13 
18   17   16  15  14   13   12   11   10   9    8    7    6    5    4    3    2     1 
14   15   16   17   18   19   20   21   22   23 
24 
1 
 
 
If the subject falls: 
Record the time of fall 
• The evaluator should ensure that the subject is OK, and then should assist 
him back to a standing position as soon as it is safe to do so. 
• If the subject is injured or cannot rise from the floor, the test is over. 
Total time and distance should be recorded, and any necessary medical 
attention should be given to the subject. 
• If the subject is uninjured, he should resume walking as soon as he is able. Say: 
“If you are alright, you should start walking again as soon as you feel like you can.”At 
the final seconds of the test count down, the timer will announce: 
“Five fifty seven, five fifty-‐eight, five fifty-‐nine, six minutes! Great job, you 
can stop now.” Bring a chair or wheelchair for him to sit and rest. Offer the 
subject a drink of water. 
• Measure the distance from the final cone passed to the point at which the 
subject stopped at 6 minutes. Multiply by 25 the number of completed 25 metre 
laps and add to the distance reached on the final lap. This is recorded as the 
total distance walked in 6 minutes. 
• Document the number of falls during the 6 minute walk test 
Safety Considerations and Additional Information 
• Subjects should have medical clearance from the study investigator prior to testing. 
• Testing staff should know the location of the nearest resuscitation cart and 
institutional emergency care procedures. Emergency contact numbers should 
be immediately accessible. 
 
 
 
 
